Molecular and Functional Characterization of P2Y12 Expression in Tumor-associated Macrophages by Kloss, Loreen
  
Aus der Klinik für Dermatologie, Venerologie und Allergologie 
Universitätsklinikum Mannheim der Medizinischen Fakultät Mannheim  
der Ruprecht-Karls-Universität Heidelberg  
(Direktor: Prof. Dr. med. S. Goerdt) 
 
 
 
 
 
 
Molecular and Functional Characterization 
of P2Y12 Expression 
in Tumor-associated Macrophages 
 
 
 
 
 
 
INAUGURALDISSERTATION 
zur Erlangung der Doktorwürde der 
Naturwissenschaftlich-Mathematischen Gesamtfakultät 
der Ruprecht-Karls-Universität Heidelberg 
 
 
 
 
 
 
Vorgelegt von 
Loreen Kloss 
  
  
 
 
DISSERTATION 
 
 
 
 
submitted to the  
Combined Faculty of Natural Sciences and Mathematics  
of the Ruperto Carola University Heidelberg, Germany  
for the degree of  
Doctor of Natural Sciences  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Presented by 
 
Loreen Kloss, M.Sc. 
Born in: Herrenberg, Germany 
 
Oral examination: June 17th, 2019 
  
  
 
 
Molecular and Functional Characterization 
of P2Y12 Expression 
in Tumor-associated Macrophages 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Referees: 
 
Prof. Dr. rer. nat. Viktor Umansky 
 
PD Dr. med. Astrid Schmieder 
 
 
Table of Contents 
___________________________________________________________________________ 
I 
Table of Contents 
 
Abstract ...................................................................................................................................... V 
Zusammenfassung ................................................................................................................... VII 
1. Introduction ....................................................................................................................... 1 
1.1 Macrophages ............................................................................................................... 1 
1.1.1 Origin and maintenance of macrophages ............................................................ 1 
1.1.2 General and tissue-specific functions of macrophages ....................................... 2 
1.1.3 Macrophage polarization and activation ............................................................. 4 
1.1.4 Macrophages in diseases ..................................................................................... 6 
1.2 Tumor-associated macrophages (TAM) ...................................................................... 8 
1.2.1 TAM promote tumor growth and metastasis ...................................................... 9 
1.2.2 TAM promote angiogenesis ............................................................................... 10 
1.2.3 TAM support an immunosuppressive tumor microenvironment ...................... 12 
1.2.4 TAM as therapeutic targets in cancer immunotherapy ..................................... 13 
1.3 Malignant melanoma ................................................................................................ 14 
1.3.1 Epidemiology, risk factors and pathophysiology ............................................... 14 
1.3.2 Melanoma immuno-microenvironment ............................................................ 16 
1.3.3 Melanoma immunotherapy ............................................................................... 18 
1.4 Purinergic receptors .................................................................................................. 19 
1.4.1 Classification and function ................................................................................. 19 
1.4.2 Purinergic signaling regulates inflammation and immunity .............................. 21 
1.4.3 Purinergic receptors in the tumor microenvironment ...................................... 23 
1.5 The purinergic receptor P2Y12 .................................................................................. 25 
1.5.1 Structure and signaling of P2Y12 ....................................................................... 25 
1.5.2 P2Y12 expression in platelets ............................................................................. 26 
1.5.3 P2Y12 expression in microglia ............................................................................ 27 
1.5.4 P2Y12 expression in leukocytes ......................................................................... 29 
1.6 Aim of the study ........................................................................................................ 31 
2. Materials .......................................................................................................................... 32 
3. Methods ........................................................................................................................... 39 
3.1 Cell culture methods.................................................................................................. 39 
3.1.1 Cell lines .............................................................................................................. 39 
Table of Contents 
___________________________________________________________________________ 
II 
3.1.2 Cryopreservation of cells .................................................................................... 40 
3.1.3 Production of lentivirus for transduction of eukaryotic cell lines ...................... 40 
3.1.4 Generation of transgenic cell lines ..................................................................... 41 
3.1.5 Isolation of CD14+ cells from human peripheral blood ...................................... 41 
3.2 In vitro Assays ............................................................................................................ 42 
3.2.1 BrdU Cell Proliferation Assay ............................................................................. 42 
3.2.2 Transwell migration assay with pBM ................................................................. 42 
3.2.3 Transwell migration assay with transgenic Raw 264.7 cells .............................. 43 
3.2.4 Adhesion of U937 to HUVECs ............................................................................. 43 
3.2.5 U937 Transmigration Assay ................................................................................ 44 
3.3 Molecular biology ...................................................................................................... 44 
3.3.1 Cloning of hsP2Y12 and mmP2Y12 .................................................................... 44 
3.3.2 RNA isolation and cDNA synthesis ..................................................................... 45 
3.3.3 Polymerase chain reaction (PCR) ....................................................................... 46 
3.3.4 Quantitative Real-time PCR (qRT-PCR) ............................................................... 46 
3.3.5 Microarrays ........................................................................................................ 47 
3.3.6 In situ hybridization ............................................................................................ 47 
3.4 Biochemical methods ................................................................................................ 47 
3.4.1 Generation of an anti-human P2Y12 antibody .................................................. 47 
3.4.2 Cell lysates and protein determination .............................................................. 48 
3.4.3 SDS-PAGE ............................................................................................................ 48 
3.4.4 Western blot analysis (WB) ................................................................................ 49 
3.4.5 Enzyme-linked immunosorbent Assay (ELISA) ................................................... 49 
3.4.6 Proteome Profiler Mouse Cytokine Array .......................................................... 49 
3.4.7 Immunocytochemistry (ICC) ............................................................................... 50 
3.4.8 Immunohistochemistry (IHC) ............................................................................. 50 
3.4.9 Immunofluorescence (IF) ................................................................................... 51 
3.4.10 Sequential staining ............................................................................................. 51 
3.4.11 Fluorescence-activated cell sorting (FACS) ........................................................ 51 
3.5 Mouse experiments ................................................................................................... 52 
3.5.1 Mice .................................................................................................................... 52 
3.5.2 B16F10 melanoma model .................................................................................. 52 
3.5.3 Isolation of murine macrophages ...................................................................... 53 
3.5.4 Generation of bone marrow-derived macrophages (BMDM) ........................... 53 
Table of Contents 
___________________________________________________________________________ 
III 
3.6 Statistical analysis ...................................................................................................... 53 
4. Results .............................................................................................................................. 54 
4.1 Characterization of P2Y12 expression in human pBM in vitro .................................. 54 
4.1.1 P2Y12 is strongly induced in MDI-treated pBM ................................................. 54 
4.1.2 MDI induces a M2-like macrophage phenotype in pBM ................................... 55 
4.1.3 Generation of an anti-P2Y12 peptide antibody and characterization of its 
specificity in transgenic U937 cells .................................................................... 58 
4.1.4 P2Y12 is expressed in MDI-treated pBM and its induction can be inhibited with 
mifepristone ....................................................................................................... 60 
4.2 Characterization of P2Y12 expression in human macrophages in vivo..................... 62 
4.2.1 P2Y12 is expressed in microglia cells and splenic macrophages ....................... 62 
4.2.2 P2Y12 is expressed in human TAM of melanoma .............................................. 63 
4.3 Characterization of P2Y12 expression in murine macrophages ................................ 67 
4.3.1 Validation of the specificity of a commercial anti-P2Y12 antibody using 
transgenic Raw 264.7 cells ................................................................................. 67 
4.3.2 P2Y12 is induced in bone marrow-derived macrophages by MDI and is 
expressed in murine macrophages in vivo ......................................................... 68 
4.4 Functional characterization of P2Y12+ macrophages ................................................ 70 
4.4.1 Gene expression analysis of ADP-treated P2Y12+ U937 cells ............................ 70 
4.4.2 Cytokine and chemokine expression in ADP-treated pBM(MDI) .......................... 77 
4.4.3 ADP-induced chemokine secretion in P2Y12+ U937 cells can be inhibited by the 
specific P2Y12 antagonist PSB0739 .................................................................... 79 
4.4.4 Analysis of P2Y12 downstream signaling pathways in macrophages ................ 80 
4.4.5 ADP promotes the migration of MDI-treated pBM ........................................... 84 
4.4.6 ADP promotes the migration of P2Y12+ Raw 264.7 cells ................................... 84 
4.4.7 Cell death induces the migration of P2Y12+ Raw 264.7 cells ............................. 88 
4.4.8 ADP induces cytokine secretion in P2Y12+ Raw 264.7 cells ............................... 89 
4.4.9 P2Y12 facilitates the adhesion and transmigration of U937 cells ..................... 90 
5. Discussion......................................................................................................................... 92 
5.1 Characterization of P2Y12 expression in human macrophages ................................ 92 
5.1.1 Characterization of P2Y12+ macrophages in vitro .............................................. 92 
5.1.2 Signaling pathways underlying the induction of P2Y12 expression .................. 94 
5.1.3 Characterization of P2Y12+ macrophages in vivo............................................... 95 
5.2 Characterization of P2Y12 expression in murine macrophages ................................ 95 
5.3 Functional characterization of P2Y12+ macrophages ................................................ 96 
Table of Contents 
___________________________________________________________________________ 
IV 
5.3.1 Gene expression analysis of P2Y12+ U937 cells ................................................. 96 
5.3.2 ADP induces cytokine and chemokine secretion ............................................. 100 
5.3.3 ADP-induced signaling pathways in P2Y12+ macrophages .............................. 101 
5.3.4 ADP promotes the migration of P2Y12+ macrophages .................................... 102 
5.3.5 Cell death induces the migration of P2Y12+ Raw 264.7 cells ........................... 104 
5.3.6 P2Y12 facilitates the adhesion and transmigration of U937 cells ................... 105 
5.4 Concluding remarks ................................................................................................. 106 
References................................................................................................................................... i 
Appendix .................................................................................................................................. xxi 
List of Figures ........................................................................................................................ xxi 
List of Tables ....................................................................................................................... xxiii 
List of Abbreviations ........................................................................................................... xxiv 
Acknowledgements ............................................................................................................... xxix 
 
 
 
Abstract 
___________________________________________________________________________
V 
Abstract 
 
Macrophages are phagocytic cells of the innate immune system that exert important functions 
for immunological and homeostatic processes. They have a high plasticity and can quickly 
adapt to different environments. While Th1 cytokines induce a pro-inflammatory macrophage 
phenotype (M1), Th2 cytokines promote an anti-inflammatory one (M2). At tumor initiation a 
M1 phenotype is predominant, which then switches to a M2-like phenotype during tumor 
progression. These tumor-associated macrophages (TAM) promote tumor growth and 
metastasis by the secretion of growth factors, matrix metalloproteinases and 
immunosuppressive mediators such as arginase-1, IL-10 and TGF-ß. In many tumor entities 
including melanoma a high TAM infiltration correlates with a poor patient outcome. Thus, 
macrophages provide a promising therapeutic target for adjuvant tumor therapies. In the past 
our group identified several novel markers for TAM such as STABILIN-1 and LYVE-1. These 
markers can be induced in vitro by the treatment of peripheral blood monocytes (pBM) with 
M-CSF/dexamethasone/IL-4 (MDI). Microarray analysis of these in vitro generated M2-like 
macrophages identified the purinergic, G protein coupled receptor P2Y12 as the highest up-
regulated gene. So far, P2Y12 has been known to be expressed on microglia and platelets and 
is targeted therapeutically with clopidogrel, ticagrelor and prasugrel to treat thrombotic 
disorders. Since the expression of P2Y12 in TAM has not been described yet, the aim of this 
study was to characterize P2Y12 expression and its function in M2-like macrophages in vitro 
as well as in TAM in vivo. Since all commercially available antibodies failed to detect P2Y12 in 
transgenic P2Y12+ U937 cells, we generated a peptide antibody against human P2Y12 and 
confirmed the expression of P2Y12 receptor in MDI-treated pBM as well as in CD68+ and CD63+ 
TAM of melanoma in situ. Like in the human system, P2y12 can also be induced by the 
treatment of murine bone marrow-derived macrophages (BMDM) with MDI. We detected 
P2y12 expression in CD11b+ cells isolated from spleen, peritoneal fluid and subcutaneously 
transplanted B16F10 tumors of tumor-bearing mice. P2Y12 expression in murine TAM was 
confirmed by immunohistochemical staining of B16F10 tumors. Treatment of murine and 
human transgenic P2Y12+ macrophage-like cell lines with the P2Y12 receptor agonist ADP 
increased the expression of several cytokines and chemokines (in the murine system CXCL2 
and TNF-α and in the human system CXCL2, CXCL7 and IL-8), indicating an immunomodulatory 
role for the receptor. Analyzing signaling pathways underlying the induction of these 
cytokines, we detected ERK as well as Akt phosphorylation in ADP-treated P2Y12+ U937 cells. 
Inhibition of these signaling pathways significantly impaired CXCL2, CXCL7 and IL-8 secretion. 
Since ADP acts as a chemoattractant for microglia cells, the migratory potential of P2Y12+ 
macrophages was evaluated. We could show that ADP promotes the migration of human 
pBM(MDI) as well as murine P2Y12+ Raw 264.7 cells in a transwell chamber. Pre-treatment with 
the P2Y12 antagonist PSB0739 abrogated the ADP-induced chemotaxis of P2Y12+ cells. Since 
it is known that dying cells release nucleotides that act as find-me signals for phagocytic cells, 
we set up a co-culture experiment with P2Y12+ Raw 264.7 cells and B16F1 melanoma cells, 
which we pre-treated with puromycin to induce cell death. Dying tumor cells promoted the 
migration of P2Y12+ macrophages. Administration of the ATP/ADP cleaving enzyme apyrase 
to the dying tumor cells or treatment of P2Y12+ Raw 264.7 cells with PSB0739 abrogated the 
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cell-death induced migration of P2Y12+ macrophages. Taken together, our results indicate that 
P2Y12 is an important immunomodulatory macrophage receptor, which triggers migration of 
these cells towards ADP-rich tumor areas and is able to modulate the inflammatory 
environment upon ADP activation. 
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Zusammenfassung 
 
Makrophagen sind Zellen des angeborenen Immunsystems, die wichtige Funktionen für 
immunologische und homöostatische Prozesse ausüben. Die Phagozyten sind plastisch und 
können sich schnell an unterschiedliche Umgebungen anpassen. Während Th1 Zytokine einen 
pro-inflammatorischen Phänotyp induzieren (M1 Makrophagen), fördern Th2 Zytokine einen 
anti-inflammatorischen Phänotyp (M2 Makrophagen). Zu Beginn der Tumorentstehung 
dominiert ein M1 Phänotyp, welcher sich während des Tumorwachstums hin zu einem M2 
Phänotyp entwickelt. Diese Tumor-assoziierten Makrophagen (TAM) fördern das 
Tumorwachstum und die Metastasierung indem sie Wachstumsfaktoren, Matrix-
Metalloproteinasen und immunsuppressive Mediatoren wie beispielsweise Arginase-1, 
Interleukin-10 und TGF-ß sezernieren. In vielen Tumorentitäten, einschließlich dem Melanom, 
korreliert eine hohe TAM Infiltration mit einem schlechten Patienten Outcome. Daher eignen 
sich Makrophagen als vielversprechendes therapeutisches Target für adjuvante 
Tumortherapien. In der Vergangenheit identifizierte unsere Gruppe mehrere neue TAM 
Marker wie z. B. STABILIN-1 und LYVE-1. Diese Marker können durch Stimulation von 
humanen peripheren Blutmonozyten (pBMZ) mit M-CSF/Dexamethason/IL-4 (MDI) induziert 
werden. Eine Genexpressions-Analyse dieser in vitro generierten M2-ähnlichen Makrophagen 
identifizierte den purinergen, G-Protein gekoppelten Rezeptor P2Y12 als das stärkste 
hochregulierte Gen. Bislang ist bekannt, dass P2Y12 von Mikrogliazellen und Thrombozyten 
exprimiert wird und das therapeutische Target für Medikamente wie Clopidogrel, Prasugrel 
und Ticagrelor ist, die zur Behandlung thrombotischer Erkrankungen verschrieben werden. Da 
die Expression von P2Y12 in TAM bislang nicht beschrieben wurde, ist das Ziel dieser Studie 
die Expression des Rezeptors sowie seine Funktion in M2-ähnlichen Makrophagen in vitro 
sowie in TAM in vivo umfassend zu charakterisieren. Da kein kommerziell erhältlicher 
Antikörper P2Y12 in transgenen P2Y12+ U937 Zellen spezifisch nachweisen konnte, stellten 
wir einen Peptid-Antikörper gegen humanes P2Y12 her und bestätigten die Expression des 
Rezeptors in MDI-behandelten pBMZ sowie in CD68+ und CD163+ TAM des Melanoms in situ. 
Ähnlich wie im Menschen kann P2y12 auch in der Maus durch die Stimulation von 
Knochenmarksmakrophagen mit MDI induziert werden. Wir detektierten P2y12 auch in 
CD11b+ myeloiden Zellen, welche aus der Milz, der Peritonealflüssigkeit sowie aus subkutan 
transplantierten B16F10 Tumoren von Tumor-tragenden Mäusen gewonnen wurden. Die 
P2Y12 Expression in murinen TAM wurde mit Hilfe von immunhistochemischen Färbungen 
von B16F10 Melanomen bestätigt. Eine Behandlung von murinen und humanen transgenen 
P2Y12+ Zelllinien mit dem Rezeptor-Agonist ADP erhöhte die Expression einiger Zytokine und 
Chemokine (in der Maus CXCL2 und TNF-α und im Mensch CXCL2, CXCL7 und IL-8), was auf 
eine immunmodulatorische Rolle des Rezeptors hindeutet. Wir analysierten Signalwege, die 
dieser Zytokininduktion zugrunde liegen könnten und fanden eine verstärkte ERK und Akt 
Phosphorylierung in ADP-behandelten P2Y12+ U937 Zellen. Eine Inhibierung dieser 
Signalwege verminderte die ADP-induzierte Sekretion von CXCL2, CXCL7 sowie IL-8. Da ADP 
als chemotaktisch wirksamer Botenstoff für Mikrogliazellen bekannt ist, untersuchten wir das 
migratorische Potential von P2Y12+ Makrophagen. Wir konnten zeigen, dass ADP sowohl die 
Migration von humanen MDI-stimulierten pBMZ als auch von P2Y12+ Raw 264.7 Zellen in einer 
Zusammenfassung 
___________________________________________________________________________
VIII 
Transwell-Kammer fördert. Eine Vorbehandlung mit dem P2Y12 Antagonist PSB0739 wirkte 
hemmend auf die ADP-induzierte Chemotaxis der P2Y12+ Zellen. Da bekannt ist, dass 
sterbende Zellen Nukleotide freisetzen, die als Aufspühr-Signale für Phagozyten fungieren, 
etablierten wir ein Co-Kultur Experiment mit P2Y12+ Raw 264.7 Zellen und B16F1 
Melanomzellen, welche wir mit Puromycin behandelten, um den Zelltod dieser Zellen zu 
induzieren. Die sterbenden Tumorzellen verstärkten die Migration der P2Y12+ Makrophagen. 
Zugabe des ATP/ADP hydrolysierenden Enzyms Apyrase zu den sterbenden Tumorzellen oder 
Behandlung der P2Y12+ Raw 264.7 Zellen mit PSB0739 verhinderten die Zelltod-induzierte 
Migration der P2Y12+ Makrophagen. Zusammengefasst deuten unsere Ergebnisse darauf hin, 
dass P2Y12 ein wichtiger immunmodulatorischer Rezeptor ist, welcher die Migration von 
Makrophagen in Richtung ADP-reicher Tumorbereiche fördern und nach Aktivierung durch 
ADP die inflammatorische Umgebung modulieren kann. 
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1. Introduction 
 
1.1 Macrophages 
 
1.1.1 Origin and maintenance of macrophages 
 
Macrophages are immune cells of the mononuclear phagocyte system comprising monocytes, 
macrophages and dendritic cells (DCs) [1]. They are found in all tissues where they exert tissue 
specific functions [2]. Macrophages differentiate from circulating monocytes. These cells 
derive from myeloid progenitor cells in the bone marrow which give rise to many other cell 
types such as granulocytes, DCs and mast cells (Figure 1) [3]. In mice, one distinguishes two 
major monocyte populations termed as inflammatory (Gr+/Ly6Chigh) and resident (Gr1-
/Ly6Clow) monocytes.  
Gr+/Ly6Chigh monocytes patrol between the blood and the bone marrow and give rise to Gr1- 
monocytes by loosing Ly6C expression [4, 5]. However, studies showed that the Gr1- subset is 
still present when Gr1+ monocytes are depleted indicating that they develop independently 
of inflammatory monocytes [6-8]. Since Gr1+ monocytes can differentiate to macrophages and 
DCs during infection they were termed as inflammatory. They are the first monocytes that 
enter the blood stream from the bone marrow and rapidly exit to give rise to distinct 
macrophage populations that can either activate or inhibit immune response [9, 10]. Long-
lived tissue-specific macrophages such as intestinal macrophages can be replenished by 
patrolling Gr1+ monocytes [11, 12]. Since Gr1-/Ly6Clow monocytes have a longer half-life and 
exist in the steady state as well as in inflamed tissue they were termed as resident monocytes 
[13]. They lack CCR2 and L-Selectin expression but have higher CX3CR1 and LFA-1 expression 
[14]. They seem to be involved in tissue repair and angiogenesis as they deposit collagens and 
express vascular endothelial growth factor (VEGF) [15]. In mice, both monocyte populations 
are equally distributed in the blood [14]. Since monocytes are a very heterogeneous 
population, it is still a matter of debate whether distinct tissue macrophages derive from 
specific monocyte populations in the blood. However, many tissue-specific macrophages do 
not origin from the bone marrow and thus are not monocyte-derived macrophages (MDM) 
[3]. Microglia, macrophages of the central nervous system (CNS), or Langerhans cells, DCs of 
the skin, for instance, do not originate from circulating monocytes but derive from yolk sac or 
fetal liver cells (Figure 1) [16-20]. Although some macrophage populations, e.g. of the kidney 
and lung, can be replenished by Gr1+ monocytes, some of them including microglia are 
replaced by tissue-resident colony forming cells [21]. 
In humans one distinguishes three monocyte populations: CD14++CD16- classical monocytes, 
CD14++ CD16+ intermediate monocytes and CD14+CD16++ non-classical monocytes [22]. 
Classical monocytes are characterized by high CCR2 and CD62L expression and are mainly 
involved in phagocytosis and the killing of pathogens by increased production of reactive 
oxygen species (ROS). They produce high amounts of IL-10 in response to LPS and are involved 
in angiogenesis and wound healing [14, 23]. CD14++CD16+ intermediate monocytes are also 
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termed inflammatory monocytes since their number is increased in inflammatory diseases. 
Furthermore, they produce higher amounts of IL-1ß and TNF-α in response to LPS. Gene 
expression analysis indicates that they are involved in antigen presentation and T cell 
activation [23]. CD14+CD16++ non-classical monocytes, also known as patrolling monocytes, 
are characterized by low CCR2 expression, low peroxidase activity, and high expression of 
CX3CR1 [24]. Like intermediate monocytes, they release IL-1ß and TNF-α in response to 
danger-associated molecular patterns (DAMPs) and pathogen-associated molecular patterns 
(PAMPs). They might be involved in autoimmune diseases including rheumatoid arthritis [25]. 
Since murine and human monocytes/macrophages differ in their phenotypes it remains 
challenging to transfer the knowledge obtained from mice studies to the human system.  
 
 
Figure 1. Origin and differentiation of murine macrophages. Macrophages originate from three 
different tissues: yolk sac, fetal liver and bone marrow. Monocyte-derived macrophages originate from 
the bone marrow and derive from myeloid progenitor cells which give rise to granulocytes, dendritic 
cells, mast cells and monocytes. The latter can be divided in Gr1- (Ly6C-) resident monocytes and Gr1+ 
(Ly6C+) inflammatory monocytes which differentiate to F4/80low tissue macrophages. Many tissue 
macrophages including microglia originate from the yolk sac, while Langerhans cells of the skin derive 
from yolk sac and fetal liver cells. Figure adapted from Wynn et al. [3].  
 
1.1.2 General and tissue-specific functions of macrophages 
 
For a long time, the focus was set on the function of macrophages as immune effector cells 
that mediate host defense. As phagocytic cells of the innate immune system they are involved 
in the killing of bacteria and viruses through the production of ROS a process which is called 
respiratory burst [26]. Macrophages recognize PAMPs with special pattern recognition 
receptors (PRR) such as Toll-like receptors (TLRs) [27]. Being antigen presenting cells (APCs), 
they play a role in activating the adaptive immune response [28]. After ingestion of a 
pathogen, antigens are processed and presented on the surface of macrophages via MHC 
class II molecules to T cells which recognize the antigen with their T cell receptor (TCR). Besides 
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this interaction a secondary co-stimulatory signal is indispensable to provide an adequate 
immune response. Macrophages express several co-stimulatory molecules (e.g. B7.1/CD80 
and B7.2/CD86) that are recognized by specific surface receptors (e.g. CD28) on T cells [29]. 
Through the secretion of interferon γ (IFN-γ), T cells promote the killing of engulfed bacteria 
and viruses by macrophages which in turn promote the proliferation of the T cells by secretion 
of the pro-inflammatory cytokine interleukin-12 (IL-12) [30]. There are also co-inhibitory 
molecules such as PD-L1 and PD-L2 that inhibit activation of T cells [31].  
Besides their immunological function, macrophages exert important functions for 
homeostatic processes such as tissue remodeling, clearance of erythrocytes, apoptotic cells 
and cellular debris [3, 32]. This homeostatic clearance is mediated by scavenger receptors, 
phosphatidyl receptor, thrombospondin receptor, integrins and complement receptors [33, 
34]. Furthermore, macrophages are the primary sensors for endogenous danger signals (e.g. 
heat shock proteins, nuclear proteins, or nucleotides) released by necrotic cells [35]. PRRs 
including TLRs and IL-1ß receptors recognize these molecules and mediate phagocytic 
clearance. Importantly, these mechanisms do not depend on the adaptive immune response 
or immune cell signaling [36]. Since maintenance of tissue integrity and homeostasis is 
important in almost all organs, macrophages are present in almost all tissues where they exert 
tissue-specific functions (Table 1).   
Due to differential expression of transcription factors, tissue specific macrophages are 
heterogenous in their phenotypes as well as in their function and turnover [3]. In the bone, 
macrophages known as osteoclasts are crucial for bone resorption thereby regulating blood 
calcium levels [37]. Although bone formation is not altered in Csf1-null mice, hematopoiesis is 
impaired due to defect formation of the bone cavities [38]. In the brain, microglia controls 
brain development and maintenance of the brain structure. Neurons express CSF1 and IL-34 
which are the major cytokines for differentiation and viability of microglia [39]. Microglia, in 
turn, regulate proliferation and survival of neurons after nerve injury. In Csf1r-null mice brain 
structure is disrupted resulting in defect neuronal processing [40]. In the lung, alveolar 
macrophages are responsible for toxin and pathogen removal [41]. In the spleen, three distinct 
macrophage populations can be distinguished based on their location within the tissue. Red 
pulp macrophages are important for the removal of erythrocytes and the recycling of iron. 
Both types of macrophages of the marginal zone, marginal zone macrophages (MZM) and 
marginal metallophilic macrophages (MMM) mediate uptake of apoptotic cells and 
pathogens. However, whereas MMM stimulate the adaptive immune response by type I IFN 
production, MZM have an immunosuppressive phenotype, for instance by expressing 
indolamine-2,3-dioxygenase (IDO) and IL-33 [42]. In adipose tissue, liver and pancreas, 
macrophages are important for metabolic homeostasis. They regulate lipolysis, insulin 
sensitivity and storage of nutrients [3]. In the kidney, mammary gland and pancreas, 
macrophages are important for tissue patterning and branching morphogenesis. Furthermore, 
they control stem cell function thereby regulating the growth of the ductal structure [38, 43]. 
In other organs such as the liver and intestine, modulation of stem cell function by 
macrophages is important for the regeneration after tissue damage [44, 45].  
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Table 1. Macrophage populations and functions in different tissues 
TISSUE MACROPHAGE SUBSET TISSUE-SPECIFIC FUNCTION 
Bone Osteoclast Bone resorption 
Hematopoiesis 
CNS Microglia Neuronal patterning 
 
Lung Alveolar macrophage Toxin and pathogen removal 
 
Liver Kupffer cell Lipid metabolism 
 
Spleen Red pulp macrophage Clearance of erythrocytes 
Iron metabolism 
Spleen Marginal zone macrophage Immunosuppression 
Removal of apoptotic cells and pathogens 
Spleen Metallophilic macrophage Activation of adaptive immune response 
Uptake of pathogens and apoptotic cells 
Adipose 
tissue 
Adipose tissue macrophage Adipogenesis 
Insulin sensitivity 
 
Besides their morphological and functional heterogeneity, macrophages also differ in their 
transcriptomic and proteomic profile [3]. Although the heterogeneity of macrophage 
populations is immense, efforts have been made to classify macrophages according to their 
different phenotypes.  
 
1.1.3 Macrophage polarization and activation 
 
Macrophages are highly plastic cells, that can quickly adapt to different environments by 
changing their phenotypes. Many attempts have been made to classify macrophages 
according to their polarization. Mills and colleagues established a model that mirrors the 
Th1/Th2 dichotomy of T lymphocytes by dividing macrophages in pro-inflammatory, classically 
activated macrophages (M1) and anti-inflammatory, alternatively activated macrophages 
(M2) (Figure 2) [46]. M1 macrophages can be induced by Th1 cytokines such as IFN-γ, and by 
TNF-α or LPS. IFN-γ is mainly secreted by Th1 cells, CD8+ T cells and NK cells whereas LPS comes 
from Gram-negative bacteria. TNF-α is produced by APC that are activated by a TLR ligand 
[32]. M1 macrophages secrete pro-inflammatory cytokines such as IL-12, IL-23 and TNF-α and 
express high levels of MHC class II molecules and the co-stimulatory molecules CD80 and 
CD68. Besides their increased endocytic functions, M1 macrophages are involved in the killing 
of intracellular pathogens and in stimulating an immune response. In the murine system, M1 
macrophages also express inducible nitric oxide synthase (iNOS) which converts L-arginine to 
nitric oxide (NO) [47]. Due to the production of ROS they also exert tumoricidal functions. 
Martinez et al. envisaged a subclassification of M1 macrophages into classical activated 
macrophages (M1a) that are activated by IFN-γ and innate activated macrophages (M1b) that 
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are activated by PAMPS such as LPS. Although both populations produce high levels of the 
pro-inflammatory cytokines IL-1ß, IL-6 and TNF-α, innate activated macrophages don’t show 
increased phagocytic activity and no increased IL-12 production [48]. In contrast to the pro-
inflammatory M1 macrophages, M2 macrophages can be induced by Th2 cytokines such as IL-
4, IL-13 as well as by IL-10 and glucocorticoids [49, 50]. M2 macrophages are involved in the 
killing of parasites and fungi, and in homeostatic processes such as matrix remodeling and 
tissue turnover. In addition, M2 macrophages support angiogenesis and wound healing. 
Through the secretion of anti-inflammatory mediators such as IL-10 and transforming growth 
factor-ß (TGF-ß) these macrophages play an important role in the counter-regulation of pro-
inflammatory conditions. Typical M2 markers are scavenger receptors such as mannose 
receptor C-type 1 (MRC1/CD206), CD163 and STABILIN-1 [47]. Furthermore, M2 macrophages 
express high levels of arginase-1 thereby promoting immune suppression by impairing T cell 
response [51]. However, this M1/M2 macrophage classification model, which is based on in 
vitro studies, is an oversimplification of the in vivo situation where mixed and overlapping 
phenotypes co-exist.   
Martinez and colleagues further subdivided the M2 population into M2a, M2b, M2c. In this 
model, M2a macrophages are induced by the typical Th2 cytokines IL-4 and IL-13, M2b by 
immune complexes plus LPS or IL-1ß and M2c by glucocorticoids, IL-10 and TGF-ß. In contrast 
to M2a cells, M2b cells express higher levels of the anti-inflammatory cytokine IL-10 but also 
secrete TNF-α, IL-1ß and IL-6 showing that these cells have no anti-inflammatory phenotype 
per se. M2c cells are a heterogenous population that is characterized by the down-regulation 
of pro-inflammatory cytokines, MHC class II as well as co-stimulatory molecules and an up-
regulation of several scavenger receptors [48].  
Mosser and colleagues classified macrophages according to their homeostatic activities: host 
defense (classically activated macrophages), wound healing (wound healing macrophages) 
and immune regulation (regulatory macrophages). They suggest that these macrophages shift 
their activation states thereby establishing macrophages with intermediate phenotypes. 
Tumor-associated macrophages, for instance, display features of both, wound healing 
macrophages and regulatory macrophages [32].  
Since all these attempts to classify macrophages fail to display the real in vivo situation it is 
crucial to analyze macrophage subpopulations in different tissues in health and diseases. This 
should help to elucidate how the local microenvironment polarizes these macrophages and 
modulates their specific functions and how these macrophages contribute to the pathological 
condition and to disease progression. 
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Figure 2. M1/M2 model of macrophage classification. Pro-inflammatory stimuli such as IFN-γ and 
TNF-α induce a M1 macrophage phenotype whereas anti-inflammatory stimuli such as IL-10, IL-4 and 
IL-13 induce a M2 phenotype. M1 macrophages express inducible nitric oxide synthase (iNOS) and the 
co-stimulatory molecules CD86 and CD80 and exert immune stimulatory functions by secreting pro-
inflammatory cytokines including IL-1, IL-6 and IL-12. M2 macrophages express arginase-1 and the 
scavenger receptors CD206 and CD163 and mediate immunosuppression by the secretion of IL-10 and 
TGF-ß. 
 
1.1.4 Macrophages in diseases 
 
Macrophages play a crucial role in chronic inflammatory diseases such as atherosclerosis, 
obesity and cancer but also in allergies and wound healing [3, 52]. In many cases the balance 
between M1 and M2 macrophages is disrupted or shifted towards the one or other 
phenotype.  
One example for a disease that is associated with a M2 macrophage phenotype is asthma [53]. 
In this allergic disorder Th2 lymphocytes, macrophages, mast cells and eosinophils are 
recruited to the lungs. Thus, in the local microenvironment high levels of the Th2-associated 
cytokines IL-4, IL-13 and IL-33 polarize macrophages to a M2-like phenotype [54]. These 
airway macrophages produce cytokines and chemokines that recruit more Th2 cells, basophils 
and eosinophils. This positive feedback loop worsens the symptoms of the IgE-mediated, 
allergic disease [55, 56].   
Contrary, in autoimmune diseases such as inflammatory bowel disease, multiple sclerosis and 
rheumatoid arthritis most macrophages exhibit a proinflammatory phenotype by producing 
IL-12, IL-23 and TNF-α which are the key drivers of chronic inflammation [57]. M1-associated 
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cytokines (IL-1, IL-6 and IL-23) are also associated with the recruitment and expansion of Th17 
cells. These cells secrete high levels of the cytokine IL-17 which mediates chronic inflammatory 
diseases such as psoriasis [58, 59]. Thus, targeting pro-inflammatory mediators or 
reprogramming of M1-polarized macrophages to an anti-inflammatory phenotype is 
beneficial for patients suffering from such disorders.   
In line with this, M2-like macrophages can exert several protective roles, for example by 
counter-regulation of pro-inflammatory situations or by impairing T cell functions. Axon 
demyelination in the CNS is inhibited by IL-10 and TGF-ß producing macrophages since these 
immunosuppressive cytokines inhibit T cell activation or even increase apoptosis of effector 
T cells [60]. M1 macrophages can also be beneficial for the treatment of several diseases. ROS 
production by M1 macrophages protected mice from arthritis by impairing T cell function 
while M1-associated, pro-inflammatory cytokines promoted the killing of pathogenic 
commensal bacteria in Crohn’s disease [61, 62].   
The interplay between pro-and anti-inflammatory macrophages is very important in many 
pathological conditions such as wound healing. This multicellular process normally evolves in 
three steps: inflammation, tissue formation and maturation. Neutrophils are the first immune 
cells that are recruited to the injured tissue followed by the recruitment of monocyte-derived 
macrophages. By producing pro-inflammatory cytokines such as TNF-α, IL-6 as well as ROS 
these cells create an inflammatory environment [63, 64]. The induction of apoptosis in 
neutrophils and increased phagocytosis of these death cells by macrophages leads to an anti-
inflammatory macrophage phenotype important for the resolution of inflammation and the 
transition to the tissue formation phase. In the final step of wound healing, macrophages 
exhibit a pro-angiogenic and pro-fibrotic phenotype characterized by the production of VEGF 
and TGF-ß [65, 66]. In chronic non-healing wounds this switch fails, and macrophages retain 
the pro-inflammatory phenotype [67].   
Obesity is also associated with chronic inflammation. In obese humans, 40–50 % of all stromal 
cells of the white adipose tissue are macrophages compared to only about 10 % in the fat 
tissue of lean humans. Adipose tissue macrophages of non-obese individuals produce IL-10, 
whereas adipose tissue macrophages of obese humans produce high amounts of the pro-
inflammatory cytokines IL-6, TNF-α, IL-1ß and CCL2 [68]. In lean adipose tissue there are high 
levels of the Th2 cytokine IL-4, which is a main inductor of M2 macrophages [69]. This switch 
from anti-inflammatory macrophages to classically activated macrophages is induced by 
stimuli such as TNF-α and free fatty acids that induce pro-inflammatory signaling pathways 
including NF-κB and JNK associated with insulin resistance and type 2 diabetes [70, 71].  
A similar phenotypic switch in macrophage polarization is also observed during atherosclerosis 
which is a prerequisite for the development of cardiovascular diseases. During the 
development of atherosclerosis monocytes are recruited to the permeable arterial wall and 
differentiate into macrophages. Due to the uptake of lipoproteins macrophages become foam 
cells which express various inflammatory mediators such as IL-1, IL-6, TNF-α and CCL2 [72-74]. 
Free cholesterol triggers activation of inflammatory signaling pathways resulting in apoptotic 
cell death [75]. Impaired clearance of apoptotic macrophages by surrounding phagocytes is 
an important factor for the rupture of atherosclerotic plaques [52].   
Not only obesity and atherosclerosis but also the development of cancer is associated with 
chronic inflammatory conditions. Tumors are complex organ-like structures that consist of 
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malignant cells, stromal cells and hematopoietic cells including macrophages [47]. Most 
neoplastic disease are caused by chronic infection, obesity, tobacco smoke, alcohol abuse or 
irradiation [76]. All these extrinsic factors are associated with chronic inflammation, which is 
one of the hallmarks of skin cancer described by Hanahan and Weinberg [77]. Furthermore, 
intrinsic factors like mutations of oncogenes such as RET, RAS or MYC result in the activation 
of signaling pathways inducing the expression of growth factors and pro-inflammatory 
mediators. Thus, it is not surprising that during tumor initiation macrophages display a pro-
inflammatory phenotype [47]. The M1-associated cytokines TNF-α and IL-6 were shown to 
promote carcinogenesis [78, 79]. During tumor progression macrophages become tumor-
educated and transit to a more M2-like phenotype. The underlying mechanisms of this M1 to 
M2 transition are poorly understood [47]. These tumor-associated macrophages (TAM) elicit 
various pro-tumoral functions as described in the following chapter. 
 
1.2 Tumor-associated macrophages (TAM) 
 
In many solid tumors TAM are the most abundant type of immune cells. Macrophages are 
recruited by the chemokines CCL2, CCL5, CXCL12 (SDF1) which are secreted by either the 
tumor cells themselves or by other inflammatory cells of the tumor microenvironment [80]. 
Although various studies show that mainly monocyte-derived macrophages contribute to the 
pool of TAM, the contribution of tissue-resident macrophages is still under investigation [52]. 
These TAM, which predominantly exhibit an anti-inflammatory M2-like phenotype, support 
tumor growth and progression through the secretion of growth factors, matrix 
metalloproteinases (MMPs), immunosuppressive mediators as well as pro-angiogenic 
molecules (Figure 3) [47]. In many tumor entities including melanoma or clear renal cell 
carcinoma the number of macrophages is a negative prognostic factor since it correlates 
inversely with patient outcome [81-83]. Thus, TAM provide an interesting target for adjuvant 
tumor therapies. Although a M2-like macrophage phenotype is predominant in most tumor 
entities, pro-inflammatory macrophages with tumoricidal functions are also present in the 
tumor microenvironment [84]. In some tumor entities such as colorectal and prostate cancer 
abundance of tumor infiltrated macrophages correlates with prolonged patient survival [85-
87]. Thus, it is important to characterize macrophage subpopulations in different tumor 
entities and to identify markers that either function as prognostic markers or serve as 
potential therapeutic targets. 
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Figure 3. TAM exert various pro-tumoral functions. TAM support tumor growth and progression by 
production of various growth factors, matrix metalloproteinases (MMPs) and cathepsins. Through the 
secretion of chemokines (e.g. CCL17/18/22) TAM attract other immunosuppressive cells including 
myeloid-derived suppressor cells (MDSC) and regulatory T cells (Tregs) to the tumor microenvironment. 
TAM support immunosuppression and angiogenesis by the secretion of IL-10 and TGF-ß as well as pro-
angiogenic mediators.  
 
1.2.1 TAM promote tumor growth and metastasis 
 
Various in vitro and in vivo studies showed that macrophages can stimulate the proliferation 
and invasion of tumor cells. TAM secrete several growth factors such as epidermal growth 
factor (EGF), hepatocyte growth factor (HGF), platelet-derived growth factor (PDGF) and 
TGF-ß that can directly promote primary tumor growth by activating signaling pathways 
responsible for cell cycle progression and survival [47, 88]. In turn, tumor cells secrete factors 
that attract and polarize macrophages, creating a positive paracrine loop. Breast cancer cells 
for instance can produce colony stimulating factor 1 (CSF1, also known as M-CSF) which is the 
major cytokine for macrophage recruitment, maintenance and survival. CSF1 induces EGF 
expression by macrophages, which promotes tumor cell invasion by stimulating proliferation 
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of endothelial cells (ECs) [89-92]. TAM also express various chemokines and chemokine 
receptors that are not only crucial for their recruitment to the tumor microenvironment but 
also mediate their tumor-promoting function [93]. Müller et al. showed that the 
CXCL12/CXCR4 axis promotes breast cancer invasion and metastasis in vitro and in vivo [94]. 
TAM-derived CCL18 was shown to promote breast cancer metastasis by mediating integrin 
rearrangements and supporting the binding of tumor cells to extracellular matrix (ECM) 
components [95]. CCL17 is associated with the progression of hepatocellular carcinoma and 
poor overall survival [96]. Under hypoxic conditions, the increased expression of hypoxia 
inducible factor 1α (HIF1α) and hypoxia inducible factor 1ß (HIF1ß) in macrophages results in 
transcription of growth factors such as VEGF, PDGF, HGF and EGF [97, 98]. Furthermore, 
MMPs such as MMP-2, MMP-7 and MMP-9 are induced resulting in increased tumor cell 
invasion and metastasis [99]. Not only MMPs but also other proteases such as cathepsins are 
frequently expressed by M2 macrophages [100]. These proteolytic enzymes do not only 
trigger matrix degradation, they also foster the release of membrane-bound growth factors 
such as heparin-binding EGF (HB-EGF), thereby supporting tumor cell invasion [101]. Recently, 
Gocheva et al. showed that TAM-derived cathepsin B and S are important for pancreatic tumor 
growth and invasiveness [102]. Another protease that is frequently expressed by TAM is 
urokinase/plasminogen activator (uPA/PLAU). uPA as well as its receptor uPAR (PLAUR) also 
play an important role in the metastatic process [103, 104]. uPA is a protease that converts 
plasminogen to plasmin. The latter cleaves various ECM components such as fibronectin and 
laminin and converts zymogens such as MMPs to their active form [101]. Various studies 
showed that uPA correlates with cancer progression and metastasis and therefore can be used 
as a prognostic biomarker [105-107]. Due to the molecular mechanisms described above, a 
high number of TAM correlates with increased tumor cell migration and invasion in many 
tumor entities [108].  
 
1.2.2 TAM promote angiogenesis 
 
Angiogenesis is a physiological process describing the formation of new blood vessels from 
already existing vasculature. It encompasses endothelial cell proliferation, migration, tube 
formation and vessel stabilization. In the context of tumor progression, angiogenesis is a 
prerequisite for the formation of metastases at distant organs. In numerous tissues including 
brain, breast and lung, TAM abundance is associated with increased angiogenesis and 
metastasis [109, 110]. The formation of blood vessels is a complex, multi-step process 
triggered by multiple pro-angiogenic stimuli. VEGF, one of the major mediators of 
angiogenesis, is strongly produced by M2-like TAM. Serum VEGF concentration correlates with 
increased metastasis and impaired patient survival in many tumor entities including gastric 
cancer and ovarian cancer [111, 112]. Various pro-inflammatory cytokines such as IL-6 can 
induce VEGF expression. CXCL12, one of the major monocyte-attracting chemokines, was 
shown to induce VEGF expression in macrophages via binding to CXCR4 [113]. Under hypoxic 
conditions HIF1α induces VEGF expression thereby enhancing the formation of new blood 
vessels [109]. Since VEGF is a main contributor to tumor angiogenesis, a lot of effort has been 
put in the development of therapeutic strategies targeting the VEGF pathway. In advanced 
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colorectal cancer, combination of chemotherapy with anti-VEGF antibodies (bevacizumab) is 
the first-line treatment strategy [114]. However, the clinical benefits are limited and often 
linked to resistance to therapy [115]. Importantly, an increased tumor growth upon anti-VEGF 
treatment was observed in several murine tumor models. Although the precise mechanisms 
are not fully elucidated, one possible explanation is the induction of HIF1α under hypoxic 
conditions, which is associated with increased invasiveness of tumor cells [116, 117]. Xu et al. 
reported increased serum concentration of CXCL12 after bevacizumab treatment associated 
with a rapid progression of rectal cancer indicating a link between CXCL12/CXCR4 axis and the 
VEGF pathway [118].   
Not only CXCL12 but also other chemokines are important mediators of angiogenesis. CXC 
chemokines with an ELR-motif (CXCL1-3, CXCL5-CXCL8, CXCL12) promote angiogenesis 
whereas others (CXCL4, CXCL9-11) display angiostatic activities [119]. TAM secrete many of 
these pro-angiogenic chemokines while ECs express the corresponding receptors CXCR1, 
CXCR2 and CXCR4. Knockdown of the cytokine receptors CXCR1 and CXCR2 using shRNA 
inhibited EC proliferation, migration and other phenotypes crucial for angiogenesis [120]. 
CXCL7 was able to stimulate both tumor cell and EC proliferation and is a prognostic marker 
for patient survival in renal cell carcinoma. Administration of an anti-CXCL7 antibody 
significantly reduced tumor growth [121]. CXCL8 (IL-8), another pro-angiogenic cytokine 
secreted by TAM, is important for neovascularization and tumor progression [122].  
Besides pro-angiogenic chemokines, macrophages also express Wnt molecules (e.g. Wnt5a) 
that can bind to Wnt receptors on ECs, regulating proliferation and migration of these cells in 
vitro [110]. TAM-derived Wnt5a can also act in an autocrine manner by stimulating the 
expression of other pro-angiogenic mediators such as IL-8 and IL-6 [123]. Furthermore, Wnt5a 
was shown to up-regulate expression of IL-6, IL-8 and CCL2 in ECs [124]. In TAM of breast and 
colon cancer, the expression of Wnt molecules is up-regulated during tumor progression 
[110].   
Likewise, Notch signaling is important for vessel growth and maturation. Outtz et al. showed 
that Notch1 signaling in macrophages regulates retinal angiogenesis. Localization of 
macrophages as well as sprouting of ECs was altered in mice with Notch1-depleted myeloid 
cells indicating that communication between myeloid cells and ECs is mediated by Notch1 
signaling [125]. 
Many TAM in the tumor microenvironment express the angiopoietin receptor TIE2. These so-
called TIE2-expressing macrophages (TEM) are a pro-angiogenetic macrophage 
subpopulation. Angiopoietins are angiogenic molecules that are expressed by perivascular 
cells and bind to TIE1 and TIE2 tyrosine kinase receptors on ECs and macrophages [126, 127]. 
Ablation of TEM results in decreased angiogenesis, tumor growth and progression in several 
mouse models [128]. The abundance of TEM differs among tumor entities and TEM seem to 
accumulate after chemotherapy, radiotherapy and anti-angiogenic treatment to restore 
vessel integrity and rebuilt the vascular structure [129]. 
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1.2.3 TAM support an immunosuppressive tumor microenvironment 
 
M2-like TAM strongly express the anti-inflammatory cytokines IL-10 and TGF-ß [32, 130]. The 
latter triggers apoptosis of lymphocytes and favors the differentiation/induction of regulatory 
T cells (Tregs) [131, 132]. IL-10 was shown to inhibit the production of pro-inflammatory Th1 
cytokines, antigen presentation by downregulation of MHC class II and co-stimulatory 
molecules and thus impairs anti-tumor immunity and facilitates tumor growth and 
progression [133]. Besides IL-10 and TGF-ß, TAM secrete various chemokines (CCL17, CCL18 
and CCL22) that attract other immunosuppressive cells including Tregs and myeloid-derived 
suppressor cells (MDSC) to the tumor microenvironment [47, 134, 135]. Tregs inhibit effector 
T cells by expressing immunosuppressive molecules such as CD39 and CD73 [136-138]. The 
ectonucleotidases CD39 and CD73 cleave ATP to AMP and finally to the immunosuppressive 
molecule adenosine which inhibits effector T cell and NK cell function via binding to the 
adenosine receptors A2AR/A2BR [139]. Furthermore, adenosine was shown to increase the 
number as well as the immunosuppressive function of Tregs and MDSC [140-142]. In the steady 
state, Tregs prevent autoimmune diseases and are important for the tolerance of self-antigens 
[143, 144]. Besides macrophages, Tregs are the main producers of the immunosuppressive 
cytokines TGF-ß and IL-10 [133]. Since IL-10 is an important stimulus for M2 polarization of 
macrophages, Tregs orchestrate an immunosuppressive tumor microenvironment [145, 146]. 
In gastric cancer, the level of CCL17 and CCL22 positively correlates with Foxp3+ Tregs in the 
tumor microenvironment [147]. In line with this, CCL22 triggers infiltration of Tregs and can be 
used as a negative prognostic marker for survival of breast cancer patients [148].   
MDSC are immature myeloid cells that fail to terminally differentiate into mature granulocytes 
or monocytes/macrophages under pathological conditions such as chronic inflammation and 
cancer [149]. These immunosuppressive cells do not only inhibit cytotoxic T cell response but 
also affect the function of NK cells, macrophages and other myeloid cells. MDSCs express high 
levels of arginase-1 and produce ROS and NO thereby inhibiting T cell function. They also 
express PD-L1 which is an immunoinhibitory molecule for T cells [150, 151].   
Like MDSC, TAM express high levels of arginase-1, which converts L-arginine to ornithine 
thereby withdrawing it for iNOS-mediated NO production. L-arginine is an amino acid that is 
crucial for intact T cell function enabling the expression of TCRζ chain [47, 149]. Thus, 
arginase-1 expression is linked to an impaired anti-tumor immune response. Rodriguez et al. 
showed that L-arginine depletion in a murine lung carcinoma model reduced CD3ζ chain 
expression and proliferation of antigen-specific T cells. Furthermore, inhibition of arginase-1 
decreased tumor growth. High arginase-1 expression was found in tumor specimens of non-
small cell lung cancer patients [152].  
Since TAM are among the most abundant immune cells within the tumor stroma and exert 
various pro-tumorigenic functions as described above, several therapeutic strategies target 
these myeloid cells in different types of cancer. 
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1.2.4 TAM as therapeutic targets in cancer immunotherapy 
 
In the last decade, immunotherapies such as cancer vaccines, adoptive T cell transfer and 
especially immune checkpoint inhibitors have been proven successful in enhancing anti-tumor 
immunity and thereby overall survival of patients in many immunogenic tumors such as renal 
cell carcinoma and melanoma. Therefore, inhibition and depletion of immunosuppressive cells 
is a promising therapeutic approach, especially when combined with other 
immunomodulatory strategies [153]. 
Three options exist to target TAM [154]:  
1. Depletion of TAM 
2. Reprogramming of TAM 
3. Molecular targeting of TAM 
TAM depletion   
Since TAM mainly derive from monocytic progenitors of the bone marrow, deletion of TAM 
can be achieved by inhibiting their recruitment to the tumor microenvironment or by shorten 
their survival [153]. CSF1 (M-CSF) is one of the crucial cytokines for recruitment and 
differentiation of macrophages. Small molecule inhibitors or antibodies targeting CSF1R (e.g. 
PLX3397, PLX73086 and BLZ945) impaired macrophage survival and therefore decreased the 
number of infiltrating TAM in several studies [155-158]. Combination of anti-CSF1R with the 
immune checkpoint inhibitor anti-PD-1 decreased melanoma growth in vivo [159]. 
Furthermore, CSF1 blockade reversed resistance to chemotherapy in a breast cancer model 
[160]. Since monocyte-derived macrophages are mainly recruited via the CCL2-CCR2 axis, 
monoclonal antibodies against CCL2 and CCR2 are currently tested in clinical trials [161, 162].  
Reprogramming of TAM   
The second option is the reprogramming of TAM from an immunosuppressive, pro-tumoral 
phenotype to a pro-inflammatory, tumoricidal one.   
The prostaglandin-synthetizing enzyme cyclooxygenase-2 (COX-2) is important for M1 to M2 
transition and application of the COX-2 inhibitor celecoxib results in a decrease of M2 
macrophages and increased IFN-γ levels in colon carcinoma [163].   
The co-stimulatory molecule CD40 is expressed on APCs and binds to CD40 ligand (CD40L) on 
T cells providing the co-stimulatory signal for T cell response [164]. Agonistic CD40 antibodies 
induced the expression of IL-12 as well as MHC molecules, activated differentiation of 
T effector cells and inhibited tumor growth in several mouse models [165]. Combined 
treatment with anti-CSF1R and CD40 agonists repolarized macrophages prior to their deletion 
enabling an efficient T cell response [166, 167].   
Since activation of transcription factors also determine whether macrophages display a M1 or 
M2 phenotype, targeting these signaling molecules is a promising tool for reprogramming 
macrophages [47]. Although increased NF-κB signaling favors the early steps of carcinogenesis 
aberrant NF-κB signaling via p50 homodimers results in reduced expression of pro-
inflammatory mediators such as IL-12 and TNF-α in TAM during tumor progression. Thus, 
targeting p50 NF-κB induces a M1 macrophage phenotype and leads to tumor regression 
[168]. Depletion of phosphatidyl inositol 3 kinase γ (PI3Kγ) reduced the expression of TGF-ß, 
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IL-10 and arginase-1 in TAM of Lewis lung carcinoma (LLC) tumors and supported cytotoxic 
T cell response. Furthermore, the PI3Kγ inhibitor TG100-15 enhanced the response to anti-
PD1 treatment and reduced growth of head and neck squamous carcinoma in vivo [169]. 
Administration of TLR7/8/9 agonists re-polarized macrophages to a pro-inflammatory, 
tumoricidal phenotype in several tumor models [170, 171]. Thus, imiquimod and other TLR 
agonists are either already established therapies or tested in clinical trials. 
Molecular targeting of TAM   
Molecular targeting of TAM molecules is another approach to inhibit their 
immunosuppressive phenotype. Two prominent examples are arginase-1 inhibitors or FcγR-
blocking antibodies. Both strategies enhanced the efficacy of anti-PD1 treatment and 
suppressed tumor growth in different mouse models [172, 173]. 
All the described TAM-targeted therapies are especially successful in immunogenic tumors 
such as melanoma since these tumors are characterized by a high infiltration of 
immunosuppressive cells. 
 
1.3 Malignant melanoma 
 
1.3.1 Epidemiology, risk factors and pathophysiology 
 
Epidemiology   
Malignant melanoma is one of the most common tumors, but the incidence strongly varies 
between different countries. Without counting other types of skin cancer, melanoma was the 
5th most common type of cancer in men and the 6th most common in women in the USA in 
2017 [174]. Although melanoma is only the 4th most common type of skin cancer, it accounts 
for approximately 80 % of skin cancer related deaths [175]. One reason is the rapid 
development of metastases in lung, liver, brain and bone marrow which cause around 90 % of 
cancer-related deaths. The median age of diagnosis is 57 years indicating that melanoma 
mostly affects middle-aged individuals. Melanoma incidence is slightly higher in men but 
increased dramatically in both sexes during the last years [176]. 
Risk factors   
Several environmental and genetic risk factors contribute to melanoma development. One of 
the major risk factors is ultraviolet (UV) light radiation. More than 80 % of melanoma cases 
can be linked to UV light exposure [177]. Interestingly, the patterns of sun light exposure 
determine the risk to develop melanoma. Studies showed that intense, intermitted exposure 
to UV light is a greater risk factor than chronic sun exposure [178, 179]. In line with this, the 
number of sunburns in childhood and adolescence positively correlates with melanoma 
incidence [180, 181]. UV radiation causes gene mutations, impairs cutaneous immunity and 
induces the production of ROS that further damage melanocytes and other cells [175]. One 
intrinsic mechanism that protects the skin against UV radiation is melanin production in 
melanocytes. α-melanocyte stimulating hormone (αMSH) and the melanocortin receptor 1 
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(MC1R) are the main players in melanin synthesis [182]. Thus, skin pigmentation and tanning 
type are determining factors for melanoma susceptibility [183]. Light-skinned and red-headed 
people often carry germ-line polymorphisms in the MC1R gene and therefore are at greater 
risk to develop melanoma [184-186]. This example shows that genetic susceptibility plays a 
crucial role in melanoma development. Besides UV radiation and genetic predisposition, 
immunosuppression is another risk factor for melanoma development. Studies have shown 
that immunocompromised patients such as organ transplant recipients, patients with HIV or 
lymphoproliferative diseases such as non-Hodgkin lymphoma or chronic lymphocytic 
leukaemia are at greater risk to develop melanoma, showing that the immune system plays a 
crucial role in melanoma biology [187]. Another risk factor is the number and type of 
melanocytic naevi [188-191]. 
Pathophysiology   
Although 25 % of melanomas develop from a pre-existing naevus, most melanomas develop 
de novo, meaning that they derive from a newly formed melanocytic lesion. However, in both 
cases some genetic alterations (point mutations, gene amplification) are responsible for the 
malignant transformation of melanocytes to metastatic melanoma [174]. Thus, melanoma is 
characterized by a high mutational load. Since UVA and UVB cause C to T and G to T transitions, 
respectively, these point mutations are frequently found in melanoma [192, 193]. Activating 
mutations of oncogenes are also commonly detected in melanoma and are required for the 
initial steps of melanocytic transformation. Somatic mutations of BRAF and NRAS are 
associated with 50 % and 15 % of melanomas, respectively, resulting in constitutive activation 
of the ERK-MAPK signaling pathway [194]. Interestingly, BRAF mutations can not only be 
detected in primary and metastatic melanoma but also in benign naevi [195]. Mutant BRAF 
can induce cell senescence by inducing the expression of inhibitor of cyclin-dependent 
kinase 4a (INK4A), thereby abrogating malignant transformation [196]. Additional mutations, 
for instance in the telomerase reverse transcriptase (TERT) promoter, are required for 
melanoma progression [197]. Inactivating mutations of tumor-suppressor genes are 
responsible for the transition of malignant melanoma to invasive melanoma. The two tumor-
suppressor genes p16/INK4A and p14/ARF, encoded by the CDKN2A locus, abrogate cell cycle 
progression by inhibiting cyclin-dependent kinases (CDK) [198]. Besides, loss-of-function 
mutations of the tumor-suppressor gene phosphatase and tensin homolog (PTEN) can be 
detected in 25–50 % of non-familial melanoma. PTEN inhibits PI3K/Akt signaling pathway 
which promotes cell survival by phosphorylation/inactivation of pro-apoptotic proteins such 
as Bcl-2 antagonist of cell death (BAD) [199]. PTEN and TP53 mutations are associated with 
metastatic melanoma [174]. 
On the protein level, integrins and cadherins play a crucial role in the development of invasive 
and metastatic melanoma [175]. Both transmembrane proteins function as cell adhesion 
molecules. While cadherins provide cell-cell contacts, integrins support adhesion to the ECM. 
Increased αVß3 integrin expression during malignant transformation promotes the invasion 
of melanoma cells, for instance by up-regulating MMP-2 expression [200, 201]. Furthermore, 
αVß3 integrin promotes the survival of melanoma cells by inducing the expression of the anti-
apoptotic protein Bcl-2 [202]. E-cadherin was shown to be involved in the adhesion of 
melanocytes to keratinocytes thereby controlling melanocytic cell growth [203]. Invasive 
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melanoma is characterized by the loss of E-cadherin and up-regulation of N-cadherin 
expression [204]. This down-regulation of E-cadherin is also linked to increased ß-catenin 
signaling [205]. Free intracellular ß-catenin acts as a co-transcription factor and induces the 
expression of genes that are responsible for proliferation, migration, and survival of 
melanoma cells. The translocation of ß-catenin to the nucleus is also induced by Wnt 
molecules that can be produced by melanoma cells [206]. Besides cyclin D1 and MMP-7, 
ß-catenin induces the expression of microphthalmia-associated transcription factor (MITF) 
[207]. Although MITF is essential for the differentiation and cell cycle arrest of normal 
melanocytes, melanoma cells evade these mechanisms [175]. By inducing Bcl-2 expression 
MITF can stimulate proliferation and survival of melanoma cells [208]. Increased copy 
numbers of a gene region containing the MITF locus were observed in melanoma, suggesting 
MITF as an oncogene. Indeed, MITF over-expression occurs mainly in melanomas with a poor 
prognosis [209]. 
Not only gene mutations and other tumor intrinsic factors but also tumor- or stroma-derived 
mediators such as growth factors, cytokines and chemokines promote melanoma growth and 
progression. Furthermore, environmental factors such as hypoxia, ECM components and 
particularly the immuno-microenvironment affect melanoma progression [174]. 
 
1.3.2 Melanoma immuno-microenvironment 
 
Due to the high mutational load in melanoma, there is a high number of neoantigens that are 
presented to effector T cells [210]. Thus, melanoma is an immunogenic tumor with a strong 
infiltration of inflammatory cells such as T cells, B cells, NK cells, macrophages and other 
immune cells [211]. However, melanoma cells have developed various strategies to evade an 
anti-tumor immune response. Melanoma-induced immunosuppression is mediated by down-
regulation of MHC class I molecules as well as tumor antigens, increased expression of 
immunoinhibitory receptors such as PD-L1, production of immunosuppressive cytokines 
(IL-10, TGF-ß) and the induction of immune tolerance. The melanoma-induced immune escape 
is accompanied and enhanced by the infiltration and activation of immunosuppressive cells in 
the tumor stroma. These cells include M2-like TAM, MDSC, Tregs, and tolerogenic/regulatory 
DCs [212]. 
TAM are the strongest immune cell population within the melanoma microenvironment and 
the presence of TAM negatively correlates with outcome of melanoma patients [82, 83, 211]. 
They exert various pro-tumorigenic and immunosuppressive functions as already described in 
chapter 2. Through the secretion of certain chemokines such as CCL22 M2-polarized TAM as 
well as melanoma cells attract other immunosuppressive cells including MDSC and Tregs to the 
tumor microenvironment [213]. MDSC are immature myeloid cells that – under chronic 
inflammation – do not differentiate into macrophages, DCs or granulocytes. In humans, they 
can be divided into HLA-DR-/low CD11b+ CD14- CD15+ granulocytic/polymorphonuclear MDSC 
(PMN-MDSC) and HLA-DR-/low CD11b+ CD14+ CD15- monocytic MDSC (M-MDSC). MDSC share 
a lot of molecular characteristics with M2-like TAM. They both up-regulate PD-L1 thereby 
blocking T cell response. In addition, increased arginase-1 expression results in L-arginine 
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depletion thereby impairing TCRζ chain expression. MDSC further up-regulate iNOS expression 
and produce high amounts of NO and ROS, that either cause apoptosis of T cells or impair T 
cell function by nitration of the TCR [134, 135, 150]. Increased numbers of M-MDSC were 
detected in the peripheral blood of stage III-IV melanoma patients compared to healthy 
donors and this is associated with elevated levels of pro-inflammatory mediators such as IFN-
γ and IL-1ß [149]. Other studies showed that the frequency of both M-MDSC and PMN-MDSC 
positively correlates with tumor burden [214, 215]. Furthermore, the number of circulating 
MDSC is associated with poor survival of melanoma patients and with decreased number of 
antigen-specific T cells [215]. MDSC also facilitate the differentiation of CD4+ T cells into 
CD4+ CD25+ Tregs that express high amounts of IL-10 and TGF-ß [216]. These 
immunosuppressive cytokines inhibit effector T cell and NK cell function. Several studies 
proofed the correlation between Treg abundance and melanoma progression [217]. 
Furthermore, a high count of Tregs is associated with low levels of IL-2 or IL-12, which both 
promote anti-melanoma immunity [218]. Recently, a negative correlation between the 
presence of Tregs and DCs was observed in advanced melanoma [217]. DCs are the most 
efficient APCs and like macrophages they show a high plasticity. Previously, they were divided 
into myeloid DCs (mDCs), exerting immune-stimulatory functions, and plasmacytoid DCs 
(pDCs) which are tolerogenic DCs [219]. In the melanoma microenvironment, DCs are 
polarized towards a tolerogenic phenotype, displaying impaired ability for antigen 
presentation. These DCs are induced by VEGF, IL-10, TGF-ß and IL-13 [220]. Defects in DC 
maturation as well as CD80 and CD86 expression were observed in melanoma [221]. 
Furthermore, melanoma cells can induce apoptosis of DCs (mainly pDCs), resulting in 
decreased IFN-α production and poor prognosis [222]. During melanoma progression there is 
a decrease in the number of both types of DCs. In stage IV melanoma, the number of mDCs 
inversely correlates with abundance of Tregs [217, 221]. Decreased number of mature DCs were 
also observed in melanoma lesions of Ret transgenic mice, accompanied by increased 
numbers of MDSC [223]. 
Anti-melanoma immune response is mainly mediated by cytotoxic T cells and innate NK cells. 
Since tumor infiltrating lymphocytes (TIL) favor tumor regression, they are a predictive marker 
for good prognosis in patients with primary melanoma [224]. However, down-regulation of 
MHC class I molecules by tumor cells and T cell anergy, induced by the immunosuppressive 
melanoma microenvironment, impair an adequate T cell response [225].  
NK cells are cytotoxic lymphocytes of the innate immune system that rapidly kill infected or 
malignant cells, either by lysis or by inducing apoptosis. Since NK cells can also destroy 
melanoma cells expressing low levels of MHC class I molecules, they are promising candidates 
to improve the anti-melanoma immunity. However, NK cell exhaustion or down-regulation of 
activating receptors was observed in melanoma patients. In addition, IFN-γ produced by NK 
cells was shown to induce IDO and prostaglandin E2 (PGE2) secretion by melanoma cells, 
which both can suppress the expression of activating receptors on NK cells [226-228]. 
Therefore, restoration of T cell and NK cell function as well as DC-based therapies (cancer 
vaccination) provide promising therapeutic tools to overcome melanoma-induced immune 
escape. 
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1.3.3 Melanoma immunotherapy 
 
Since melanoma is a highly immunogenic tumor characterized by a strong infiltration of 
immune cells, efforts have been made to improve the anti-melanoma immune response [229]. 
In general, two signals are needed for an adequate T cell response (Figure 4). The first signal 
is the binding of the TCR to MHC I or MHC II on tumor cells and APCs, respectively. The second 
signal (co-stimulatory signal) is provided by binding of B7 molecules (B7.1 = CD80 and 
B7.2 = CD86), expressed on APCs, to CD28 on T cells or by CD40-CD40 ligand (CD40L) 
interactions. However, B7 molecules can also bind to CTLA-4 on T cells, providing a co-
inhibitory signal for T cells. In addition, tumor cells and myeloid cells can express PD-L1 and 
PD-L2 which bind to PD-1 on T cells, transmitting an inhibitory signal [230]. This results in 
suppression of T cell proliferation and reduced effector T cell function. Under physiological 
conditions these inhibitory signals are important to prevent chronic inflammation [231]. 
However, in melanoma and other tumor entities such as renal cell carcinoma, a high 
expression of the inhibitory molecules PD-L1 and PD-L2 is associated with accelerated tumor 
growth and progression as well as with impaired overall survival [232, 233]. Thus, negative 
checkpoint inhibitors have been developed to block these co-inhibitory signals, thereby 
activating cytotoxic T cell response and promoting anti-tumor immunity. Ipilimumab, an anti-
CTLA4 antibody, was the first drug that was approved for the treatment of metastatic 
melanoma in 2011 by the US Food and Drug Administration (FDA) [234]. In 2014, the two anti-
PD1 antibodies pembrolizumab and nivolumab were approved by the FDA for the treatment 
of advanced melanoma [235, 236]. Later, they were also approved for the treatment of other 
tumor entities including renal cell carcinoma and non-small cell lung cancer. A combination of 
nivolumab and ipilimumab is now approved as a first-line treatment for advanced renal cell 
carcinoma and melanoma (https://www.drugs.com/history/keytruda.html 
https://www.drugs.com/history/opdivo.html). The next generation of immune checkpoint 
inhibitors, anti-PD-L1 antibodies (atezolizumab), are already approved for the treatment of 
advanced bladder cancer and specific types of lung cancer. Clinical trials using anti-PD-L1 
antibodies for the treatment of melanoma are still ongoing.  
Although immune checkpoint therapy is quite successful in melanoma, renal cell carcinoma or 
lung cancer, it is less efficient in non-immunogenic tumors such as breast or pancreatic cancer. 
One possible explanation for the resistance to checkpoint inhibitors is the low mutation rate 
in some tumor entities linked to a low number of neoantigens that are presented to CD8+ 
T cells [210]. Furthermore, these tumors exhibit a low number of TIL while most T cells 
accumulate in the peritumoral stroma and only few infiltrate the tumor parenchyma [237, 
238]. However, also in immunogenic tumors immunotherapy is still not satisfactory. 
Melanoma cells evade immune surveillance by down-regulation of MHC class I expression 
resulting in impaired antigen presentation and thus diminished anti-tumor immunity [239]. 
Furthermore, the presence of immunosuppressive cells within the tumor stroma limits 
effector T cell function [212]. Thus, combining immune checkpoint inhibitors with TAM-
targeted therapies is a promising novel approach to fight against cancer [240]. Depletion of 
TAM by targeting CCR2 or CSF1R was shown to efficiently improve anti-tumor immune 
response mediated by immune checkpoint inhibitors [157, 161]. However, until now, there is 
only pre-clinical data available and clinical trials are still ongoing. Since research in this field is 
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still in the beginning, identifying targetable TAM molecules is of huge interest. In general, 
many molecules that can be targeted pharmaceutically are G protein coupled receptors 
(GPCR). Chemokine receptors and many purinergic receptors are GPCRs that are frequently 
expressed by immune cells present in the tumor microenvironment. Elucidating the function 
of these receptors on immunosuppressive cells such as TAM might help to identify novel 
therapeutic targets. 
 
Figure 4. Immune checkpoint inhibitors in melanoma. Besides binding of the T cell receptor (TCR) to 
the MHCII – antigen complex, a second signal is required to activate T cells. The co-stimulatory 
molecules CD80 and CD86 induce T cell response by binding to CD28. If they bind to CTLA4 or when 
PD-L1 binds to PD1 the T cell response is inhibited. Checkpoint inhibitors including anti-CTLA-4, anti-
PD1 and anti-PD-L1 antibodies target these immunoinhibitory receptors to improve anti-melanoma 
immune response. 
 
1.4 Purinergic receptors 
 
1.4.1 Classification and function 
 
Purinergic receptors are expressed in nearly all mammalian tissues triggering distinct 
physiological processes including heart rate, muscle tonus, neuronal processing, nociception, 
bone homeostasis, immunity and inflammation. Purinergic receptors can be divided into P1 
receptors, also known as adenosine receptors, and P2 receptors (Figure 5). Whereas P1 
receptors are GPCRs activated by adenosine, P2 receptors are activated by nucleotides and 
can be further subdivided into P2X receptors which are ligand gated ion channels and P2Y 
receptors which are metabotropic GPCRs. P2X receptors are activated only by ATP while P2Y 
receptor are activated by diverse nucleotides. P2Y1, P2Y12 and P2Y13 are activated by ADP, 
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whereas ATP activates P2Y2 and P2Y11. UTP is the agonist for P2Y2 and P2Y4. P2Y6 is activated 
by UDP and UDP-glucose is the ligand for P2Y14. Interestingly, P2Y11 can interact with P2Y1 
and is absent in rodents [241]. 
 
 
Figure 5. Classification of purinergic receptors. P1 receptors, also known as adenosine receptors, are 
activated by adenosine whereas P2 receptors are activated by nucleotides. There are 7 members of 
P2X family that are all activated by ATP and 8 members of the P2Y family with different substrate 
specificity. 
 
Adenosine receptors can be further subdivided in 4 subtypes: A1, A2A A2B and A3. All these 
receptors exert different but partially overlapping functions. Adenosine receptors have a 
broad tissue distribution and are expressed almost ubiquitously throughout the body [242, 
243]. Caffeine and other xanthine derivates such as theophylline are natural antagonist of 
adenosine receptors [244].   
In the heart, adenosine receptors regulate heart rate and blood flow by triggering 
vasoconstriction [245]. In the CNS, they regulate release of neurotransmitters such as 
dopamine [246]. A2AR is also strongly expressed in lymphatic organs such as the spleen and 
thymus and is expressed on immune cells including lymphocytes and macrophages [247]. Like 
A2AR, A2BR plays an important role in innate immunity and inflammation. A3R is involved in 
chemotaxis of neutrophils and macrophages [248, 249]. In general, adenosine receptors 
mediate immunosuppression, thereby counteracting pro-inflammatory conditions and 
limiting tissue damage [250].  
Like adenosine receptors P2X receptors are present in almost all tissues. Functional receptors 
consist of homotrimers or heterotrimers while each subunit consist of two transmembrane 
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domains. Extracellular binding of ATP binding results in conformational change of the receptor 
followed by opening of ion channels. Cations such as Na+ and Ca+ enter through these pores 
thereby depolarizing the cell membrane. In the heart, musculature or vasculature this results 
in contraction of cardiac muscle, skeletal muscle and smooth muscle cells, respectively. P2X 
receptors are also expressed in neurons and glial cells mediating synaptic transmission, signal 
integration and nociception. On immune cells they modulate activation, proliferation and 
apoptosis [251]. P2X1, P2X4 and P2X7 receptors, for instance, are expressed on leukocytes 
including T cells, macrophages and DCs. Besides being important for T cell activation, they 
trigger chemotaxis of myeloid cells [252]. P2X7 has a unique physiology since it has a low 
affinity for ATP and is only activated in highly inflamed tissue. Furthermore, it can build large 
pores by which endogenous ATP can be released [253]. 
P2Y receptors are GPCRs that signal via heterotrimeric G proteins. There are various subtypes 
of G proteins consisting of different alpha subunits that activate distinct signaling pathways 
P2Y1/2/4/6 and 11 are coupled to Gq/11 that activates phospholipase Cß (PLCß), resulting in 
increased intracellular calcium levels through the second messenger IP3. Besides Gq/11, P2Y11 
couples to Gs that activates adenylyl cyclase, triggering cAMP generation from ATP. P2Y12, 
P2Y13, and P2Y14 are coupled to Gi proteins that inhibit adenylyl cyclase. The Gßγ subunit of 
the heterotrimeric G proteins can activate other effector enzymes such as PI3Kγ [241, 254]. 
Like other purinergic receptors, P2Y receptors are universally expressed and exert various 
functions throughout the body. They mediate platelet activation and aggregation, 
vasodilatation and chemotaxis of microglial cells as well as other immune cells [255, 256]. Like 
P2X receptors, they are involved in proliferation, migration and activation (e.g. cytokine 
production) of leukocytes thereby modulating immune responses [252]. 
 
1.4.2 Purinergic signaling regulates inflammation and immunity 
 
During the last decade, various P1 and P2 receptors have been identified on immune cells 
indicating that they influence inflammation and immunity [252, 257]. In inflamed tissue, 
necrotic and apoptotic cells release high levels of ATP and other nucleotides which act as find-
me or danger signals for phagocytic cells such as macrophages, neutrophils and DCs [258, 259]. 
Purinergic receptors on these myeloid cells are essential to sense the extracellular 
nucleotides. The purinergic receptor P2Y2 is important for the chemotaxis of neutrophils, 
eosinophils, DCs as well as monocytes [252, 260]. After recruitment to the site of inflammation 
they trigger phagocytic clearance of dead or dying cells [260]. Not only damaged or stressed 
cells can release nucleotides but also intact cells including leukocytes themselves. Controlled 
ATP release was first observed in neurons that release ATP via vesicles [261]. However, in the 
last years, several other mechanisms of ATP release were discovered. ATP can be released by 
connexin and pannexin hemichannels, voltage-dependent anion channels as well as by the 
purinergic receptor P2X7 itself [262]. Several types of immune cells including activated T cells 
or neutrophils were shown to release ATP via pannexin-1 hemichannels [263-266]. 
Interestingly, the released ATP does not only provide a paracrine signal for other immune cells 
but also signals in an autocrine manner. In neutrophils, chemotactic stimuli – IL-8 in humans 
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or fMLP in mice – induce ATP release, promoting chemotaxis of these cells by autocrine 
purinergic signaling via P2Y2 [267]. In macrophages, the complement component 5a (C5a) 
induces ATP release, creating a positive feedback loop by purinergic signaling via P2Y2 and 
P2Y12 [268]. In DCs, extracellular ATP promotes the migration of the cells by stimulating ATP 
release through pannexin-1 channels and autocrine purinergic signaling via P2X7 receptors 
[269]. These results indicate that autocrine purinergic signaling induced by extracellular 
stimuli or paracrine signals promotes the chemotaxis of myeloid cells. ATP does not only 
promote directed migration but also modulates maturation, activation and polarization of 
myeloid cells. In DCs, several purinergic receptors are involved in cell maturation [270]. P2Y11, 
for instance, was shown to be down-regulated upon differentiation of monocyte-derived DCs 
[271]. In macrophages, extracellular ATP triggers inflammation and innate immunity by 
activation of the NLRP3 inflammasome. Released ATP in response to DAMPS and PAMPs 
induces autocrine purinergic signaling via P2X7. This results in processing and release of IL-1ß 
and IL-18 from the inflammasome in a caspase-1 dependent manner. In P2X7 deficient mice, 
IL-1ß release upon LPS and ATP treatment is abrogated [272, 273]. T cells can also release ATP 
in response to extracellular signals or upon TCR activation. By autocrine signaling via P2X1, 
P2X4 and P2X7, ATP promotes IL-2 production and T cell proliferation [265, 274]. 
Extracellular ATP is rapidly metabolized by ectonucleotidases comprising four family 
members: the ectonucleoside triphosphate diphosphohydrolase (ENTPD) family, the 
ectonucleotide pyrophosphatase/phosphodiesterase (ENPP) family, alkaline phosphatase and 
ecto-5’-nucleotidase (CD73). ENTPD family members, including ENTPD1 (CD39), hydrolyze ATP 
or ADP to AMP while ENPPs cleave ATP to AMP and pyrophosphate. Alkaline phosphatases 
hydrolyze ATP, ADP and AMP to adenosine whereas CD73 only converts AMP to adenosine. 
Ectonucleotidases have a broad tissue distribution pattern and are expressed on several 
immune cells, including Tregs and macrophages [275, 276]. In monocytes/macrophages 
adenosine reduced the secretion of the pro-inflammatory cytokines TNF-α, IL-6 and IL-8 and 
induced the expression of IL-10, revealing that adenosine is an immunosuppressive mediator 
[277, 278]. Thus, ectonucleotidases are important to resolve inflammatory conditions. The 
suppressive effect of the produced adenosine mainly occurs via A2A receptors, which are up-
regulated during inflammation. In T cells and NK cells, A2AR signaling inhibits their cytotoxic 
function by suppressing IL-2 and IFN-γ expression [252]. In neutrophils, A2AR signaling is 
involved in limiting ATP-induced chemotaxis [279]. Thus, A2AR-deficient mice showed 
increased tissue damage and inflammation in several disease models [280]. Accordingly, 
Entpd1-deficient mice developed severe inflammation after tissue injury [281]. While A2AR is 
widely expressed by immune cells, the adenosine receptor A2BR is mainly expressed by 
macrophages and DCs [252]. Hamidzadeh and Mosser proposed that A2BR is involved in 
terminating pro-inflammatory response of M1 macrophages. They showed that TLR-
stimulated macrophages release ATP through pannexin 1 channels. The extracellular ATP is 
rapidly cleaved by CD39 and CD73 which are both expressed on macrophages. The generated 
adenosine binds to A2AR and A2BR receptors and suppresses the expression of the pro-
inflammatory cytokines IL-12 and TNF-α while increasing the expression of IL-10 [282]. 
Adenosine receptors were shown to be strongly up-regulated by TLR ligands, DAMPs and 
hypoxia [252]. A2BR-deficient macrophages secrete higher levels of pro-inflammatory 
cytokines but less immunosuppressive mediators [283]. Consequently, A2BR-deficient mice 
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showed severe inflammation after tissue injury. Interestingly, A2BR also contributes to 
angiogenesis and fibrosis by inducing VEGF and IL-6 expression [284, 285].  
Besides signaling through P1 receptors, adenosine can be metabolized by adenosine 
deaminases (ADAs) that convert adenosine to inosine. ADAs are expressed on leukocytes and 
promote T cell response by the production of Th1 cytokines and stimulation of T cell 
proliferation [286, 287]. Besides being enzymatically converted, adenosine can also be up-
taken by cells expressing specific nucleoside transporters. They were shown to be involved in 
the activation and proliferation of lymphocytes and macrophages [288, 289]. Thus, blocking 
adenosine uptake or conversion provides an additional therapeutic strategy for the treatment 
of chronic inflammatory diseases and autoimmune disorders. The application of adenosine 
receptor agonists for the treatment of rheumatoid arthritis is currently tested in clinical trials. 
In contrast, adenosine receptor antagonists might be helpful in diseases with increased A2BR 
signaling including chronic obstructive pulmonary disease (COPD) and asthma. Since 
adenosine promotes immunosuppression and limits anti-tumor immunity blockade of 
adenosine signaling might also be efficient in the tumor microenvironment [252, 290]. 
 
1.4.3 Purinergic receptors in the tumor microenvironment 
 
Due to inflammation, necrosis and hypoxia there are high levels of ATP and adenosine in the 
tumor microenvironment. Both directly modulate tumor growth and progression as well as 
the activity and function of immune cells of the tumor microenvironment thereby affecting 
the anti-tumor immunity (Figure 6) [252]. Besides Tregs and macrophages, tumor cells can 
express the ectonucleotidase CD73 that converts AMP to adenosine thereby creating an 
immunosuppressive tumor microenvironment. Ectonucleotidases were shown to be up-
regulated under hypoxic conditions [291]. In several murine tumor models, deletion or 
blocking of CD73 reduced primary tumor growth and metastasis and restored CD8+ T cell 
activity [292, 293]. In human breast cancer patients, CD73 expression is associated with poor 
outcome [294]. The generated adenosine exerts multiple functions on distinct immune cell 
populations in the tumor microenvironment. On the one hand, adenosine signaling via A2AR 
suppresses cytotoxic T cell response and NK cell activity and on the other hand adenosine 
enhances the immunosuppressive capacity of macrophages, MDSC and Tregs [252]. A2AR-
deficient myeloid cells exhibited reduced IL-10 expression resulting in reduced tumor growth 
and lung metastasis [295]. Although global A2AR deletion was shown to increase the number 
of TILs and decelerated tumor growth, specific deletion of A2AR in T cells can result in 
increased T cell exhaustion and apoptosis and thus enhanced tumor growth, indicating that 
A2AR regulates not only cytotoxicity but also survival of T cells [296]. Besides expressing A2AR, 
T cells express several P2 receptors, including P2X1, P2X4, P2X7 and P2Y12. Whereas 
adenosine receptors suppress the proliferation and cytotoxicity of T cells, ATP receptors 
activate NF-κB signaling and promote proliferation and cytotoxicity of T cells [252]. 
The balance between ATP and adenosine in the tumor microenvironment also determines 
macrophage polarization (Figure 6). Binding of ATP to P2 receptors (e.g. P2X7) on 
macrophages promotes a pro-inflammatory M1 phenotype by inducing the expression of pro-
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inflammatory cytokines whereas adenosine triggers a M2 polarization of macrophages via 
A2AR [252]. Besides expressing IL-10 and TGF-ß, M2 macrophages express higher levels of 
CD39 and CD37 compared to M1 macrophages, thereby augmenting the immunosuppressive 
microenvironment [297].  
As discussed previously, macrophages also express the adenosine receptor A2B. Besides 
reducing the expression of the proinflammatory cytokines TNF-α and IL-12, A2BR signaling 
induces the expression of the pro-angiogenic mediators VEGF and IL-6 [252, 282]. Since tumor 
cells themselves also express A2BR, blockade of A2BR can reduce tumor growth and 
metastases formation [298, 299]. Furthermore, tumor cells express P2X7 receptors that are 
involved in proliferation and P2X7 blockade reduced tumor growth. This pro-tumoral role of 
P2X7 is quite contradictory to the role of P2X7 in myeloid cells where P2X7 signaling induces 
IL-1ß secretion, activates CD8+ T cells and is important for the chemotaxis of DCs [252]. P2X7-
deficient mice exhibited decreased numbers of tumor-infiltrating inflammatory cells, while 
tumor growth and progression were significantly enhanced [300]. Cancer therapy including 
chemotherapy was shown to induce ATP release from damaged tumor cells [301]. This ATP 
can activate P2X7 receptors on DCs and macrophages resulting in IL-1ß production and 
increased anti-tumor immunity, for instance by activating IFN-γ-producing T cells [302]. 
Targeting adenosine receptors might be a promising approach to reduce tumor growth and 
progression. Due to the dual role of A2AR regarding T cell function and survival it might be 
more efficient to block A2BR signaling that mainly modulates myeloid cells in the tumor 
microenvironment [252]. 
 
 
Figure 6. Purinergic signaling in the tumor microenvironment. Adenosine and ATP directly affect 
tumor cell proliferation and metastasis and modulate the function of macrophages and CD8+ T cells. 
ATP induces M1 polarization of macrophages and promotes T cell proliferation and cytotoxicity by 
inducing NF-κB signaling via P2 receptors. Contrary, adenosine signaling via A2AR induces M2 
polarization of macrophages, inhibits TCR signaling and thus cytotoxic T cell response. Adenosine binds 
to A2BR on tumor cells promoting metastasis. On macrophages A2BR signaling induces M2 polarization 
and promotes angiogenesis by the secretion of VEGF and IL-6. Figure adapted from Cekic and Linden 
[252]. 
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1.5 The purinergic receptor P2Y12 
 
1.5.1 Structure and signaling of P2Y12 
 
Like other P2Y receptors, P2Y12 is a GPCR with 7 transmembrane domains. It has an 
extracellular N terminus, three extracellular loops, three intracellular loops and an 
intracellular C terminus. Two extracellular disulfide bridges are built by four cysteine residues. 
The human P2Y12 proteins contains 342 amino acids and there is an 83 % sequence homology 
between mouse and human [241]. The two existing N-linked glycosylation sites are important 
for signal transduction but not for ligand binding [303]. Among P2Y12 agonists the synthetic 
ADP analogue 2-methylthio-adenosine-5'-diphosphate (2-MeSADP) has the highest affinity, 
followed by ADP (Figure 7). Although P2Y12 was considered to be a selective ADP receptor, 
recent studies showed that ATP also activates P2Y12, but it is less potent and higher 
concentrations are needed to induce P2Y12 signaling [304]. Signal transduction of GPCRs is 
mediated via heterotrimeric G proteins consisting of the 3 subunit Gα, Gß and Gγ (Figure 7). 
There are several types of G proteins that activate different signaling molecules. Like P2Y13 
and P2Y14, P2Y12 couples to Gi proteins. Upon agonist binding there is a conformational 
change of the receptor resulting in exchange of G protein-bound GDP by GTP. Consequently, 
the Gα subunit dissociates from the Gßγ subunit and inhibits adenylyl cyclase resulting in 
reduced intracellular cAMP levels. The Gßγ subunit activates PI3K and its downstream 
effectors Akt and Rap1b (Figure 7) [241, 305, 306]. Thienopyridine compound such as 
clopidogrel and prasugrel are irreversible antagonist of the receptor. These prodrugs 
covalently bind to the receptor and must be metabolized in the liver to generate their active 
form. Ticagrelor is a reversible, competitive P2Y12 antagonist (Figure 7). It is an orally active 
compound and acts faster than the thienopyridine compounds [307, 308].   
As described in the following chapters, P2Y12 is strongly expressed on platelets and in 
neuronal tissue, particularly in microglial cells. Recently, P2Y12 was also shown to be 
expressed by several leukocytes, including DCs and macrophages [308].  
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Figure 7. P2Y12 signaling pathway. The purinergic receptor P2Y12 is a GPCR with 7 transmembrane 
domains that bind 2-MeSADP, ADP and ATP with decreasing affinity. The clinically approved drugs 
clopidogrel, prasugrel and ticagrelor are P2Y12 antagonists. Signal transduction is mediated via 
heterotrimeric Gi proteins. While the Gi alpha subunit (Gαi) inhibits adenylyl cyclase (AC) that converts 
ATP to cyclic AMP (cAMP) the Gßγ subunit activates effectors such as phosphatidyl-inositol-3 kinase 
(PI3K). PI3K induces downstream signaling via Akt, ERK and Rap1b. 
 
1.5.2 P2Y12 expression in platelets 
 
Platelets mediate hemostasis, a process that stops bleeding and initiates wound healing after 
tissue injury. During plug formation, platelets adhere to the endothelium and are activated by 
collagen resulting in the release of platelet granules containing ADP and thromboxane A2. This 
results in recruitment of more platelets and subsequent aggregation and thrombus formation 
[309]. Various receptors are involved in this process, including the purinergic ADP receptors 
P2Y1 and P2Y12 which together mediate platelet activation and aggregation [310]. ADP 
binding results in shape change and aggregation of platelets via activation of the αIIbβ3 
integrin [311]. Compared to other agonists of platelet activation (thrombin, thromboxane A2, 
collagen) ADP is only a weak agonist of platelet aggregation. When strong agonists such a 
thrombin and collagen bind to platelets, ADP is released from platelet dense granules resulting 
in amplification of the platelet response [307, 308]. P2Y12-deficient mice showed reduced 
platelet activation and aggregation and thus increased bleeding [312, 313]. In the clinics, 
P2Y12 receptor antagonists such as clopidogrel and ticagrelor are used to treat or prevent 
thrombotic disorders [307, 308]. 
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Besides hemostatic disorders, platelets also contribute to inflammation and chronic 
inflammatory diseases such as arthritis, atherosclerosis, allergic asthma and cancer. Platelets 
express various growth factors and surface molecules including PDGF, P-selectin, CD40 and 
CD40L which enable platelet-leukocyte interactions and activation of immune cells [314]. 
Thus, anti-platelet drugs might also target inflammatory actions mediated by platelets [315]. 
The P2Y12 antagonist clopidogrel was shown to reduce experimental transplant 
atherosclerosis in mice [316]. P2Y12 is also necessary for the leukotriene E4 (LTE4)-mediated 
pro-inflammatory actions in allergic asthma. Although the precise mechanisms are not clear 
yet, the authors hypothesized that P2Y12 associates with a co-receptor of the phylogenetically 
related cysteinyl leukotriene family [317]. Previously, Nonaka et al. showed that LTE4 can also 
bind to P2Y12 [318]. Platelets and their receptors also play a role in tumor progression and 
metastasis. Wang et al. reported reduced metastasis in P2y12-/- mice. P2Y12+ platelets 
facilitated tumor extravasation by enabling platelet-tumor cell interactions. By increasing 
TGF-ß secretion, P2Y12+ platelets also promoted an epithelial-mesenchymal transition of 
tumor cells, which is a key feature of the metastatic process [319]. Furthermore, Gebremeskel 
et al. showed that mice treated with the P2Y12 receptor antagonist ticagrelor exhibited less 
metastatic foci in the liver and lung after intravenous injection of B16 melanoma cells [320]. 
However, it is largely unclear whether all these effects are only linked to P2Y12 expression on 
platelets or also to its expression on other hematopoietic cells. 
 
1.5.3 P2Y12 expression in microglia 
 
Besides platelets, P2Y12 is also expressed in the CNS especially in microglial cells. These brain-
resident macrophages are involved in almost all CNS pathologies. Brain injury or 
neuroinflammation are associated with the release of nucleotides and purinergic receptors 
function as sensor of these danger signals. Microglial cells express various P1 (adenosine) 
receptors and P2 receptors, which are responsible for process extension, migration, cytokine 
release and phagocytosis (Figure 8). Among P2 receptors, P2X4, P2X7, P2Y6 and P2Y12 are 
expressed by microglial cells [255]. While P2X7 was shown to be involved in proliferation and 
pro-inflammatory cytokine release, P2Y6 triggers phagocytosis of apoptotic neurons [321-
323]. P2X4 is involved in migration after tissue injury and is strongly up-regulated during 
microglial activation [324]. In contrast to P2X4, P2Y12 is involved in branch extension and 
chemotaxis during early stages of microglial activation. Haynes et al. showed that P2Y12 is 
expressed on resting microglia and is down-regulated during late stages when microglial cells 
change their conformation to an amoeboid state. Furthermore, P2Y12 is down-regulated after 
microglial activation induced by LPS injection or experimental neural injury [325]. Haynes et 
al. revealed that P2Y12 deficiency delayed but did not completely abrogate activation and 
function of microglial cells [325]. This might be at least in part due to overlapping and 
redundant functions of purinergic receptors on microglial cells. Administration of the P2Y12 
antagonist ticagrelor attenuated the number of infiltrating microglial cells and the expression 
of pro-inflammatory mediators such as IL-1, iNOS and CCL2 [326]. In an ex vivo study, the 
P2Y12 antagonist PSB0739 reduced the release of the chemokines CXCL1 and CCL2 form 
microglia cells [327]. Cytokines also modulate P2Y12 expression and function. TGF-ß increased 
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P2Y12 expression and the ADP-induced migration of microglial cells, whereas LPS-treated 
microglia showed reduced P2Y12 expression and migration towards ADP [328]. P2Y12 also 
plays a role in neuropathic pain. In a partial sciatic nerve ligation model used by Kobayashi et 
al. P2Y12 expression was up-regulated and administration of a P2Y12 antagonist inhibited the 
development of pain behaviour [329]. Besides on microglia, P2Y12 is also expressed on 
oligodendrocytes which are neuroglia cells that create the myelin sheaths around the axons 
of neurons [330]. Thus, P2Y12 might be involved in neurodegenerative or neuroinflammatory 
diseases including amyotrophic lateral sclerosis and multiple sclerosis (MS). In the brain of MS 
patients there is an inverse correlation between the number of demyelinated lesions and 
P2Y12 expression [331-333]. However, whether this P2Y12 down-regulation is a cause or 
consequence of the disorder, remains to be elucidated. 
 
 
Figure 8. Purinergic signaling during microglial activation. Microglia express multiple P1 and P2 
receptors. Purinergic receptor expression is strongly regulated during microglial activation. P2Y12 is 
expressed on resting microglia and is responsible for the sensing of nucleotides, branch extension and 
chemotaxis while P2X4 plays a role in migration during the late stages of microglial activation. A3 
receptors are also involved in process extension and migration. Microglial activation is characterized 
by morphological changes that are associated with P2Y12 down-regulation and up-regulation of P2X4. 
Other P2 receptors mediate microglial proliferation (P2X7) and phagocytosis (P2Y6). Figure adapted 
from Domerq et al. [255]. 
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1.5.4 P2Y12 expression in leukocytes 
 
Previously, P2Y12 was found to be expressed on various leukocyte populations including 
lymphocytes, eosinophils, mast cells, DCs and macrophages [308]. Most of the studies 
detected P2Y12 expression on mRNA level and only few studies analyzed its cell type specific 
function. Furthermore, most of the conducted in vivo studies used P2Y12 antagonists such as 
clopidogrel and ticagrelor to investigate the effect of P2Y12 on inflammation and immunity. 
Diehl et al., for instance, showed that P2Y12 is expressed on leukocytes and that ADP-induced 
platelet aggregation correlates with leukocyte count. Treatment of patients suffering from 
coronary artery disease with clopidogrel abrogated leukocyte activation and their interaction 
with platelets resulting in diminished ADP-induced platelet aggregation [334]. Reduced 
platelet-leukocyte aggregates upon administration of P2Y12 antagonists were observed in 
several studies [335, 336]. Furthermore, clopidogrel reduced the risk of infections after 
surgery in ischemic stroke patients [337]. From these studies it is difficult to conclude whether 
the observed effects are only linked to P2Y12 expression on platelets or also to its expression 
on distinct leukocytes. 
Lymphocytes   
Wang et al. detected P2Y12 mRNA in human lymphocytes derived from the peripheral blood 
of healthy donors [338]. However, not much is known about its cell-type specific function. 
Interestingly, P2Y12 is involved in the differentiation of Th17 cells. P2Y12-/- mice or WT mice 
treated with P2Y12 antagonists exhibited reduced levels of IL-17 and Th17 cells in 
experimental autoimmune encephalomyelitis [339]. 
Eosinophils   
P2Y12 expressed on eosinophils is involved in inflammatory conditions. Clopidogrel treatment 
reduced Th2 cytokine production and eosinophil infiltration after parasite infection in vivo 
[340]. Similarly, P2Y12 blockade reduced airway inflammation by decreasing the number of 
infiltrating eosinophils and reducing CCL5, IL-4 and IL-13 levels in a mouse model of allergic 
asthma [341]. 
Mast cells   
P2Y12 expressed on blood-derived human mast cells might be involved in the resolution of 
inflammation since ATP and ADP limited the production of several pro-inflammatory cytokines 
and chemokines (e.g. TNF-α, CCL4, IL-8) in response to TLR2 ligands or leukotriene D4 (LTD4) 
[342]. Contrary, P2Y12 is crucial for LTE4-mediated mast cell activation, CCL4 and 
prostaglandin D2 (PGD2) production, and pulmonary inflammation [317]. These results 
suggest that P2Y12 on mast cells exerts opposing roles dependent on the presence of 
environmental stimuli or inflammatory mediators. 
Dendritic cells  
In DCs, P2Y12 modulates antigen presentation and T cell activation. Ben Addi et al. showed 
that P2Y12 is expressed on DCs stimulating endocytosis of antigens and activation of T cell 
response [343]. Treatment of DCs with the P2Y12 antagonist ticagrelor decreased the uptake 
of antigens and attenuated the activation of antigen-specific T cells [344]. Clopidogrel reduced 
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the number of infiltrating DCs in a mouse model of transplant atherosclerosis, suggesting that 
P2Y12 is also involved in the chemotaxis of DCs [316]. 
Macrophages   
Lattin et al. showed that P2Y12 is expressed in murine bone marrow-derived macrophages 
(BMDM) as well as peritoneal macrophages on mRNA level [345]. While Isfort et al. confirmed 
P2Y12 protein expression in mouse peritoneal macrophages by Western blot analysis, Haynes 
et al. failed to detect P2Y12 protein expression in splenic macrophages [325, 346]. Although 
P2Y12 was shown to be expressed on several macrophage populations not much is known 
regarding its specific function in these cells. In several mouse models, the P2Y12 antagonist 
clopidogrel reduced the number of infiltrating macrophages [316, 347]. However, these 
clopidogrel-mediated effects were linked to an abolished platelet function since platelets are 
important mediators of inflammation. Recent evidence from one study suggests that 
clopidogrel and other P2Y12 antagonists might directly target P2Y12+ macrophages. Kronlage 
et al. showed that autocrine P2Y12 signaling is important for chemotaxis of murine peritoneal 
macrophages in response to complement component C5a [268]. These results suggest that 
P2Y12 is involved in the migration of macrophages to the inflammatory site and that the 
reduced infiltration of macrophages upon clopidogrel treatment is caused by abrogated 
migratory function of P2Y12+ macrophages. Regarding human macrophages, P2Y12 mRNA 
expression was reported in peripheral blood monocytes as well as in MDM differentiated in 
vitro [338, 348]. However, human alveolar macrophages were shown to lack P2Y12 mRNA 
expression [349]. Whether other tissue-resident macrophages express P2Y12 remains to be 
elucidated. To our knowledge no study detected P2Y12 protein expression, neither in MDM 
nor in tissue-resident macrophages, except microglia. One explanation for the lack of studies 
focusing on P2Y12 is the sparse availability of specific anti-hsP2Y12 antibodies. Thus, not much 
is known about the presence and function of P2Y12+ macrophages in different tissues in health 
and disease. Especially the role of P2Y12+ macrophages in the development and progression 
of chronic inflammatory diseases including cancer is largely unknown.  
  
Introduction 
___________________________________________________________________________
31 
1.6 Aim of the study 
 
TAM provide an interesting therapeutic target especially when combined with immune 
checkpoint inhibitors. Thus, it is crucial to identify novel TAM markers that can be targeted 
therapeutically. Previously, we could show that most of the classical TAM markers that are 
expressed in vivo need M-CSF/dexamethasone/IL-4 (MDI) for their induction in peripheral 
blood monocytes (pBM) in vitro. To identify other markers that might be expressed by TAM in 
vivo, we performed gene expression analysis of MDI-treated pBM. We identified the 
purinergic receptor P2Y12 as the highest up-regulated gene. The aim of this doctoral thesis is 
to characterize P2Y12 expression and its function in TAM. The study focusses on the following: 
Generation and/or characterization of an antibody that specifically detects the human and 
murine P2Y12 protein in vitro and in vivo 
We will generate a rabbit polyclonal anti-hsP2Y12 peptide antibody to detect the human 
P2Y12 protein in pBM(MDI) in vitro as well as in TAM in vivo. Specificity of this antibody will be 
validated using transgenic P2Y12+ U937 cells. To detect P2Y12 in murine macrophages we will 
use a commercially available anti-P2Y12 antibody and test its specificity using transgenic 
P2Y12+ Raw 264.7 cells. 
Characterization of P2Y12 expression in M2-like macrophages in vitro 
We will use the self-generated anti-hsP2Y12 antibody to identify P2Y12 expression in M2-like 
macrophages in vitro. A time course experiment will reveal the kinetics of P2Y12 induction. 
We will also test other combinations of pro- and anti-inflammatory cytokines and their impact 
on the induction of P2Y12 expression. Finally, we will use small molecule inhibitors to analyze 
signaling pathways underlying the induction of P2Y12. 
Characterization of P2Y12 expression in TAM of melanoma in vivo 
To verify P2Y12 expression on human TAM, we will stain melanoma sections with our self-
generated anti-hsP2Y12 antibody. To analyze whether P2Y12 is expressed on CD68+ M2-like 
macrophages in melanoma we will analyze the co-expression of P2Y12 and CD163+ in TAM. In 
the murine system, we will stain B16F10 xenografts to analyze P2Y12 expression in TAM. We 
will confirm P2y12 expression in ex vivo isolated CD11b+ myeloid cells from B16F10 tumors, 
spleen and peritoneal fluid by qRT-PCR. 
Functional analysis of P2Y12 in transgenic cell lines and pBM(MDI) in vitro 
To identify ADP-induced genes in macrophages, we will perform gene expression analysis of 
ADP-treated transgenic U937 cells. We will investigate ADP-induced downstream signaling 
pathways in P2Y12+ cells. Using small molecule inhibitors, we will assess whether blockade of 
the signaling pathways will abrogate the expression of the ADP-induced genes. Since P2Y12 is 
an important chemotaxis receptor for microglia, we will investigate whether ADP also acts as 
a chemoattractant for P2Y12+ macrophages triggering migration of these cells in a transwell 
chamber in vitro. Furthermore, we will assess whether dying tumor cells promote the 
migration of P2Y12+ cells. 
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2. Materials 
 
Table 2. Chemicals and reagents 
CHEMICAL / REAGENT COMPANY 
0.5 M Tris (pH 6.8) Bio-Rad 
1.5 M Tris (pH 8.8) Bio-Rad 
10 x Tris Glycine Buffer (TGS) Bio-Rad 
30 % Acrylamide mix Bio-Rad 
2-MeSADP (ADP) Tocris 
4-Aminophenylmercuric acetate (APMA) Sigma Aldrich 
β-Mercaptoethanol Sigma Aldrich 
Acetic Acid Roth 
Acetone Roth 
AEC Chromogen Substrate Dako 
Agarose Sigma Aldrich 
Akt inhibitor VIII Calbiochem 
Ammonium persulfate (APS) Sigma Aldrich 
Amphotericin B Sigma Aldrich 
Ampicillin Sigma Aldrich 
Antibody Diluent Dako 
Antigen Retrieval Solution pH 6 Leica 
Antigen Retrieval Solution pH 9 Leica 
Apyrase Sigma Aldrich 
Biocoll Biochrom 
Bovine Serum Albumin (BSA) Sigma Aldrich 
CD11b MicroBeads Miltenyi 
CD14 MicroBeads Miltenyi 
Cell Dissociation Solution non-enzymatic 1x Sigma Aldrich 
CFSE Biolegend 
CIAP Fermentas 
Collagenase IV Genaxxon 
Crystal violet Roth 
Dexamethasone Sigma Aldrich 
DFS-TAQ DNA Polymerase Bioron 
DH5 α competent E. coli Invitrogen 
DMSO Sigma Aldrich 
DNA Ladder Thermo Fisher Scientific 
DNase I Fermentas 
dNTP Thermo Fisher Scientific 
DPBS Gibco 
Dulbeccos’s Modified Eagle Medium (DMEM) Gibco 
Earl’s balanced salt solution (EBSS) Gibco 
EcoMount Biocare Medical 
Endothelial Cell Growth Medium (EGM) Lonza 
ERK inhibitor III Calbiochem 
Ethanol Roth  
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CHEMICAL / REAGENT COMPANY 
Ethylenediaminetetraacetic acid (EDTA) Sigma Aldrich 
Faramount Aqueous Mounting Medium Dako 
Fc Block BD Biosciences 
Fetal Calf Serum (FCS) Biochrom 
Fluorescent Mounting Medium Dako 
Gelatin Sigma Aldrich 
Gentamycin Sigma Aldrich 
Heparin Sigma Aldrich 
Hydrogen peroxide (H2O2) Merck 
Interferon-γ (IFN-γ) Invitrogen 
Interleukin-4 Peprotech 
Interleukin-10 Peprotech 
Isopropanol Roth 
Ketamine 10 % Medistar 
Laemmli Buffer Bio-Rad 
Lipopolysaccharide (LPS) Invitrogen 
Luminata Forte Western HRP Substrate Merck 
Lysogeny broth (LB) Agar Roth 
Lysogeny broth (LB) Medium Roth 
Macrophage colony-stimulating factor (M-CSF) Peprotech 
Mayer’s Haematoxylin Merck 
Medium 199 Sigma Aldrich 
Methanol Sigma Aldrich 
Mifepristone Sigma Aldrich 
Minimum Essential Medium Eagle Sigma Aldrich 
Mlu I Thermo Fisher Scientific 
Nancy 520 Sigma Aldrich 
NF-κB activation inhibitor Calbiochem 
Non-Essential Amino Acid (NEAA) Biochrom 
Oligo(dT)18 Primer Thermo Fisher Scientific 
PageRuler Prestained Protein Ladder Thermo Fisher Scientific 
Paraformaldehyde (PFA) Roth 
Penicillin / Streptomycin Biochrom 
Percoll GE Healthcare 
Peroxidase Blocking Solution Dako 
Phosphate buffered saline (PBS) Invitrogen 
Phosphatase Inhibitor Cocktail Roche 
Protease Inhibitor Cocktail Roche 
PSB0739 Tocris 
Puromycin Invitrogen 
RiboLock RNase inhibitor Thermo Fisher Scientific 
RIPA Buffer Sigma Aldrich 
RNAscope® Hydrogen Peroxide Reagent ACDbio 
RNAscope® Protease Plus Reagent ACDbio 
RNAscope® Target Retrieval Reagent ACDbio 
Rompun 2 % Bayer 
Rotiophorese Buffer TAE Roth 
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CHEMICAL / REAGENT COMPANY 
RPMI-1640 Gibco 
SB203580 p38 MAPK inhibitor Calbiochem 
Skim milk powder Roth 
SOC Medium Invitrogen 
Sodium dodecyl sulphate (SDS) Bio-Rad 
Sodium azide (NaN3) Sigma Aldrich 
Sodium chloride (NaCl) Sigma Aldrich 
Sodium pyruvate (C3H3NaO3) Sigma Aldrich 
SYBR® Green PCR Master Mix Applied Biosystems 
T4 DNA Ligase Thermo Fisher Scientific 
Tetramethylethylenediamine (TEMED) GenAxxon 
Transforming growth factor-β (TGF-β) Peprotech 
Tris / HCl Sigma Aldrich 
Triton X-100 Sigma Aldrich 
Trypsin / EDTA Gibco 
Tumor necrosis factor-α (TNF-α) Peprotech 
Tween 20 Sigma Aldrich 
Xba I Thermo Fisher Scientific 
X-treme Gene 9 DNA transfection reagent Roche 
X-VIVO Lonza 
Xylene Roth 
 
Table 3. Kits 
KIT COMPANY 
BrdU Cell Proliferation Kit ELISA (colorimetric) Abcam 
DC™ Protein Assay Bio Rad 
GeneChip™ Human Gene 2.0 ST Array  Applied Biosystems 
hROS Detection Kit Cell Technology 
Human CXCL2 DuoSet ELISA R&D Systems 
Human CXCL7 DuoSet ELISA R&D Systems 
Human IL-8 DuoSet ELISA R&D Systems 
innuPREP RNA Mini Kit Analytik Jena 
Intracellular Fixation & Permeabilization Buffer Set eBioscience 
KAPA HiFi HotStart PCR Kit  VWR / Peqlab 
Maxima Reverse Transcriptase Thermo Fisher Scientific 
Mouse CCL4 DuoSet ELISA R&D Systems 
Mouse CXCL2 DuoSet ELISA R&D Systems 
Mouse TNF-α DuoSet ELISA R&D Systems 
Nitric Oxide Synthase Detection Kit Cell Technology 
Omnipure-OLS Purification Kit Omni Life Science 
Plasmid Midi Kit Qiagen 
Proteome Profiler Mouse Cytokine Array Kit, Panel A R&D Systems 
RNAscope® 2.5 HD Assay-Red ACDbio 
VECTOR NovaRED Peroxidase (HRP) Substrate Kit Vector laboratories 
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Table 4. Instruments 
INSTRUMENT COMPANY 
Axio VERT.A1 Microscope Zeiss 
Azure c400 Azure Biosystems 
Centrifuge 5417R Eppendorf 
Centrifuge 5810R Eppendorf 
Cryotome CM3050S Leica 
Cytospin 3 Shandon 
DS-U3 Digital Camera Control Unit  Nikon 
FACS Canto™ II BD Biosciences 
Freezer MDF U743V Sanyo 
HeraSafe KS Laminar Flow Thermo Fisher Scientific 
Incubator Heracell L50 i Thermo Fisher Scientific 
Infinite M 200 Pro Tecan 
Kelvitron T Heraeus 
Microtome RM2065 Leica 
Mupid-One Electrophoresis Chamber Biozym 
Nanodrop 2000 Thermo Fisher Scientific 
pH Meter FG2 / EL2 Mettler Toledo 
PowerPac Basic Bio-Rad 
Quadro MACS™ Separator Miltenyi 
Rotator SB2 Stuart 
Shaker DRS12 Peqlab 
Stratagene Mx3005P Agilent Technologies 
TC20™ Automated Cell Counter Bio-Rad 
Thermoblock Thermomixer Eppendorf 
Thermocycler T100 Bio-Rad 
Trans-Blot Turbo Device Bio-Rad 
Upright motorized Microsope Eclipse Ni-E  Nikon 
UV Systems N-90 m Intas 
Vortex Genie-2 Scientific Industries 
Water bath Memmet 
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Table 5. Consumables 
CONSUMABLE COMPANY 
6-well plates  Greiner bio-one 
12-well plates Greiner bio-one 
24-well plates  Greiner bio-one 
96-well plates  Greiner bio-one 
Cell scraper Greiner bio-one 
Cell culture flask 25 cm2 (T25) Greiner bio-one 
Cell culture flask 75 cm2 (T75) Greiner bio-one 
Cell culture flask 175 cm2 (T175) Greiner bio-one 
Cell strainer 100 µm BD Falcon 
Eppendorf Safe-Lock Tubes 0.5 mL Eppendorf 
Eppendorf Safe-Lock Tubes 1.5 mL Eppendorf 
Eppendorf Safe-Lock Tubes 2.0 mL Eppendorf 
Hyperfilm™ ECL GE Healthcare 
Immune-Blot PVDF Membrane Bio-Rad 
LS Columns Miltenyi 
MS Columns Miltenyi 
Transwell® polycarbonate membrane cell 
culture inserts (12 mm with 3 µm pore) 
 
Corning 
Transwell® polycarbonate membrane cell 
culture inserts (6.5 mm with 5 µm pore) 
 
Corning 
Vivaspin Columns (MWCO=100,000 PES) Sartorius 
 
Table 6. Software 
Adobe Photoshop 6.0 Software 
FlowJo V 10.1 
GraphPad Prism 6.0 
Image J 
MxPro Software 
NIS-Elements Advanced software 
Zeiss Software System 
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Table 7. Primers 
PRIMER TARGET SEQUENCE 
Hs Arg1 fw CGG AGA CCA CAG TTT GGC A 
Hs Arg1 rev TAC AGG GAG TCA CCC AGG AG 
Hs CCL2 fw GCT CAG CCA GAT GCA ATC AAT G 
Hs CCL2 rev GTG TCT GGG GAAA GCT AGG G 
Hs CCL20 fw GGA CAT AGC CCA AGA ACA GAA A 
Hs CCL20 rev GTC CAG TGA GGC ACA AAT TAG A 
Hs CCL3L3 fw CTG ACT ACT TTG AGA CGA GCA G 
Hs CCL3L3 rev GAC GTA TTT CTG GAC CCA CTC 
Hs CXCL2 fw CAC AGT GTG TGG TCA ACA TTT C 
Hs CXCL2 rev ACA GAG GGA AAC ACT GCA TAA T 
Hs CXCL3 fw GGA CAG CTG GAA AGG ACT TAA T 
Hs CXCL3 rev TCA GGA CTG AGC TAT GTT TGA TG 
Hs CXCL7 fw AAC TCC GCT GCA TGT GTA TAA 
Hs CXCL7 rev CCA TCC TTC AGT GTG GCT ATC 
Hs FOSL1 fw TGA TCC ACC CAA CCC TAT CT 
Hs FOSL1 rev AAT GGC CTG GTC CAA TCAC 
Hs GAPDH fw TGC ACC ACC AAC TGC TTA GC 
Hs GAPDH rev GGC ATG GAC TGT GGT CAT GA 
Hs HB-EGF fw GCT ACC TCT GAG AAG ACA CAA G 
Hs HB-EGF rev AAT TAT GGG AGG CCC AAT CC 
Hs IL10 fw ACA TCA AGG CGC ATG TGA AC 
Hs IL10 rev GCC ACC CTG ATG TCT CAG TT 
Hs IL1ß fw CTT CGA GGC ACA AGG CAC AA 
Hs IL1ß rev GGT GGT CGG AGA TTC GTA GC 
Hs IL8 fw CCT GAT TTC TGC AGC TCT GT 
Hs IL8 rev AAA CTT CTC CAC AAC CCT CTG 
Hs jun fw CCT GAT GTA CCT GAT GCT ATG G 
Hs jun rev CCT CCT GAA ACA TCG CAC TAT 
Hs P2Y12 fw CCA GGG TCA GAT TAC AAG AGC 
Hs P2Y12 rev GTT GTC GAC GGC TTG CAT TT 
Hs P2Y12_Xba_fw GCA TCT AGA CCA GAA TCA ACA GTT ATC AG 
Hs P2Y12_Mlu_rev GTA ACG CGT GCC ATT GGA GTC TCT TCA TTT GG 
Hs ß-actin fw GGC ACC ACA CCT TCT ACA ATG A 
Hs ß-actin rev TCT CCT TAA TGT CAC GCA CGA T 
Hs TGFß fw TAC CTG AAC CCG TGT TGC TC 
Hs TGFß rev CCG GTA GTG AAC CCG TTG AT 
Hs TNF fw AGC CCA TGT TGT AGC AAA CC 
Hs TNF rev CAG ACT CGG CAA AGT CGA GA 
Mm P2Y12 fw GAA CCA GGA CCA TGG ATG TGC 
Mm P2Y12 rev GTG TAC AGC AAT GGG AAG AGA ACC 
Mm P2Y12_Xba_fw TGC ATC TAG ACA CTC ATA TCC TTC AGA TT 
Mm P2Y12_Mlu_rev TGT AAC GCG TGC CAT TGG GGT CTC TTC GCT 
Mm ß-actin fw ACC CGC GAG CAC AGC TTC TTT 
Mm ß-actin rev CTT TGC ACA TGC CGG AGC CGT TG 
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Table 8. Primary antibodies 
1ST ANTIBODY APPLICATION DILUTION COMPANY 
anti-hsP2Y12 WB 
IHC (Ag retrieval pH 6) 
1/500 
1/50 
Self-generated 
(Peptide-specialties Lab) 
anti-P2Y12  WB 
ICC/IHC 
1/1000 
1/50 
Alomone 
(APR-012) 
Anti-Flag M2 
 
WB 
ICC 
1/500 
1/50 
Sigma-Aldrich 
F1804 
anti-hsCD68 
 
IHC 
(Ag retrieval pH 6) 
1/200 Dako 
(M087629-2) 
anti-hsCD163 
 
IHC 
(Ag retrieval pH 6) 
1/500 Leica 
(CD163-L-CE) 
anti-GAPDH WB 1/2500 Cell signaling Technology 
(2118S) 
anti-P-ERK1/2 WB 1/1000 Cell signaling Technology 
(4370S) 
anti-ERK1/2 WB 1/1000 Cell signaling Technology 
(4695S) 
anti-P-Akt WB 1/1000 Cell signaling Technology 
(9271S) 
anti-Akt WB 1/1000 Cell signaling Technology 
(9272S) 
 
Table 9. Secondary antibodies 
2ND ANTIBODY APPLICATION DILUTION COMPANY 
anti-mouse IgG HRP 
 
IHC undiluted Dako 
(K4005) 
anti-rabbit IgG HRP 
 
IHC undiluted Dako 
(K4009) 
anti-mouse IgG HRP 
 
WB 1/5000 GE Healthcare 
(NXA931V) 
anti-rabbit IgG HRP 
 
WB 1/5000 GE Healthcare 
(NA934V) 
anti-rabbit IgG DL-488 IF 1/400 Dianova 
(711-486-152) 
anti-mouse IgG Cy3 
 
IF 1/400 Dianova 
(712-165-153) 
 
Table 10. Probes 
PROBE TARGET ENTREZ GENE ID 
Hs P2RY12 121–1283 64805 
Mm P2RY12 739–1854 70839 
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3. Methods 
 
3.1 Cell culture methods 
 
3.1.1 Cell lines 
 
Cell lines were cultured in 75 cm2 or 175 cm2 cell culture flasks at 37 °C and an atmosphere of 
5 % CO2. Cell lines were regularly tested for mycoplasma contamination, and growth as well 
as morphology were controlled under an inverted microscope. 
 
Human cell lines 
U937 
The monocytic U937 cells were purchased from ATCC. Cells were cultured in RPMI-1640 
medium supplemented with 10 % fetal calf serum (FCS), 100 U Penicillin, as well as 100 μg/mL 
Streptomycin (Pen/Strep). Medium was replaced every two to three days by centrifugation of 
the suspension cells for 5 min at 300 g. Cells were split at a ratio of 1:10. 
Human umbilical vein endothelial cells (HUVEC) 
The cells were cultured in endothelial cell growth medium (EGM) mixed 1:2 with Medium 199, 
supplemented with 10 % FCS, 50 μg/mL gentamycin, 50 μg/mL heparin and 2.5 μg/mL 
amphotericin B. For sub-cultivation, adherent cells were washed twice with PBS and treated 
with Trypsin/EDTA for 5 min at 37 °C. To stop the reaction, complete medium was added and 
cells were centrifuged for 5 min at 300 g. Supernatant was discarded, and the pellet was 
resuspended in new culture medium. Cells were split with a ratio of 1:3. 
 
Murine cell lines 
Raw 264.7 
The murine macrophage cell line Raw 264.7 was purchased from ATCC and cells were cultured 
in DMEM complete containing 10 % FCS and 100 U Penicillin and 100 μg/mL Streptomycin 
(DMEM complete). For sub-cultivation cells were washed with PBS, scraped off the plate and 
spun at 300 g for 5 min. Cells were split at a ratio of 1:10. 
B16F1 
This melanoma derived cell line was cultured in DMEM complete. For sub-cultivation the 
adherent cells were washed twice with PBS followed by treatment with Trypsin/EDTA for 
5 min at 37 °C. Complete growth medium was used to stop the reaction. Cell suspension was 
centrifuged, cell pellet was resuspended in DMEM complete and cells were split with a ratio 
of 1:10. 
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B16F10 
This melanoma derived cell line was used for in vivo tumor experiments and was cultured in 
DMEM complete. For sub-cultivation, B16F10 cells were treated as described for B16F1 cells. 
Prior to injection in C57BL/6 mice, adherent cells were washed twice with PBS, detached from 
the plates by treatment with cell dissociation buffer. Subsequently, cells were washed twice 
with PBS and cell concentration was adjusted to 10 x 106 cells/mL. 
 
3.1.2 Cryopreservation of cells 
 
Cells were frozen in complete growth medium supplemented with 10 % DMSO and aliquoted 
into cryovials at a concentration of approximately 2 x 106 cells/mL. The cryovials were placed 
in isopropanol-containing freezing boxes which were stored at -80 °C. For long-term storage, 
the cells were transferred to liquid nitrogen tanks. 
The frozen cells were thawed quickly by placing the cryotubes in a 37 °C water bath for a few 
minutes. The cell suspension was added to 5 mL pre-warmed complete growth medium and 
cells were centrifuged at 300 g for 5 min. The supernatant was discarded, and the cell pellet 
was resuspended in fresh complete growth medium. Cells were seeded in cell culture flasks 
and the medium was renewed the other day. 
 
3.1.3 Production of lentivirus for transduction of eukaryotic cell lines 
 
For lentiviral transfection, HEK293/T17 producer cells were seeded in T175 cm2 flasks and 
grown until 80 % confluency. Cells were transfected with the ADR6 vector carrying the P2Y12 
gene (section 3.3.1) and 3rd generation lentiviral plasmids (pMD2.G L1, pRSV rev L2, pMDLg / 
pRRE L3 and pCDNA3.1/p 35 E 71) using X-treme GENE 9 DNA transfection reagent. To 
promote plasmid uptake and thus transfection efficacy 100 mM natrium pyruvate was added 
to the DMEM complete medium. The next day medium was replaced by new culture medium 
supplemented with 10 mM natrium butyrate to stimulate the release of newly produced 
viruses. The following morning, medium was replaced by harvesting medium (DMEM + 1 % 
Pen/Strep) which, after 8 h of virus production was collected and filtered through a 0.22 µm 
filter to obtain sterile and cell-free supernatants containing lentiviruses. This harvesting step 
was repeated three times to obtain adequate virus amounts. Finally, harvesting media 
containing the viruses was concentrated using Vivaspin columns. Virus suspensions were 
aliquoted and stored at -80 °C. 
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3.1.4 Generation of transgenic cell lines 
 
Lentiviruses (see section 3.1.3) were used for the transduction of the eukaryotic cell lines U937 
and Raw 264.7. 1 x 106 cells were seeded in 6 well plates in 10 mL complete growth medium. 
The following day, medium was renewed and 100 μL virus suspension was added dropwise. 
After 48 h of transduction, the medium was replaced by selection medium (complete growth 
medium + 2 μg/mL puromycin). Untreated cells were cultured in selection medium to 
determine puromycin concentration and time point when cells were dying. As soon as this 
happened, the surviving transduced cells were expanded in complete growth medium. The 
expression of the transgene P2Y12 was verified by qRT-PCR, Western blot analysis and 
immunocytochemistry. 
 
3.1.5 Isolation of CD14+ cells from human peripheral blood 
 
Buffy coat samples from healthy donors were obtained from German Red Cross Blood 
Donation Service, Baden-Württemberg. In the first step peripheral blood mononuclear cells 
(PBMCs) were isolated by density gradient centrifugation. Therefore, the buffy coats were 
diluted 1:1 with PBS, and 30 mL of the diluted blood was carefully layered over 15 mL Biocoll 
separation solution. The samples were centrifuged at 1200 g for 30 min without break. The 
mononuclear cells (monocytes, lymphocytes, some granulocytes) visible as a white ring just 
above the Biocoll layer were transferred to a new collection tube containing PBS. Cells were 
spun down at 300 g for 10 min and washed twice with PBS. To get rid of residual red blood 
cells and to further separate lymphocytes from monocytes another density gradient 
centrifugation step with Percoll was performed. Thus 15 mL Minimal essential eagle medium 
was mixed with 13.5 mL Percoll separating solution and 1.5 mL Earls Balanced Salt Solution 
and the gradient was achieved by centrifugation at 10,000 g for 10 min. 3 mL of the PBMC 
solution were layered slowly on top of the Percoll separation solution. After centrifugation at 
1200 g for 30 min without breaks, the white layer of mostly monocytes was transferred to a 
new collection tube. Cells were washed two times with PBS. In the second step CD14+ cells 
were isolated by magnetic-activated cell sorting (MACS). Therefore, cells were resuspended 
in MACS buffer (PBS containing 0.5 % BSA and 2 mM EDTA) labelled with CD14 MicroBeads 
and incubated for 15 min at 4 °C. Cells were washed once with MACS buffer and loaded on LS 
MACS columns which were used for positive selection of CD14+ cells. After washing the 
columns three times with MACS buffer, the magnetically labeled cells were flushed out by 
inserting the plunger in the columns. Cells were spun down at 300 g for 10 min, washed once 
with PBS and resuspended in 10 mL X-VIVO medium. The cell concentration was determined 
by hematocytometer and cells were seeded at a concentration of 1 x 106 cells/mL in 6 well 
plates. Cell were differentiated to macrophages using the following stimuli: 
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STIMULI CONCENTRATION 
M-CSF 100 ng/mL 
Dexamethasone 1 x 10-7 (1000 U/mL) 
IL-4 10 ng/mL 
LPS 1 µg/mL 
IFN-γ 50 ng/mL 
TNF-α 10 ng/mL 
IL-10 10 ng/mL 
TGF-ß 100 ng/mL 
p38 MAPK inhibitor (SB203580) 50 µM 
NF-κB Inhibitor 5 µM 
Mifepristone 100 nM 
 
3.2 In vitro Assays 
 
3.2.1 BrdU Cell Proliferation Assay 
 
1 x 104 transgenic Raw 264.7 cells were seeded in 96 well plates. After cells became adherent, 
medium was replaced by DMEM complete containing 50 nM 2-Methylthio-adenosine-5'-
diphosphate (ADP) and cells were incubated for 48 h. During the final 16 h, BrdU was added 
to the wells. Assay was performed according to the manufacturer’s instructions (BrdU Cell 
Proliferation Kit ELISA (colorimetric)). Absorbance was read at 450 nm with a reference 
wavelength of 550 nm using a microplate reader.  
 
3.2.2 Transwell migration assay with pBM 
 
CD14+ cells were isolated and differentiated as described before (section 3.1.5). After seven 
days of stimulation, MDI- and M-CSF-treated pBM were harvested by scraping the cells off the 
plate. Cell numbers were determined by hematocytometer and 2 x 105 cells in X-VIVO medium 
were seeded in 6.5 mm transwell inserts of a 24 well plate with a pore size of 5 µm. X-VIVO 
medium supplemented with 50 nM ADP was used as a chemoattractant in the lower chamber 
of the transwell. After letting the cells migrate for 6 h at 37 °C medium was removed from the 
transwells, and remaining cells in the transwell insert were removed with a cotton swab. 
Transwells were washed once with PBS followed by fixation with 100 % methanol for 10 min. 
Subsequently, cells on the bottom of the transwell membrane were stained with 5 % crystal 
violet for 15 min and cells were washed once in PBS and once in dH2O. Pictures of migrated 
cells were taken using an inverted microscope (Zeiss Axiovert). Crystal violet was then 
dissolved in methanol and quantified measuring the absorbance at 570 nm. 
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3.2.3 Transwell migration assay with transgenic Raw 264.7 cells 
 
5 x 105 transgenic Raw 264.7 cells were seeded in DMEM w/o FCS in the upper chamber of a 
6.5 mm transwell insert with a 5 µm pore size. 50 nM ADP was used as a chemoattractant in 
the lower chamber. DMEM complete or DMEM w/o FCS were used as controls. In another set 
of experiments, Raw 264.7 cells were pre-treated with 10 µM of the P2Y12 specific antagonist 
PSB0739 prior to inducing cell migration with ADP-supplemented medium. Migration was 
assessed after 16 h at 37 °C as described before (section 3.2.2).  
For migration experiments with conditioned medium (CM) of transgenic Raw cells. 1 x 106 
P2Y12+ Raw cells and empty vector (EV) cells were seeded in 6 well plates. The following day, 
cells were washes once with PBS and cultured in DMEM w/o FCS or in DMEM w/o FCS 
supplemented with 50 nM ADP for 24 h. CM was harvested, and supernatants were 
centrifuged at 1000 g for 10 min to obtain cell-free supernatants. 700 µL of the CM (with or 
without 1 U/mL apyrase) was used as a chemoattractant in the lower chamber of a transwell. 
Number of migrated cells was determined after 6 h of migration as described in section 3.2.2. 
For migration experiments with dying tumor cells 2 x 104 B16F1 melanoma cells were seeded 
in 24 well plates. The following day, cell death was induced with 2 µg/mL puromycin for 24 h. 
Cell death was assessed by morphological changes observed using an inverted microscope. 
Transwell inserts loaded with 5 x 105 transgenic Raw 264.7 cells in 100 µL DMEM were added 
to the 24 well plate containing the puromycin-treated B16F1 cells. Untreated B16F1 cells and 
complete growth medium served as controls. For several experiments 1 U/mL apyrase was 
added to the puromycin-treated B16F1 cells or transgenic Raw 264.7 cells were pre-treated 
with 10 µM of the P2Y12 antagonist PSB0739. Migration was assessed after 6 h as described 
in section 3.2.2. 
 
3.2.4 Adhesion of U937 to HUVECs 
 
Wells of a 12 well plate were coated with 500 µL 0.1 % gelatin in PBS and the plate was 
incubated for 1 h at 37 °C. Wells were washed twice with PBS and 2 x 105 HUVECs were seeded 
and grown for 24–48 h until they formed a monolayer. To activate the cells, they were 
stimulated with 10 ng/mL TNF-α for 16 h. Meanwhile, transgenic U937 cells were seeded at 
1 x 106 cells/well in 6 well plates and treated with 50 nM ADP for 24 h. The following day, U937 
cells were harvested, washed twice and counted by hematocytometer. 1 x 106 cells were 
resuspended in 100 µL of a 5 µM CFSE solution and incubated for 20 min at RT. The staining 
was quenched by addition of 1 mL RPMI complete medium. Cells were centrifuged and 
resuspended in 1 mL RPMI complete. 500 µL cells suspension (≙ 5 x 105 cells) were added to 
the wells containing the endothelial monolayer. Cells were incubated for 1 h at 37 °C. Non-
adherent cells were removed by washing the plate two times with PBS. Cells were lysed with 
500 µL RIPA lysis buffer, incubated for 5 min at RT with shaking and fluorescence intensity at 
480/520 nm was measured using a microplate reader. 
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3.2.5 U937 Transmigration Assay 
 
1 x 105 HUVECs were seeded in inserts of a 12 mm transwell plate (3 µm pore size) and grown 
for 24–48 h until they formed a monolayer. Subsequently, cells were treated with 10 ng/mL 
TNF-α for 16 h. Meanwhile, transgenic U937 cells were seeded at 1 x 106 cells/well in 6 well 
plates and treated with 50 nM ADP for 24 h. Untreated cells served as a control. U937 cells 
were harvested, washed twice with PBS, and concentration was adjusted to 2.5 x 106 cells/mL. 
200 µL of the cell suspension was added to the transwell insert containing the endothelial 
monolayer. 1 mL medium w/o FCS was added to the lower chamber of the transwell plate. 
Plates were incubated for 6 h at 37 °C. Medium in the lower well containing transmigrated 
U937 cells was collected, centrifuged and pellet was resupended in 200 µL PBS. Cells were 
counted by flow cytometry (number of events was recorded for 40 s using medium flow rate). 
 
3.3 Molecular biology 
 
3.3.1 Cloning of hsP2Y12 and mmP2Y12 
 
HsP2Y12 and mmP2Y12 were cloned in an ADR6 expression vector containing the eukaryotic 
promoter sequence of EF1α, a multiple cloning site (MCS) with a Flag tag, an internal 
ribosomal entry site (IRES), a puromycin resistance as a selection marker, and red fluorescent 
protein (RFP) as a reporter gene to identify successfully cloned genes.   
As a first step cDNA of mmP2Y12 (clone IRAVp968D0977D) and hsP2Y12 (clone 
IRAUp969F0383D) was amplified with primers that add the restriction sites for the restriction 
enzymes Xba I and Mlu I (Table 7). The PCR was performed with κ-HiFi HotStart DNA 
Polymerase according to the manufacturer’s instructions: 
COMPONENT VOLUME 
5 x κ-HiFi Buffer 10 µL 
10 mM dNTP 1.5 µL 
Forward Primer (10 µM) 1.5 µL 
Reverse Primer (10 µM) 1.5 µL 
κ-Polymerase (1 U/µL) 1 µL 
cDNA  1 ng 
Nuclease-free water to 50 µL 
 
PCR was performed using the following thermocycler settings: 
STEP TEMPERATURE TIME CYCLE 
Hot Start 95 °C 3 min 1 
Denaturation 98 °C 20 s  
  18 or 22 Annealing Tm of primer (60–75 °C) 15 s 
Elongation 72 °C 60 s 
Final extension 72 °C 5 min 1 
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The PCR product was purified using the Omnipure-OLS Purification Kit. The PCR product and 
the vector construct were digested with the restriction enzymes Xba I and Mlu I for 1.5 h at 
37 °C. After 1 h, the enzyme CIAP was added to the vector DNA but not to the DNA of the PCR 
product (insert). CIAP prevents re-ligation of the linearized vector by removing the 
5' phosphate group. DNA was purified again, and ligation of vector and insert was performed 
using the enzyme T4 DNA ligase either for 1 h at RT or overnight at 4 °C. 
COMPONENT VOLUME 
Vector DNA 20–100 ng 
Insert DNA 3:1 molar ratio over vector 
10 x T4 Ligase Buffer 2 µL 
T4 DNA Ligase (5 U/µL) 0.2 µL 
Nuclease-free water to 20 µL 
 
For heat shock transformation, 50 µL of DH5 α competent E. coli were thawed on ice, mixed 
with 3 µL of the ligated vector and incubated on ice for 10 min. Heat shock transformation 
was performed at 42 °C for 45 s, followed by cooling the bacteria quickly on ice and addition 
of 500 µL SOC medium. After shaking the bacteria suspension for 1 h at 37 °C and 800 rpm, 
approximately 500 µL was seeded on LB agar plates containing 100 µg/mL ampicillin. Plates 
were incubated overnight at 37 °C. Several colonies were picked and transferred to conical 
flasks containing LB medium plus ampicillin. Bacteria were shaken overnight at 37 °C. Bacteria 
suspension was centrifuged, and plasmid DNA was purified using QIAGEN Plasmid Midi Kit 
according to the manufacturer’s instruction. Finally, the DNA pellet was resolved in nuclease-
free water, and the DNA concentration was determined using Nanodrop. The sequencing of 
the plasmid was performed by LGC Genomics GmbH (Berlin). 
 
3.3.2 RNA isolation and cDNA synthesis 
 
After cells were harvested and washed once in PBS, the cell suspension was spun down and 
the supernatant was discarded. The cell pellets were used for RNA isolation by using the 
innuPREP RNA Mini Kit according to the manufacturer’s protocol. RNA was eluted in a volume 
of 40 μL RNase free water. RNA concentration of the samples was determined using the 
photometer Nanodrop 2000. The RNA was directly used for cDNA synthesis or stored at -80 °C. 
cDNA synthesis was performed using Maxima Reverse Transcriptase according to the 
manufacturer’s protocol: 
RNA 1 µg 
Oligo dT Primer 1 µL (100 pmol) 
dNTP Mix (10 mM) 1 µL 
Nuclease-free water to 14.5 µL 
 
The premix was incubated for 5 min at 65 °C and quickly chilled on ice prior to addition of the 
following components: 
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5 x RT Buffer 4 µL 
RiboLock RNase Inhibitor 0.5 µL (20 U) 
Maxima Reverse Transcriptase  1 µL (200 U) 
 
Reverse transcription was performed at 50 °C for 30 min followed by heat-induced 
inactivation of the enzyme for 5 min at 85 °C. cDNA samples were stored at -20 °C. 
 
3.3.3 Polymerase chain reaction (PCR) 
 
For PCR, cDNA was diluted 1:10 in ddH2O and the following reaction mix was prepared: 
10 x Complete Buffer 1.2 µL 
dNTP (2 mM) 0.6 µL 
Forward Primer (10 µM) 0.5 µL 
Reverse Primer (10 µM) 0.5 µL 
DFS-TAQ DNA Polymerase 0.1 µL 
cDNA (1:10) 1 µL 
ddH2O 6.1 µL 
 
The cycling conditions were as follows: 
TEMPERATURE TIME REPEATS 
95 °C 3 min 1x 
95 °C 30 s  
  34x 60 °C (adjusted to primer) 30 s 
72 °C 45 s 
72 °C 5 min 1x 
4 °C ∞ 1x 
 
PCR products were loaded on 1–2 % agarose gels containing 10 % Nancy-520, a fluorescent 
stain for double-stranded DNA. Agarose electrophoresis was performed at 100 V for 30 min. 
DNA bands were visualized using Azur c400. 
 
3.3.4 Quantitative Real-time PCR (qRT-PCR) 
 
Template cDNA was diluted 1:50 in ddH2O, mixed with primers and SYBR® Green PCR Master 
Mix containing the fluorescent dye, dNTPs, DNA Polymerase and buffer.  
cDNA (1:50) 10 µL 
Forward Primer (2 µM) 3.5 µL 
Reverse Primer (2 µM) 3.5 µL 
SYBR® Green PCR Master Mix 17 µL 
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10 µL of each sample was pipetted in triplicates on a 96 well qRT-PCR plate. The housekeeping 
gene ß-actin was used for normalization of the template amount. The PCR was run under 
standard conditions with an MX3000P sequence detection system (Stratagene). 
 
3.3.5 Microarrays 
 
Transgenic U937 cells were seeded at a concentration of 1 x 106 cells/mL and stimulated with 
50 nM ADP for 4 h and 24 h, respectively. Cells were harvested, washed twice with PBS and 
total RNA was isolated as described before. Concentration was adjusted to 100 ng/µL. 1 µg 
RNA was used for each microarray. Technical triplicates were performed for each sample. 
Microarrays (GeneChip™ Human Gene 2.0 ST Array) were run and analyzed at the Affymetrix 
core facility of the UMM. 
 
3.3.6 In situ hybridization 
 
In situ hybridization was performed using the RNAScope 2.5 HD Detection Kit for FFPE tissue. 
Paraffin sections (4 µm) were baked for 1 h at 60 °C. To deparaffinize the sections, they were 
rinsed in xylene two times for 5 min and then in 100 % ethanol twice for 1 min. Finally, the 
sections were air dried for 5–15 min at RT. 5 drops of hydrogen peroxide solution were applied 
to each section for 10 min at RT. Slides were washed twice in dH2O for 1 min. Antigen retrieval 
was performed by boiling the slides in 1 x antigen retrieval solution for 15 min. Section were 
washed shortly in dH2O, followed by 100 % ethanol. After air drying the slides, a barrier was 
created with a hydrophobic barrier pen. Slides were air dried overnight at RT. The following 
day, 5 drops of Protease Plus were added to the slides and incubated for 30 min at 40 °C. Slides 
were washed twice in dH2O. The probes were hybridized two hours at 40 °C followed by 
hybridization of the amplifiers as indicated in the manufacturer’s instructions. Signal was 
detected by applying 100 µL of a 1:60 mixture of RED-B and RED-A for 10 min at RT. Slides 
were washed three times in dH2O followed by counterstaining with 50 % hematoxylin for 90 s. 
After rinsing the slides in dH2O, they were placed in 0.02 % ammonia water for 10 s and 
washed again in dH2O three times. Finally, slides were dried at 60 °C for 15 min and mounted 
using EcoMount. Tissue sections were examined under a bright field microscope. 
 
3.4 Biochemical methods 
 
3.4.1 Generation of an anti-human P2Y12 antibody 
 
A polyclonal antibody against human P2Y12 was generated in rabbit, targeting the peptide 
sequence SQDNRKKEQDGGDPNEETPM referring to amino acid 323 to 342 of the C-terminus 
(sequence ID NP_073625.1). The synthetized peptide coupled to a KLH carrier protein was 
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used as an immunogen in a commercial process (Peptide Specialty Laboratories GmbH, 
Heidelberg). The anti-hsP2Y12 antibody was purified by affinity chromatography using a 
specific peptide column provided by the company. The antibody specificity was validated by 
immunocytochemical stainings and Western blot analysis of generated transgenic U937 cells. 
 
3.4.2 Cell lysates and protein determination 
 
Cells were harvested and washed twice with PBS. Cell pellets were resuspended in RIPA lysis 
buffer containing protease and phosphatase inhibitors. The samples were incubated on ice for 
20 min and centrifuged at 14,000 g for 10 min at 4 °C to remove cellular debris. The 
supernatant was transferred to a new collection tube. Protein concentration was determined 
by the colorimetric DC™ Protein Assay, which is based on the Lowry assay. A bovine serum 
albumin (BSA) dilution series ranging from 10 mg/mL to 0.16 mg/mL was prepared to create 
a standard curve. 
 
3.4.3 SDS-PAGE 
 
10 % polyacrylamide gels were prepared just prior to use.  
Resolving gel 
dH2O 5.9 mL 
30 % Acrylamide 5.0 mL 
1.5 M Tris, pH = 8.8 3.8 mL 
10 % SDS 0.15 mL 
10 % APS 0.15 mL 
TEMED 6 µL 
 
After casting the resolving gel, it was covered with isopropanol to avoid drying. After 
polymerization, isopropanol was removed, the gel was washed with dH2O and the stacking gel 
was added followed by insertion of a comb. 
Stacking gel 
dH2O 1.72 mL 
30 % Acrylamide 0.50 mL 
0.5 M Tris, pH = 6.8 0.76 mL 
10 % SDS 0.03 mL 
10 % APS 0.03 mL 
TEMED 3 µL 
 
After 20 min of gel polymerization samples were loaded. Protein samples were mixed with 
Laemmli buffer containing β-mercaptoethanol and SDS to denaturate tertiary and secondary 
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structure. The samples were boiled at 95 °C for 5 min. The SDS gels were placed in 
electrophoresis chambers which were filled with TGS buffer. Of each sample 40 µg protein 
was loaded on the gels. 6 µL pre-stained protein ladder was used for the assignment of protein 
size. Electrophoresis was performed at 20 mA for approximately 2 h. 
 
3.4.4 Western blot analysis (WB) 
 
After electrophoresis, the proteins in the gels were transferred horizontally to PVDF 
membranes. Semi-dry blotting was performed for 35 min at 0.45 A (max. 25 V) in the Trans-
Blot Turbo device. Subsequently, the membranes were blocked in 5 % skimmed milk powder 
for 1 h at RT. The membranes were then incubated with primary antibodies diluted in 5 % milk 
powder overnight at 4 °C. The following day, the membranes were washed three times for 
10 min with PBS and incubated with a horse-radish-peroxidase (HRP)-conjugated secondary 
antibody diluted in 5 % milk powder for 1 h at RT. After washing again three times for 10 min 
with PBS, the membranes were incubated with Luminata Forte Western HRP Substrate for 
3 min. Chemiluminescence was detected using Azur c400. 
 
3.4.5 Enzyme-linked immunosorbent Assay (ELISA) 
 
1 x 106 transgenic Raw 264.7 and U937 cells were seeded in 2 mL complete growth medium in 
6 well plates and stimulated with 50 nM ADP for 24 h. Cell supernatants were collected and 
centrifuged at 1000 g for 10 min to obtain cell free supernatants. All ELISAs were performed 
according to the manufacturer’s instructions. 100 µL of cell supernatant was used in each 
experiment and all standards and samples were read in duplicates. Optical density (OD) was 
measured at 450 nm using TECAN microplate reader. 
 
3.4.6 Proteome Profiler Mouse Cytokine Array 
 
The proteome Profiler Mouse Cytokine Array is a membrane-based antibody array that allows 
the detection of 40 different mouse cytokines and chemokines. Transgenic Raw 264.7 cells 
were seeded at a concentration of 1 x 106 cells/mL and stimulated with 50 nM ADP for 24 h. 
Cell supernatants were collected and centrifuged at 1000 g to obtain cell-free conditioned 
media. 500 µL cell supernatant was used to incubate each membrane. The assay was 
performed according to the manufacturer’s instructions. Chemiluminescent signal was 
detected using Azure c400. 
 
 
Methods 
___________________________________________________________________________
50 
3.4.7 Immunocytochemistry (ICC) 
 
Transgenic Raw 264.7 cells were grown to 80 % confluency on coverslips whereas U937 cells 
were centrifuged onto glass slides as cytospins. The coverslips or cytospins were washed 
thoroughly with PBS, fixed with 2 % PFA for 10 min and permeabilized with 0.5 % Triton X-100 
in PBS for 15 min. After fixation with 4 % PFA for 10 min, the cells were washed two times with 
PBS and once with 0.01 % Tween 20 in PBS (PBST). Fixed cells were treated with Peroxidase 
Blocking Solution for 10 min at RT to block intrinsic peroxidase. After washing the slides or 
coverslips two times in PBS and once in PBST, cells were treated with 2 % BSA in PBS for 20 min 
at RT to prevent unspecific staining. Cells were incubated with the desired primary antibodies 
diluted in Antibody Diluent for either 2 h at RT or overnight at 4 °C. Cells were washed again 
and incubated with the appropriate HRP conjugated secondary antibody diluted in Antibody 
Diluent for 1 h at RT. After washing three times a described before, samples were incubated 
with the ready-to-use AEC chromogen substrate for 5–10 min. The samples were rinsed in 
dH2O and counterstained in 10 % hematoxylin for 8 min. After rinsing in H2O for several 
minutes, slides and cytospins were embedded in Faramount aqueous mounting media. 
Pictures were taken using the Nikon Eclipse NI microscope and the NIS-Elements Advanced 
software (Nikon). Images were adjusted with Adobe Photoshop 6.0 software. 
 
3.4.8 Immunohistochemistry (IHC) 
 
Cryo-sections (7 µm) of murine B16F10 tumors were air-dried overnight, fixation was 
performed with ice-cold acetone for 10 min at RT and sections were washed three times in 
PBS.   
Paraffin sections (1 µm) of human tissue samples were dried overnight at 60 °C. To 
deparaffinize the sections, they were rinsed in xylene three times for 4 min and then 
rehydrated in a decreasing alcohol series ranging from 100–70 % ethanol for 3 min each. 
Finally, the sections were washed twice with dH2O for 3 min. For antigen retrieval the sections 
were incubated at 95 °C for 20 min either in pre-heated citrate buffer (pH 6) or EDTA buffer 
(pH 9). Sections were cooled down in the buffer for 30 min at RT followed by washing once in 
dH2O and once in PBS.  
Circles were drawn around the tissue sections using a DAKO pen and specimens were treated 
with Peroxidase Blocking Solution for 10 min at RT. After washing slides two times in PBS and 
once in PBST, samples were incubated with 2 % BSA in PBS for 20 min. Subsequently, tissue 
samples were incubated with the desired primary antibody diluted in Antibody Diluent either 
for 2 h at RT or overnight at 4 °C. After washing again three times as described before, the 
appropriate HRP-labelled secondary antibody diluted in Antibody Diluent was applied to the 
tissue specimens for 1 h at RT. Washing was conducted and samples were incubated with the 
AEC substrate for up to 10 min. Slides were washed in dH2O and counterstaining was 
performed using 10 % hematoxylin. After rinsing in H2O for several minutes, tissue sections 
were embedded in Faramount aqueous mounting media. Pictures were taken using the Nikon 
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Eclipse NI microscope and the NIS-Elements Advanced software (Nikon). Images were 
adjusted with Adobe Photoshop 6.0 software. 
 
3.4.9 Immunofluorescence (IF) 
 
Paraffin sections (1 µm) of human melanomas were prepared as described before (section 
3.4.8). Circles were drawn around the tissue sections using a DAKO pen and samples were 
blocked with 5 % donkey serum in PBS for 20 min at RT. Subsequently, tissue samples were 
incubated with the desired primary antibody diluted in 1 % donkey serum in PBS overnight at 
4 °C. After washing three times in PBS the appropriate fluorochrome-labelled secondary 
antibody diluted in Antibody Diluent was applied to the tissue specimens for 45 min at RT. 
Washing was conducted and tissue sections were embedded in Fluorescent mounting 
medium. Pictures were taken using the Nikon Eclipse NI microscope and the NIS-Elements 
Advanced software (Nikon). Images were adjusted with Adobe Photoshop 6.0 software. 
 
3.4.10 Sequential staining 
 
Paraffin sections (1 µm) of human melanoma samples were prepared as described before 
(section 3.4.8). Circles were drawn around the tissue sections using a DAKO pen and samples 
were blocked in 5 % skimmed milk powder in PBS for 20 min. Subsequently, tissue samples 
were incubated with the desired primary antibody diluted in antibody diluent either for 2 h at 
RT or overnight at 4 °C. After washing three times with PBS, the samples were incubated with 
Peroxidase Blocking Solution for 8 min at RT. The specimens were washed again three times 
with PBS followed by incubation with the appropriate HRP labelled secondary antibody diluted 
in Antibody Diluent for 1 h at RT. Washing was conducted as described before and samples 
were incubated with the HRP substrate VECTOR NovaRED Peroxidase solution for up to 
10 min. Slides were washed in dH2O for 5 min and counterstaining was performed using 10 % 
hematoxylin. After rinsing in H2O for several minutes, tissue sections were embedded in 
Faramount aqueous mounting media. After pictures were taken with the Nikon Eclipse NI 
microscope, the slides were placed in PBS to allow the coverslips to detach overnight. 
Specimens were destained in stripping buffer (2 % SDS, 62.5 mM Tris-HCL (pH 7.5), 0.8 % ß-
mercaptoethanol) for 1 h at 50 °C. Samples were washed two times in dH2O and once in PBS 
and were used again to stain another antigen of interest. 
 
3.4.11 Fluorescence-activated cell sorting (FACS) 
 
For surface staining, cells were harvested, washed in PBS and resuspended in 100 µL FACS 
surface buffer. The samples were incubated with 1.0 μL Fc block per 1 x 106 cells for 10 min 
and stained with the fluorochrome conjugated antibody for 20 min at room temperature in 
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the dark. After washing two times with FACS surface buffer, cells were resuspended in 200 μL 
FACS surface buffer (10 % BSA + 0.05 % NaN3 in PBS) and analyzed by flow cytometry using 
FACS-Canto™ II. Data analysis was conducted using FlowJo V 10.1 software. For intracellular 
staining, the Intracellular Fixation & Permeabilization Buffer Set was used. Cells were 
harvested, washed in PBS and fixed in 100 µL IC Fixation buffer for 20 min at RT. Cells were 
washed two times with 1 x Permeabilization Buffer and cell pellet was resuspended in 100 µL 
1 x Permeabilization Buffer and directly conjugated primary antibodies were added and 
incubated for 20 min at RT in the dark. After washing two times with 1 x Permeabilization 
Buffer, the cells were resuspended in 200 μL FACS buffer. Samples were analyzed by flow 
cytometry.  
For detection of reactive oxygen species (ROS) the hROS Detection Kit was used. pBMs were 
harvested, washed once in PBS and incubated with the probe Hydroxyphenyl fluorescein (HPF) 
for 30 min at 37 °C in the dark. In the presence of ROS, the probe is converted to a fluorescent 
dye. Cells were washed twice with PBS, resuspended in 200 µL PBS and analyzed by FACS.  
For nitric oxide synthase (NOS) detection, the NOS Detection Kit was used. pBMs were washed 
once in PBS and incubated with the probe DAF-2DA for 30 min at 4 °C. In the presence of NOS, 
the probe is converted to a fluorescent dye. Cells were washed twice with PBS, resuspended 
in 200 µL PBS and analyzed by flow cytometry. 
 
3.5 Mouse experiments 
 
3.5.1 Mice 
 
C57BL/6 were purchased from The Jackson Laboratory. Mice were housed under specific 
pathogen-free conditions at the animal facility at the UMM, Mannheim. All animal 
experiments were approved by the animal ethics committee (Regierungspräsidium Karlsruhe, 
Az: 35-9185.81/G-42/14). 
 
3.5.2 B16F10 melanoma model 
 
10–12-week-old female C57BL/6 mice were anesthetized by intraperitoneal injection of 
150 µL of a 10 % Ketamine/Rompun (20 mg/mL) mixture. 1 x 106 B16F10 cells were injected 
subcutaneously in the right flank of C57BL/6 mice. Mice were sacrificed after 10–14 days or 
when the tumors reached a diameter of 1.5 cm. Tumors were harvested and either directly 
processed further for isolation of CD11b+ cells or immediately shock frosted in liquid nitrogen, 
followed by storage at -80 °C to perform IHC of cryosections. 
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3.5.3 Isolation of murine macrophages 
 
Tumor-bearing mice were sacrificed 14 days after B16F10 cell injection or when the tumors 
reached a diameter of 1.5 cm. Peritoneal macrophages were isolated by injection of 10 mL ice 
cold PBS through the peritoneal wall flowed by aspiration of the fluid from the peritoneal 
cavity. Tumor and spleen were harvested and homogenized by squeezing through a 100 µm 
cell strainer. Collection tubes were filled up with ice cold PBS and samples were centrifuged 
at 300 g for 10 min. Spleen and intraperitoneal fluid were not enzymatically digested but 
directly used for MACS sorting. The tumor cell pellet was resuspended in 10 mL RPMI 
containing collagenase IV (190 U/mL) and DNAse I (500 U/mL). Tumor digestion was 
performed at 37 °C for 1 h, followed by washing once with PBS. Cell numbers were determined 
by hematocytometer and the cell pellets (tumors, spleen, intraperitoneal fluid) were 
resuspended in the appropriate amount of MACS buffer and CD11b MicroBeads according to 
the manufacturer’s instructions. Magnetic labelling of the cells was performed at 4 °C for 
20 min. Collection tubes were filled up with 10 mL MACS buffer, centrifuged at 300 g for 
10 min and cell pellets were resuspended in 1 mL MACS buffer. Cell suspensions were loaded 
on MS columns and cell sorting was performed as described in section 3.1.5. After washing 
the cells once in PBS, the pellet was directly used for RNA isolation. 
 
3.5.4 Generation of bone marrow-derived macrophages (BMDM) 
 
Bone marrow cells of C57BL/6 mice were isolated by flushing of femur and tibia with PBS. Cells 
were seeded at a concentration of 1 x 106 cells/mL in DMEM complete supplemented with 
30 ng/mL M-CSF and incubated at 37 °C and 7.5 % CO2 for 4 days. Subsequently, cell culture 
medium was replaced by DMEM complete containing 30 ng/mL M-CSF plus different pro- and 
anti-inflammatory stimuli as indicated. Cells were incubated for three additional days. 
STIMULI CONCENTRATION 
M-CSF 30 ng/mL 
IL-4 10 ng/mL 
Dexamethasone 5 x 10-7 M 
IFN-γ 10 ng/mL 
LPS 1 µg/mL 
 
3.6 Statistical analysis 
 
Data was analyzed using GraphPad Prism 6.0 software. Statistical significance was calculated 
by using standard Student’s t-test or by one-way ANOVA and Bonferroni as a post-test. The 
level of significance is indicated by asterisks (*** ≤ 0.001; ** ≤ 0.01 and * ≤ 0.05). Data is 
expressed as mean. Error bars depict standard error of mean (SEM) of each experiment. All 
experiments were performed at least in triplicates. 
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4. Results 
 
4.1 Characterization of P2Y12 expression in human pBM in vitro 
 
4.1.1 P2Y12 is strongly induced in MDI-treated pBM 
 
Our group aims to identify signaling pathways involved in the recruitment, expansion and 
differentiation of human TAM in melanoma. Since the whole melanoma is needed for 
diagnostic purposes and thus cannot be used for research applications such as ex vivo isolation 
of TAM, we had to generate an in vitro model that mirrors the TAM situation in vivo. We could 
show that many typical human TAM markers such as STABILIN-1 and LYVE-1 that are 
expressed in vivo need M-CSF/dexamethasone/IL-4 (MDI) for their induction in human 
peripheral blood monocytes (pBM) in vitro [350]. To identify possible novel therapeutic 
targets in human TAM, we performed microarray analysis of our in vitro generated M2-like 
macrophages (pBM(MDI)). We found the purinergic receptor P2Y12 as one of the highest up-
regulated genes in MDI- versus M-CSF-treated pBM. Various other prominent macrophage 
receptors such as LYVE1, ADORA3, CLEC10A were also significantly up-regulated in pBM(MDI) 
(Table 11). Since P2Y12 is a G protein coupled receptor (GPCR) that has not yet been described 
in TAM and is the target of clinically-approved oral anti-coagulation therapies (clopidogrel, 
prasugrel and ticagrelor), we further focused on the characterization of this molecule. 
 
Table 11. Microarray analysis of MDI-treated pBM. CD14+ pBM were isolated from the blood of three 
healthy donors and stimulated for 7 days with M-CSF or M-CSF/dexamethasone/IL-4 (MDI). Microarray 
analysis was performed and the fold change of MDI vs. M-CSF-treated pBM was calculated. 
GENE SYMBOL GENE NAME FOLD CHANGE 
P2RY12 purinergic receptor P2Y, G-protein coupled, 12 44.4 
P2RY14 purinergic receptor P2Y, G-protein coupled, 14 40.8 
CCL13 chemokine (C-C motif) ligand 13 33.9 
F13A1 coagulation factor XIII, A1 polypeptide 31.6 
FCER2 Fc fragment of IgE, low affinity II, receptor for (CD23) 30.8 
PDK4 pyruvate dehydrogenase kinase, isozyme 4 28.8 
GLDN gliomedin 22.9 
ADORA3 adenosine A3 receptor 21.3 
CD200R1 CD200 receptor 1 20.1 
LYVE1 lymphatic vessel endothelial hyaluronan receptor 1 15.0 
DAAM2 dishevelled associated activator of morphogenesis 2 14.5 
EPS8 epidermal growth factor receptor pathway substrate 8 12.1 
SESN1 sestrin 1 12.0 
SEP3 septin 3 11.7 
MAOA monoamine oxidase A 11.3 
CD209 CD209 molecule 11.2 
FGL2 fibrinogen-like 2 10.2 
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GENE SYMBOL GENE NAME FOLD CHANGE 
SHMT1 serine hydroxymethyltransferase 1 (soluble) 9.5 
MTSS1 metastasis suppressor 1 9.1 
SOCS1 suppressor of cytokine signaling 1 9.1 
HRH1 histamine receptor H1 9.0 
KCNJ2 potassium inwardly-rectifying channel, subfamily J, member 2 8.7 
MYC v-myc myelocytomatosis viral oncogene homolog (avian) 8.4 
SUCNR1 succinate receptor 1 8.3 
IL17RB interleukin 17 receptor B 8.2 
SCN9A sodium channel, voltage-gated, type IX, alpha subunit 8.2 
TGFBR3 transforming growth factor, beta receptor III 7.9 
FLT3 fms-related tyrosine kinase 3 7.8 
GGT5 gamma-glutamyltransferase 5 7.7 
MS4A6E membrane-spanning 4-domains, subfamily A, member 6E 7.4 
GCNT1 glucosaminyl (N-acetyl) transferase 1, core 2 6.9 
SLAMF1 signaling lymphocytic activation molecule family member 1 6.6 
CLEC10A C-type lectin domain family 10, member A 6.6 
 
 
4.1.2 MDI induces a M2-like macrophage phenotype in pBM 
 
Since we found P2Y12 to be up-regulated in MDI-treated pBM we wanted to know whether 
our in vitro generated macrophages exhibit a M2 phenotype. The scavenger receptor CD163 
as well as mannose receptor C-type 1 (CD206) are commonly used to identify human M2 
macrophages [351]. We isolated CD14+ pBM from the blood of healthy donors, differentiated 
them with MDI and M-CSF for 7 days and analyzed the expression of macrophage markers, 
chemokine receptors as well as ectonucleotidases by FACS analysis. We found that CD206, 
CD163 as well as CD73, which generates the immunosuppressive mediator adenosine, were 
significantly up-regulated whereas the cytokine receptors CCR2 and CXCR4 were significantly 
down-regulated in MDI-treated pBM. Expression of the ATP-hydrolyzing enzyme CD39 did not 
significantly differ between M-CSF and MDI-treated pBM. There was also no significant 
difference regarding the expression of the MHC class II surface receptor human leukocyte 
antigen (HLA-DR), CD11b and CD14 (Figure 9). 
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Figure 9. Characterization of MDI-treated pBM by FACS. pBM were stimulated for 7 days with M-CSF 
or MDI and the expression of macrophage markers, chemokine receptors as well as ectonucleotidases 
was analyzed by FACS. Live cells were gated on FSC/SSC and the percentage of positive cells was 
calculated from live cells (n=3). 
 
Besides their characteristic surface marker profile, M2 macrophages are also known to express 
high levels of anti-inflammatory cytokines and low levels of pro-inflammatory cytokines [48]. 
We stimulated pBM for 7 days with MDI and assessed gene expression of various cytokines 
and other mediators by qRT-PCR. We detected an up-regulation of the anti-inflammatory and 
immunosuppressive cytokines TGF-ß and IL-10 as well as arginase-1 in pBM(MDI) compared to 
pBM(MCSF). In contrast, pro-inflammatory cytokines associated with a M1 phenotype such as 
TNF-α and IL-1ß as well as the chemokine CCL2 were significantly down-regulated in pBM(MDI) 
compared to pBM(MCSF) (Figure 10 a). Levels of pro-inflammatory cytokines in the cell 
supernatants of pBM were determined by ELISA. We detected significantly reduced 
concentrations of TNF-α and IL-1ß in the supernatants of MDI-treated pBM (Figure 10 b).  
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Figure 10. pBM(MDI) express higher levels of anti-inflammatory and lower levels of pro-inflammatory 
cytokines. (a) pBM were stimulated with M-CSF or MDI for 7 days and the expression of pro- and anti-
inflammatory mediators was analyzed by qRT-PCR (n=6). (b) Cell supernatants of pBM treated with 
M-CSF or MDI for 7 days were collected, and the concentration of the indicated mediators was 
determined by ELISA (n=4).  
 
Whereas in M2-like TAM arginase-1 is mainly responsible for L-arginine depletion, pro-
inflammatory M1 macrophages deplete L-arginine via iNOS activation to produce NO. 
Furthermore, M1 macrophages show a high ROS production, which is important for the killing 
of bacteria and viruses [48]. We assessed the production of ROS as well as the expression of 
NOS in pBM by FACS analysis. Whereas pBM(MDI) produce significantly lower levels of ROS 
compared to pBM(MCSF), there was no significant difference regarding the percentage of NOS-
expressing cells (Figure 11). 
Taken together, our results indicate that treatment of pBM with MDI results in a M2-like 
macrophage phenotype based on their marker expression and cytokine profile. 
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Figure 11. ROS production is impaired in pBM(MDI). pBM were stimulated for 7 days with M-CSF or 
MDI. Presence of reactive oxygen species (ROS) and nitric oxide synthase (NOS) was detected by 
loading the cells with the probes HPF and DAF-2, respectively. The median fluorescence intensity (MFI) 
of ROS and NOS producing cells was analyzed by FACS (n=8).  
 
4.1.3 Generation of an anti-P2Y12 peptide antibody and characterization of its 
specificity in transgenic U937 cells 
 
Since we detected an up-regulation of P2Y12 in pBM(MDI) by gene expression analysis, we next 
aimed at verifying P2Y12 expression in MDI-treated pBM on protein level. A rabbit polyclonal 
anti-hsP2Y12 peptide antibody against the C-terminal peptide sequence 
SQDNRKKEQDGGDPNEETPM was generated (Figure 12 a) as none of the commercially 
available anti-hsP2Y12 antibodies proofed specific. Our anti-hsP2Y12 antibody unambiguously 
detected P2Y12 in self-generated transgenic U937 cells, that stably express P2Y12 on mRNA 
level (Figure 12 b), by Western blot analysis (Figure 12 c), Immunocytochemistry (Figure 12 d) 
as well as by FACS analysis (Figure 12 e). Since the transgene P2Y12 is tagged with a Flag tag 
we used an anti-Flag M2 antibody to confirm P2Y12-Flag expression on protein level 
(Figure 12 c–f). In the Western blot analysis, we detected a specific band at a molecular weight 
of 43 kDa in P2Y12+ U937 cells, whereas empty vector (EV) cells did not show this band. FACS 
analysis also revealed that P2Y12 and Flag are over-expressed in P2Y12+ U937 cells. However, 
40 % of all EV cells were P2Y12 positive, while only around 10 % were positive for the Flag tag 
(Figure 12 e). Immunofluorescence revealed co-expression of P2Y12 and Flag in P2Y12+ U937 
cells, whereas EV cells neither showed P2Y12 nor Flag expression (Figure 12 f).  
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Figure 12. Validation of an anti-hsP2Y12 peptide antibody using transgenic U937 cells. (a) A 
polyclonal anti-hsP2Y12 antibody targeting the intracellular, C-terminal sequence 
SQDNRKKEQDGGDPNEETPM was generated by immunization of a rabbit with the synthesized peptide. 
(b) P2Y12 mRNA expression in transgenic U937 cells was assessed by qRT-PCR (n=4). (c–f) P2Y12 and 
Flag expression of transgenic U937 cells were assessed by Western blot analysis (c), 
immunocytochemistry (d), FACS analysis (e) and immunofluorescence (f) using the self-generated 
rabbit anti-hsP2Y12 antibody and an anti-Flag M2 antibody, respectively. Scale bar = 100 µm. 
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4.1.4 P2Y12 is expressed in MDI-treated pBM and its induction can be inhibited 
with mifepristone 
 
qRT-PCR analysis corroborated the microarray result showing that MDI strongly induces P2Y12 
mRNA in in vitro stimulated pBM whereas M-CSF leads to no induction (Figure 13 a). Western 
blot analysis with the self-generated anti-hsP2Y12 antibody confirmed P2Y12 expression on 
protein level in 4 different donors (Figure 13 b). The induction of P2Y12 expression was time 
dependent reaching the highest mRNA expression level after 5 days of stimulation whereas 
protein expression was even stronger after 7 days of MDI treatment (Figure 13 c–d).  
We next determined whether other anti- or pro-inflammatory cytokines can induce P2Y12 
expression in pBM. Treatment of pBM with IL-4 or dexamethasone alone as well as with LPS, 
TNF- or TNF- + IFN-γ did not induce P2Y12 expression on mRNA level, while IFN-γ alone 
showed a slightly P2Y12 induction (Figure 13 e). However, on protein level, P2Y12 expression 
was not detectable in IFN-γ-treated pBM (Figure 13 f). Besides IL-4/dexamethasone, no other 
tested anti-inflammatory cytokines (IL-10 and TGF-β) induced P2Y12 expression on the protein 
level (Figure 13 f).   
Treatment of pBM with the glucocorticoid receptor inhibitor mifepristone significantly 
abrogated the MDI-induced P2Y12 expression on mRNA level (Figure 13 g). Treatment with 
other signaling pathway inhibitors such as a NF-κB inhibitor or a p38 MAPK inhibitor did not 
significantly alter P2Y12 induction (Figure 13 h).  
Taken together, our results indicate that P2Y12 can only be induced by the combined 
treatment of pBM with MDI and its expression can be inhibited with the GC receptor inhibitor 
mifepristone.  
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Figure 13. P2Y12 expression is induced in MDI-treated pBM. (a–b) P2Y12 expression in pBM treated 
with MDI or M-CSF for 7 days was analyzed by qRT-PCR (a) and Western blot analysis (b) (n=11). (c–d) 
Time dependent induction of P2Y12 expression after 3 days, 5 days and 7 days was analyzed by qRT-
PCR (c) and Western blot analysis (d) (n=6). (e–f) P2Y12 expression was assessed after treatment of 
pBM with M-CSF alone or M-CSF plus the indicated pro-and anti-inflammatory cytokines for 7 days by 
qRT-PCR (e) or Western blot analysis (f) (n=7). For all experiments one representative Western blot is 
depicted. (g) P2Y12 induction in pBM treated with M-CSF, MDI or MDI plus mifepristone for 7 days was 
assessed by qRT-PCR. Cells treated with equivalent concentrations of ethanol (EtOH) were used as 
control (n=4). (h) P2Y12 expression in pBM treated with M-CSF, MDI, MDI plus NF-κB inhibitor or MDI 
plus p38 MAPK inhibitor was assessed by qRT-PCR. Cells treated with equivalent concentrations of 
dimethyl sulfoxide (DMSO) were used as control (n=8).  
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4.2 Characterization of P2Y12 expression in human macrophages in vivo 
 
4.2.1 P2Y12 is expressed in microglia cells and splenic macrophages 
 
Since it has been described that P2Y12 is expressed by microglia cells in vivo, we stained 
human glioblastoma sections immunohistochemically to verify specificity of our self-
generated anti-hsP2Y12 antibody in formalin-fixed paraffin embedded (FFPE) tissue. We 
found P2Y12 strongly expressed in a subpopulation of CD68+ brain-resident macrophages 
(Figure 14 a). In situ hybridization of glioblastoma tissue also revealed P2Y12 mRNA 
expression in microglia cells (Figure 14 b). 
 
Figure 14. Identification of P2Y12+ cells in human glioblastoma. (a) Immunohistochemical staining of 
a human glioblastoma using anti-hsP2Y12, anti-hsCD68 and isotype control of the anti-hsP2Y12 
antibody (rabbit IgG). One representative picture is shown for each staining and magnification. Scale 
bar = 100 µm. (b) In situ hybridization of P2Y12 mRNA in human glioblastoma. One representative 
picture is shown. Scale bar = 100 µm. 
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To investigate whether P2Y12 is also expressed by other tissue macrophages, we stained 
human spleen sections with the self-generated anti-hsP2Y12 antibody. P2Y12 was strongly 
expressed in the spleen. Like in human glioblastoma, not all CD68+ splenic macrophages co-
expressed P2Y12. CD68+ P2Y12+ macrophages were mostly found in the marginal zone of the 
splenic follicles and not so much in the germinal center and in the red pulp (Figure 15). 
 
 
Figure 15. Identification of P2Y12+ cells in human spleen. Immunohistochemistry of human spleen 
sections using anti-hsP2Y12, anti-hsCD68 and the respective isotype control of the anti-hsP2Y12 
antibody (rabbit IgG). One representative picture is shown for each staining. Scale bar = 100 µm. 
 
 
4.2.2 P2Y12 is expressed in human TAM of melanoma 
 
Since our self-generated antibody proofed specific, we analyzed the expression of P2Y12 in 
human TAM of melanoma in situ. By immunohistochemistry we detected P2Y12 expression 
on a subset of CD68+ macrophages in human primary melanoma (Figure 16 a). P2Y12+ 
macrophages were mainly situated at the tumor periphery. In addition, we found P2Y12 not 
only expressed in macrophages of the primary tumor but also in skin metastatic lesions of 
melanoma (Figure 16 b). To detect P2Y12 mRNA expression in TAM of metastatic melanoma, 
we performed in situ hybridization. P2Y12 mRNA was identified in human skin metastases 
(Figure 16 c).  
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Figure 16. Identification of P2Y12+ macrophages in human melanoma. (a) Serial 
immunohistochemical staining of a human primary melanoma using anti-hsP2Y12 and anti-hsCD68 
antibodies. One representative picture is shown for each staining. Scale bar = 100 µm. (b) 
Immunohistochemistry of a skin metastases using anti-hsP2Y12 and anti-hsCD68 antibodies. One 
representative picture is shown for each staining. Scale bar = 50 µm. (c) In situ hybridization of 
melanoma skin metastases using a P2Y12-specific probe. Small red dots indicate P2Y12 mRNA. Two 
representative pictures are shown. Scale bar = 25 µm. 
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To specifically detect P2Y12 in CD68+/CD163+ macrophages in melanoma, we established a 
sequential staining protocol which allows staining of the same slide consecutively with three 
different antibodies (anti-P2Y12, anti-CD68 and anti-CD163). We found P2Y12 to be co-
expressed on a subpopulation of CD68+ and CD163+ cells in human primary melanoma 
(Figure 17 a). Immunofluorescent stainings confirmed this co-expression in TAM within the 
tumor tissue (Figure 17 b). 
 
Figure 17. P2Y12 is co-expressed in CD68+ and CD163+ macrophages. (a) Sequential staining of a 
human melanoma section using anti-P2Y12, anti-CD68 and anti-CD163 antibodies. (b) 
Immunofluorescent double staining of primary melanoma using anti-P2Y12 (green) / anti-CD68 (red) 
and anti-P2Y12 (green) / anti-CD163 (red) antibodies. One representative picture is shown for each 
staining. Scale bar = 100 µm. 
 
After identification of P2Y12+ macrophages in primary as well as metastatic melanoma, we 
analyzed P2Y12 expression in melanocytic naevi. Immunohistochemical stainings did not 
reveal P2Y12 expression in human naevi, though CD68+ macrophages were present in the 
tissue (Figure 18 a). To visualize P2Y12 mRNA in melanocytic naevi, we performed in situ 
hybridization with a P2Y12-specific probe. Likewise, we could not detect P2Y12 mRNA 
expression in naevi sections (Figure 18 b). 
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Figure 18. P2Y12 is not expressed in melanocytic naevi. (a) Immunohistochemical staining of human 
naevi using anti-hsP2Y12 and anti-hsCD68 antibodies as well as isotype control of the anti-hsP2Y12 
antibody (rabbit IgG). Two representative pictures are shown. Scale bar = 100 µm. (b) In situ 
hybridization of P2Y12 mRNA in human melanocytic naevi. Two representative pictures are shown. 
Scale bar = 50 µm. 
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4.3 Characterization of P2Y12 expression in murine macrophages 
 
4.3.1 Validation of the specificity of a commercial anti-P2Y12 antibody using 
transgenic Raw 264.7 cells 
 
Since we could show that P2Y12 is expressed in human TAM as well as in splenic and brain 
macrophages, we hypothesized that the purinergic receptor is also expressed in murine 
macrophages. To detect murine P2Y12, we first validated the specificity of a commercially 
available anti-P2Y12 antibody using transgenic P2Y12+ Raw 264.7 cells that stably overexpress 
P2y12. qRT-PCR confirmed mRNA over-expression, and Western blot analysis as well as 
immunocytochemical staining verified protein over-expression in transgenic P2Y12+ Raw 
264.7 cells (Figure 19).  
 
Figure 19. Characterization of a commercially available anti-P2Y12 antibody in transgenic Raw 264.7 
cells. (a) qRT-PCR analysis of P2y12 mRNA in transgenic Raw 264.7 cells (n=3). (b) Western blot analysis 
of transgenic Raw 264.7 cells using an anti-P2Y12 antibody. (c) Transgenic Raw 264.7 cells were 
immunocytochemically stained using an anti-P2Y12 antibody. One representative picture is shown. 
Scale bar = 50 µm. 
 
Results 
___________________________________________________________________________
68 
4.3.2 P2Y12 is induced in bone marrow-derived macrophages by MDI and is 
expressed in murine macrophages in vivo 
 
We further characterized P2Y12 expression in murine macrophages in vitro and in vivo. First, 
we investigated whether similar stimulations as used in the human system can induce P2y12 
also in in vitro generated murine BMDM. P2y12 mRNA was significantly induced in BMDM by 
MDI compared to M-CSF + IFN- and M-CSF + LPS but not compared to M-CSF treatment. 
Compared to M-CSF-treated BMDM there was a significant down-regulation of P2y12 mRNA 
in M-CSF + LPS treated BMDM (Figure 20 a)  
 
 
Figure 20. P2Y12 is induced in MDI-treated BMDM in vitro and is expressed by murine macrophages 
in vivo. (a) qRT-PCR analysis of P2y12 expression in BMDM stimulated with the indicated cytokines 
(n=4). (b) CD11b+ cells were isolated from the peritoneal fluid, spleen and from subcutaneously grown 
B16F10 tumors by MACS technology. P2y12 expression was assessed by qRT-PCR analysis (n=4). (c) 
Immunohistochemical staining of a murine B16F10 tumor using an anti-P2Y12 antibody. One 
representative picture is shown. Scale bar = 50 µm. (d) In situ hybridization of P2y12 mRNA in a B16F10 
tumor. One representative picture is shown. Scale bar = 50 µm. 
 
Results 
___________________________________________________________________________
69 
To investigate P2y12 expression in murine TAM ex vivo, we isolated CD11b+ cells from 
subcutaneously grown B16F10 tumors. In addition, P2y12 expression was analyzed in 
peritoneal as well as splenic macrophages from tumor-bearing as well as tumor-free mice. 
P2y12 was expressed by TAM as well as by peritoneal and splenic macrophages. Interestingly, 
P2y12 expression in splenic and peritoneal macrophages was significantly higher in tumor-
free mice compared to tumor-bearing mice (Figure 20 b).   
Immunohistochemical stainings of B16F10 tumors with an anti-P2Y12 Ab revealed that P2Y12 
was mainly expressed in macrophages situated in the tumor periphery (Figure 20 c). To 
confirm P2y12 mRNA expression in B16F10 tumors, we performed in situ hybridization. 
Comparable to our protein data, we detected P2y12 mRNA in the periphery of B16F10 tumors 
(Figure 20 d). 
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4.4 Functional characterization of P2Y12+ macrophages 
 
4.4.1 Gene expression analysis of ADP-treated P2Y12+ U937 cells 
 
To identify genes that are up-regulated by the P2Y12 receptor agonist 2-Methylthio-
adenosine-5'-diphosphate (ADP) in transgenic U937 cells, we performed microarray analysis 
after two time points (4 h and 24 h) of ADP stimulation. We identified several genes up-
regulated in ADP-treated P2Y12+ U937 cells (P2Y12 ADP) compared to untreated P2Y12+ U937 
cells (P2Y12 CTRL) that are associated with cell motility migration and invasion. Among these 
genes were the matrix metalloproteinases MMP7 and MMP14, urokinase/plasminogen 
activator (PLAU), urokinase/plasminogen activator receptor (PLAUR), the plasminogen 
activator inhibitors SERPINE1 and SERPINB2 as well as heparanase (HPSE) (Figure 21). These 
genes were not significantly up-regulated in ADP-treated EV cells (EV ADP) compared to 
untreated EV U937 cells (EV CTRL) (Figure 21 and Table 12). The highest up-regulated gene in 
P2Y12 ADP compared to P2Y12 CTRL was the chemokine CXCL8 (IL-8), followed by the 
chemokine CXCL7 (PPBP, pro-platelet basic protein) (Table 12). We identified several other 
chemokines (CCL3L3, CXCL3, CCL20, CXCL2), cytokines (IL-1ß, TGF-ß3, TNFSF15, TNFSF8) and 
growth factors (HB-EGF) up-regulated in P2Y12 ADP compared to P2Y12 CTRL (Table 12 and 
Figure 22). Interestingly, CXCL7, CXCL8 as well as TGF-ß3 were also induced in EV ADP 
compared to EV CTRL, but the fold change (FC) was much lower than in P2Y12 ADP (Table 12). 
 
 
Figure 21. Heatmap showing a selection of genes associated with cell motility, invasion and 
migration up-regulated by ADP in P2Y12+ U937 cells after 4 h. 
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Table 12. Gene expression analysis of transgenic U937 cells showing up-regulated genes after 4 h of 
ADP stimulation. 
GENE SYMBOL GENE NAME 
FC 
P2Y12 ADP vs. 
P2Y12 CTRL 
FC 
EV ADP vs. 
EV CTRL 
CXCL8  chemokine (C-X-C motif) ligand 8  62.8 2.0 
PPBP  pro-platelet basic protein (CXCL7)  60.0 1.3 
IL1B  interleukin 1, beta  31.3 ns 
TRAC  T cell receptor alpha constant  27.7 ns 
TM4SF1  transmembrane 4 L six family member 1  27.2 4.9 
DCSTAMP  dendrocyte expressed seven transmembrane protein  17.9 3.1 
KIAA0226L  KIAA0226-like  13.7 1.6 
SERPINE1  serpin peptidase inhibitor, clade E  13.5 ns 
USP53  ubiquitin specific peptidase 53  12.5 ns 
SHC4  SHC (Src homology 2 domain containing) family member 4 11.7 ns 
TGFB3  transforming growth factor, beta 3  11.5 1.8 
HAVCR2  hepatitis A virus cellular receptor 2  10.8 2.3 
BCL2A1  BCL2-related protein A1  9.2 1.5 
GLIPR1  GLI pathogenesis-related 1  9.1 2.1 
TNFSF15  tumor necrosis factor (ligand) superfamily member 15 8.9 ns 
CCL3L3  chemokine (C-C motif) ligand 3-like 3  8.6 ns 
CXCL3  chemokine (C-X-C motif) ligand 3  8.4 ns 
SERPINB2  serpin peptidase inhibitor, clade B  8.4 ns 
PHLDA1  pleckstrin homology-like domain, family  7.9 ns 
LUCAT1  lung cancer associated transcript 1  7.4 ns 
TGFBI  transforming growth factor, beta-induced  6.3 ns 
TRAF1  TNF receptor-associated factor 1  6.1 ns 
MGAM  maltase-glucoamylase  6.0 ns 
MAML2  mastermind-like transcriptional coactivator  5.7 ns 
PLAUR  plasminogen activator, urokinase receptor  5.4 ns 
TMEM158  transmembrane protein 158  5.2 ns 
DLGAP1-AS2  DLGAP1 antisense RNA 2  4.9 ns 
PLAU  plasminogen activator, urokinase  4.9 ns 
MACC1  metastasis associated in colon cancer 1  4.7 ns 
MAFB  v-maf avian musculoaponeurotic fibrosarcoma  4.6 ns 
NT5E  5'-nucleotidase, ecto (CD73)  4.4 ns 
DUSP16  dual specificity phosphatase 16  4.4 ns 
CCL20  chemokine (C-C motif) ligand 20  4.3 ns 
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Among the genes that were down-regulated by ADP in P2Y12+ U937 cells compared to P2Y12 
CTRL were the chemokine receptors CXCR4 and CCR2 (Table 13 and Figure 22). Furthermore, 
ADP suppressed the expression of the purinergic receptor P2RY8 in P2Y12 ADP compared to 
P2Y12 CTRL. These genes were not significantly down-regulated in EV ADP compared to EV 
CTRL (Table 13). 
 
 
Table 13. Gene expression analysis of transgenic U937 cells showing down-regulated genes after 4 h 
of ADP stimulation. 
GENE SYMBOL GENE NAME 
FC 
P2Y12 ADP vs. 
P2Y12 CTRL 
FC 
EV ADP vs. 
EV CTRL 
KIT  v-kit Hardy-Zuckerman 4 feline sarcoma v  0.2 ns 
BTLA  B and T lymphocyte associated  0.2 ns 
MYB  v-myb avian myeloblastosis viral oncogene  0.3 ns 
FGL2  fibrinogen-like 2  0.3 ns 
CXorf21  chromosome X open reading frame 21  0.3 ns 
CXCR4  chemokine (C-X-C motif) receptor 4  0.3 ns 
KBTBD7  kelch repeat and BTB (POZ) domain 0.3 ns 
BCL11A  B-cell CLL/lymphoma 11A  0.3 ns 
MIR223  microRNA 223  0.3 ns 
CCR2  chemokine (C-C motif) receptor 2  0.4 ns 
JMY  junction mediating and regulatory protein 0.4 ns 
CD34  CD34 molecule  0.4 ns 
NR1D2  nuclear receptor subfamily 1, group D  0.4 ns 
RAP1GAP2  RAP1 GTPase activating protein 2  0.4 ns 
ZMYM3  zinc finger, MYM-type 3  0.4 ns 
LOC102723703  uncharacterized LOC102723703  0.4 ns 
FLJ42627  uncharacterized LOC645644  0.4 ns 
ZBTB12  zinc finger and BTB domain containing 12  0.4 ns 
PHLPP1  PH domain and leucine rich repeat protein 0.4 ns 
FAM117B  family with sequence similarity 117, member B 0.4 ns 
P2RY8  purinergic receptor P2Y, G-protein coupled, 8 0.4 ns 
DTX4  deltex 4, E3 ubiquitin ligase  0.4 ns 
TFAP4  transcription factor AP-4 0.4 ns 
FUT7  fucosyltransferase 7 (alpha (1,3) fucosyltransferase) 0.4 ns 
KANK2  KN motif and ankyrin repeat domains 2  0.4 ns 
NCF1C  neutrophil cytosolic factor 1C pseudogene  0.5 ns 
TRIM71  tripartite motif containing 71  0.5 ns 
KCTD21-AS1  KCTD21 antisense RNA 1  0.5 ns 
DBP  D site of albumin promoter 0.5 ns 
ASB13  ankyrin repeat and SOCS box containing 13  0.5 ns 
PARP8  poly (ADP-ribose) polymerase family, member 8 0.5 ns 
CNOT6L  CCR4-NOT transcription complex, subunit 6 like 0.5 ns 
HSH2D  hematopoietic SH2 domain containing protein 0.5 ns 
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Figure 22. Heatmap showing a selection of chemokines, cytokines, growth factors and chemokine 
receptors up-regulated and down-regulated by ADP in P2Y12+ U937 cells after 4 h. 
 
 
After 24 h of ADP stimulation, the chemokine CXCL7 was still strongly induced in P2Y12 ADP 
compared to P2Y12 CTRL (Table 14). Furthermore, the microglia marker GPR34 as well as the 
macrophage markers MRC1 (CD206) and CD68 were up-regulated upon ADP treatment of 
P2Y12+ U937 cells. Additional surface molecules that were found to be up-regulated in P2Y12 
ADP versus P2Y12 CTRL were the tetraspanins CD82 and TSPAN7 as well as CD52 and CD34. 
These genes were not induced in EV ADP compared to EV CTRL (Table 14 and Figure 23). 
Among the genes that were significantly down-regulated in P2Y12 ADP versus P2Y12 CTRL 
were SERPINE2, CD48 and the adhesion receptor ADGRA3 (Table 15). 
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Table 14. Gene expression analysis of transgenic U937 cells showing up-regulated genes after 24 h 
of ADP stimulation. 
GENE SYMBOL GENE NAME 
FC 
P2Y12 ADP vs. 
P2Y12 CTRL 
FC 
EV ADP vs. 
EV CTRL 
PPBP  pro-platelet basic protein (CXCL7)  25.2 ns 
IFI44L  interferon-induced protein 44-like  8.2 ns 
OAS2  2'-5'-oligoadenylate synthetase 2 6.9 ns 
CD82  CD82 molecule  4.7 ns 
OAS3  2'-5'-oligoadenylate synthetase 3 4.1 ns 
IFI6  interferon, alpha-inducible protein 6  3.8 ns 
ISG15  ISG15 ubiquitin-like modifier  3.7 ns 
OAS1  2'-5'-oligoadenylate synthetase 1  3.6 ns 
CD34  CD34 molecule  3.6 ns 
GPR34  G protein-coupled receptor 34  3.4 ns 
MRC1  mannose receptor, C type 1  3.4 ns 
TSPAN7  tetraspanin 7  3.1 ns 
DDX60  DEAD (Asp-Glu-Ala-Asp) box polypeptide 60  3.0 ns 
XAF1  XIAP associated factor 1  3.0 ns 
HERC6  HECT and RLD domain containing E3 ubiquitin  2.7 ns 
IFIT3  interferon-induced protein with tetratricopeptide  2.7 ns 
IRF9  interferon regulatory factor 9  2.6 ns 
IFIT1  interferon-induced protein with tetratricopeptide  2.6 ns 
CLNK  cytokine-dependent hematopoietic cell linker  2.5 ns 
SAMD9L  sterile alpha motif domain containing 9-like  2.5 ns 
CD52  CD52 molecule  2.4 ns 
SAMD9  sterile alpha motif domain containing 9  2.4 ns 
SIGLEC17P  sialic acid binding Ig-like lectin 17, pseudogene  2.4 ns 
IFI27  interferon, alpha-inducible protein 27  2.4 ns 
ADAM28  ADAM metallopeptidase domain 28  2.4 ns 
BTLA  B and T lymphocyte associated protein 2.4 ns 
UBA7  ubiquitin-like modifier activating enzyme 7 2.3 ns 
CD68  CD68 molecule  2.3 ns 
GSN  gelsolin  2.2 ns 
MILR1  mast cell immunoglobulin-like receptor 1  2.2 ns 
SP110  SP110 nuclear body protein  2.1 ns 
RNASE6  ribonuclease, RNase A family, K6  2.1 ns 
S100A10  S100 calcium binding protein A10  2.0 ns 
 
 
 
 
Results 
___________________________________________________________________________
75 
 
Figure 23. Heatmap showing a selection of surface molecules and receptors up-regulated in P2Y12+ 
U937 cells after 24 h of ADP treatment. 
 
Table 15. Gene expression analysis of transgenic U937 cells showing down-regulated genes after 24 h 
of ADP stimulation. 
GENE SYMBOL  GENE NAME 
FC 
P2Y12 ADP vs. 
P2Y12 CTRL 
FC 
EV ADP vs. 
EV CTRL 
AKR1C3  aldo-keto reductase family 1, member C3  0.48 ns 
CSAD  cysteine sulfinic acid decarboxylase  0.60 ns 
CTH  cystathionine gamma-lyase  0.66 ns 
CHAC1  glutathione-specific gamma-glutamylcyclotransferase 1 0.68 ns 
PAXIP1-AS1  PAXIP1 antisense RNA 1 (head to head)  0.69 ns 
DDIT4  DNA-damage-inducible transcript 4  0.69 ns 
GPT2  glutamic pyruvate transaminase 2 0.69 ns 
DANCR  differentiation antagonizing non-protein coding RNA 0.70 ns 
QPCTL  glutaminyl-peptide cyclotransferase-like  0.70 ns 
MYT1  myelin transcription factor 1  0.70 ns 
NME1  NME/NM23 nucleoside diphosphate kinase 1  0.71 ns 
TUBE1  tubulin, epsilon 1  0.72 ns 
SNHG10  small nucleolar RNA host gene 10  0.72 ns 
SERPINE2  serpin peptidase inhibitor, clade E  0.72 ns 
PWAR5  Prader Willi/Angelman region RNA 5  0.73 ns 
FBXL13  F-box and leucine-rich repeat protein 13  0.73 ns 
IPO4  importin 4  0.73 ns 
GCLM  glutamate-cysteine ligase, modifier subunit 0.74 ns 
TRBV10-2  T cell receptor beta variable 10-2  0.74 ns 
METTL2A  methyltransferase like 2A  0.75 ns 
HID1  HID1 domain containing  0.75 ns 
CD48  CD48 molecule  0.76 ns 
PSMD3  proteasome 26S subunit, non-ATPase 3  0.76 ns 
CKMT2-AS1  CKMT2 antisense RNA 1  0.77 ns 
ADGRA3  adhesion G protein-coupled receptor A3  0.77 ns 
ANKRD39  ankyrin repeat domain 39  0.77 ns 
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Since it is known that P2Y12 is an important immunomodulatory receptor in microglia cells, 
we focused on cytokines and chemokines induced by ADP in P2Y12+ U937 cells. We confirmed 
expression of the highest up-regulated cytokines and chemokines (IL-8, CXCL7, CXCL2, IL-1ß, 
CCL3L3, CXCL3, HB-EGF, CCL20 and TGF-ß3) in P2Y12 ADP by qRT-PCR (Figure 24). 
 
 
 
Figure 24. Validation of microarray data by qRT-PCR focusing on cytokines and chemokines. 
Transgenic U937 cells were treated with 50 nM ADP for 4 h and gene expression of the indicated 
cytokines and chemokines was assessed by qRT-PCR (n=3). 
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4.4.2 Cytokine and chemokine expression in ADP-treated pBM(MDI) 
 
In order to analyze whether the same genes that were up-regulated in ADP-treated P2Y12+ 
U937 cells are also induced in P2Y12-expressing MDI-treated pBM upon ADP stimulation, we 
isolated human pBM and stimulated them for 7 days with MDI followed by ADP treatment for 
the indicated time points. Except for TGF-ß, which was not induced by ADP, and CXCL2, which 
was suppressed by ADP, all analyzed cytokines and chemokines that were induced in ADP-
treated P2Y12+ U937 cells were also found to be up-regulated in ADP-stimulated pBM(MDI) 
when compared to unstimulated pBM(MDI) (Figure 25). In contrast to P2Y12+ U937 cells, up-
regulation of most analyzed mRNAs occurred after 1–2 h in MDI-treated pBM and reached 
basal levels already after 4 h stimulation with ADP. Induction of CXCL7, which was one of the 
highest up-regulated genes in ADP-treated P2Y12+ U937 cells, was not significantly up-
regulated in ADP-treated pBM(MDI) (Figure 25).  
 
Figure 25. Cytokine and chemokine mRNA expression is also induced in ADP-treated pBM(MDI). CD14+ 
pBM were isolated from the blood of healthy donors and stimulated with MDI for 7 days followed by 
treatment with 50 nM ADP for the indicated time points. Gene expression of the indicated cytokines 
and chemokines was assessed by qRT-PCR (n=4). 
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Since we detected induction of the pro-inflammatory cytokine IL-1ß in ADP-treated pBM(MDI) 
we analyzed other typical cytokines associated with a pro-inflammatory and anti-
inflammatory macrophage phenotype. We showed before that expression of TNF-α and CCL2 
is significantly down-regulated in pBM(MDI) compared to pBM(M-CSF) whereas the expression of 
IL-10 and TGF-ß is induced upon MDI-treatment (Figure 10). We now assessed the expression 
of these mediators after treatment of pBM(MDI) with 50 nM ADP for 30 min, 1 h, 2 h and 4 h. 
ADP induced the expression of the pro-inflammatory cytokine TNF-α and the chemokine CCL2 
whereas it suppressed the expression of the anti-inflammatory and immunosuppressive 
cytokines TGF-ß and IL-10 (Figure 26). These data suggest that ADP reprograms macrophages 
towards a pro-inflammatory phenotype. 
 
 
 
Figure 26. ADP up-regulates pro-inflammatory mediators in MDI-treated pBM. CD14+ pBM were 
treated with MDI for 7 days followed by stimulation with 50 nM ADP for the indicated time points. 
Gene expression of the indicated cytokines and chemokines was assessed by qRT-PCR (n=4). 
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4.4.3 ADP-induced chemokine secretion in P2Y12+ U937 cells can be inhibited by 
the specific P2Y12 antagonist PSB0739 
 
To assess whether cytokine secretion is also enhanced by ADP in P2Y12+ U937 cells, we 
analyzed concentrations of IL-8 (CXCL8), CXCL7 and CXCL2 in the cell supernatants of ADP-
treated P2Y12+ U937 cells by ELISA. Indeed, ADP treatment promoted the secretion of all three 
chemokines. CXCL7 levels in the cell supernatant of P2Y12 ADP were highest (511 pg/mL), 
followed by IL-8 (454 pg/mL) and CXCL2 (14 pg/mL) (Figure 27 a). When P2Y12+ U937 cells 
were pre-treated with the P2Y12 specific antagonist PSB0739 prior to stimulation with ADP, 
chemokine secretion was significantly reduced (Figure 27 b). 
 
 
Figure 27. Chemokine secretion is induced in P2Y12+ U937 cells and can be inhibited with the P2Y12 
antagonist PSB0739. (a) 2 x 106 transgenic U937 cells were treated with 50 nM ADP for 24 h. Cell 
supernatants were harvested, and chemokine concentrations were assessed by ELISA (n=3). (b) 2 x 106 
P2Y12+ U937 cells were pre-treated with 10 µM PSB0739 for 30 min prior to stimulation with 50 nM 
ADP for 24 h. Chemokine concentrations in the cell supernatants were determined by ELISA (n=3). 
 
We next assessed whether chemokine secretion is also induced in pBM(MDI) upon ADP 
treatment. Thus, we isolated CD14+ pBM from the blood of healthy donors and stimulated the 
cells for 7 days with MDI to induce P2Y12 expression. Subsequently, cells were treated with 
50 nM ADP for 24 h and presence of IL-8, CXCL2 and CXCL7 in the cell supernatants was 
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analyzed by ELISA. In contrast to P2Y12+ U937 cells, ADP-treated pBM(MDI) did not show an 
enhanced CXCL2 or CXCL7 release and only a slightly but not significant increase of IL-8 
secretion (Figure 28). Since we showed that pro-inflammatory cytokine expression is induced 
in ADP-treated pBM(MDI), we also assessed the release of IL-1ß and TNF-α. Also here, secretion 
of these cytokines was not enhanced in pBM(MDI) upon ADP stimulation (data not shown). 
 
 
Figure 28. Chemokine secretion is not enhanced in ADP-treated pBM(MDI). CD14+ pBM were treated 
with MDI for 7 days, followed by stimulation with 50 nM ADP for 24 h. Concentrations of the indicated 
chemokines in the cell supernatant were assessed by ELISA (n=4). 
 
 
4.4.4 Analysis of P2Y12 downstream signaling pathways in macrophages 
 
Aiming at analyzing signaling pathways that might lead to the induction of the found 
ADP/P2Y12-dependent cytokines in macrophages, we stimulated transgenic U937 cells with 
50 nM ADP for 5, 15 and 30 min and performed Western blot analysis. We detected ERK1/2 
as well as Akt phosphorylation after ADP treatment of P2Y12+ U937 cells whereas these 
signaling pathways were only weakly induced in ADP-treated EV cells. While ERK1/2 
phosphorylation was strongly induced after 5 min of ADP treatment, Akt phosphorylation was 
induced after 5 min as well as after 30 min (Figure 29 a) in P2Y12+ U937 cells. Furthermore, 
ADP induced the expression of the transcription factor subunits FOSL1 and JUN, suggesting 
that the transcription factor AP-1 might be a key activator of the transcription of the 
chemokines (Figure 29 b). Expression of FOSL1 and JUN was significantly reduced when P2Y12+ 
U937 cells were pre-treated with an Akt inhibitor prior to ADP stimulation. Pre-treatment with 
an ERK inhibitor only slightly decreased expression of both transcription factor subunits 
(Figure 29 c). 
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Figure 29. ADP promotes AKT and ERK phosphorylation and induces the expression of the 
transcription factors JUN and FOSL1 in P2Y12+ U937 cells. (a) 2 x 106 transgenic U937 cells (P = P2Y12+ 
U937 cells, EV = empty vector U937 cells) were treated with 50 nM ADP for the indicated time points 
and Western blot analysis was performed using anti-P-ERK1/2, anti-ERK1/2, anti-P-Akt and anti-Akt 
antibodies. (b) 2 x 106 transgenic U937 cells were treated with ADP for 4 h and expression of JUN and 
FOSL1 was assessed by qRT-PCR (n=3). (c) 2 x 106 P2Y12+ U937 cells were pre-treated with 1 µM ERK 
inhibitor or 1 µM Akt inhibitor for 30 min prior to stimulation with 50 nM ADP for 4 h. JUN and FOSL1 
expression was assessed by qRT-PCR. Cells treated with equivalent concentrations of DMSO were used 
as control (n=3). 
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To test the hypothesis that ADP induces chemokine expression via Akt and/or ERK signaling, 
we treated transgenic P2Y12+ U937 cells with specific Akt and ERK inhibitors for 30 min, 
followed by stimulation with ADP for 24 h. We analyzed concentration of the ADP-induced 
chemokines CXCL2, CXCL7 as well as IL-8 in the cell supernatants by ELISA. Secretion of all 
three chemokines was significantly reduced upon ERK and Akt inhibition (Figure 30). While 
pre-treatment of P2Y12+ cells with an ERK inhibitor only weakly reduced chemokine secretion, 
Akt inhibition was more effective in inhibiting ADP-induced chemokine release. A combined 
treatment with Akt and ERK inhibitors strongly reduced ADP-induced CXCL2, CXCL7 and IL-8 
secretion. While CXCL2 and CXCL7 concentration in the cell supernatants nearly reached levels 
of the unstimulated control, IL-8 release could only be reduced by 50 % upon combined 
treatment with ERK and Akt inhibitors (Figure 30). 
 
 
Figure 30. ADP-induced chemokine secretion can be inhibited with ERK and Akt inhibitors. 2 x 106 
P2Y12+ U937 cells were seeded in 6 well plates and pre-treated with 1 µM ERK inhibitor, 1 µM Akt 
inhibitor or combination of both for 30 min prior to stimulation with 50 nM ADP for 24 h. Cell 
supernatants were collected, and chemokine concentrations were determined by ELISA. Cells treated 
with equivalent concentrations of DMSO were used as control (n=3). 
 
To test whether the same signaling pathways that are activated in P2Y12+ U937 are also 
induced in MDI-treated pBM upon ADP stimulation, we isolated CD14+ pBM from the blood of 
healthy donors and treated the cells for 7 days with MDI. Subsequently, cells were treated 
with ADP for 5, 15 and 30 min and ERK1/2 as well as Akt phosphorylation were assessed by 
Western blot analysis. Like in P2Y12+ U937 cells, ADP induced ERK1/2 phosphorylation in 
pBM(MDI) after 5 min of ADP treatment (Figure 31 a). Interestingly, Akt phosphorylation was 
not detected in ADP-treated pBM(MDI) (Figure 31 a). Nevertheless, expression of the AP-1 
transcription factor subunits JUN and FOSL1 was induced in pBM(MDI) after 2–4 h of ADP 
treatment (Figure 31 b). 
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Figure 31. ADP induces ERK phosphorylation and expression of FOSL1 and JUN in pBM(MDI). 3 x 106 
CD14+ pBM were seeded in 6 well plates and stimulated with MDI for 7 days. Subsequently, cells were 
treated with 50 nM ADP for the indicated time points and ERK1/2 as well as Akt phosphorylation was 
analyzed by Western blot analysis. Stainings with anti-ERK1/2 and anti-Akt antibodies served as loading 
controls. One representative Western blot is shown for each antibody (n=4). (b) pBM(MDI) were treated 
with 50 nM ADP for the indicated time points and expression of JUN and FOSL1 was assessed by qRT-
PCR (n=4). 
 
To investigate whether ADP induces cytokine expression in pBM(MDI) via the ERK signaling 
pathway, we pre-treated pBM(MDI) with a specific ERK inhibitor prior to stimulation with ADP 
and assessed cytokine expression by qRT-PCR. ERK inhibition did not reduce ADP-induced 
expression of IL-8, IL-1ß or TNF-α (Figure 32). The P2Y12 antagonist PSB0739 completely 
abrogated TNF-α expression, while IL-8 and IL-1ß expression were significantly reduced but 
did not reach the basal levels of the unstimulated control (Figure 32). These data suggest that 
ADP might also activate other purinergic receptors and signaling pathways. 
 
 
Figure 32. The P2Y12 antagonist PSB0739 but not the ERK inhibitor reduces cytokine expression in 
pBM(MDI). 3 x 106 CD14+ pBM were stimulated with MDI for 7 days. Cells were pre-treated with 1 µM 
ERK inhibitor or 10 µM PSB0739 for 30 min prior to stimulation with 50 nM ADP for 1 h. Gene 
expression of the indicated cytokines was assessed by qRT-PCR (n=4). 
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4.4.5 ADP promotes the migration of MDI-treated pBM 
 
It is well known that nucleotides such as ATP released by dying cells act as find-me signals for 
purinergic receptors. Since P2Y12 is expressed on microglia cells triggering migration of these 
cells to the site of inflammation, we investigated whether ADP might also act as a 
chemoattractant for P2Y12+ macrophages. We set up a transwell migration assay and seeded 
2 x 105 M-CSF and MDI-treated pBM in the inserts of a transwell plate. 50 nM ADP were added 
to the medium in the lower chamber and migration was assessed after 6 h. ADP significantly 
promoted the migration of MDI-treated pBM whereas it was no chemoattractant for M-CSF-
treated pBM (Figure 33). 
 
 
Figure 33. ADP promotes the migration of MDI-treated pBM in a transwell chamber assay. pBM were 
treated with M-CSF or MDI for 7 days, harvested, and 2 x 105 cells were seeded in the insert of a 
transwell chamber with a 5 µm pore size. 50 nM ADP was added to X-VIVO medium in the lower 
chamber. Migration was assessed after 6 h by fixing the cells at the bottom of the transwell membrane 
with methanol followed by staining with crystal violet. (a) Pictures of the stained migrated cells at the 
bottom of the transwell membrane were taken using an inverted microscope. (b) Crystal violet was 
resolved with 100 % methanol and absorbance at 570 nm was measured by microplate reader (n=3). 
 
 
4.4.6 ADP promotes the migration of P2Y12+ Raw 264.7 cells 
 
We next used transgenic Raw 264.7 cells as another model to investigate the ADP-induced 
migration of P2Y12+ macrophages. Like in MDI-treated pBM that express the purinergic 
receptor P2Y12, ADP also acted as a chemoattractant for P2Y12+ Raw 264.7 cells by promoting 
the migration of these cells in a transwell chamber assay (Figure 34 a–b). Interestingly, also 
medium without FCS significantly induced the migration of P2Y12+ cells. Addition of ADP to 
the medium w/o FCS significantly enhanced the migration of P2Y12+ Raw 264.7 cells. These 
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results indicate that under serum starvation cells might release nucleotides that trigger the 
migratory ability of P2Y12+ macrophages in an autocrine manner. To exclude that ADP 
promotes the proliferation of P2Y12+ cells, we performed a BrdU assay showing that the 
proliferation was not affected by ADP treatment for 48 h (Figure 34 c). 
 
Figure 34. ADP promotes the migration of P2Y12+ Raw 264.7 cells in a transwell chamber assay. (a-b) 
5 x 105 cells were seeded in a transwell insert with a 5 µm pore size. 50 nM ADP was added to the 
medium in the lower chamber. Migration was assessed after 16 h by fixing the cells at the bottom of 
the transwell membrane with methanol followed by staining with crystal violet. (a) Pictures of the 
stained migrated cells at the bottom of the transwell membrane were taken using an inverted 
microscope. (b) Crystal violet was then resolved with 100 % methanol and absorbance at 570 nm was 
measured by microplate reader (n=3). (c) 1 x 104 transgenic Raw cells were seeded in 96 well plate and 
treated with 50 nM ADP for 48 h. Proliferation was assessed by BrdU assay (n=3). 
 
In the next experiment, transgenic Raw 264.7 cells were pre-treated with the specific P2Y12 
antagonist PSB0739 und migration towards ADP was assessed after 16 h. Blockade of the 
P2Y12 receptor significantly abrogated the ADP-induced chemotaxis of P2Y12+ Raw 264.7 
cells. Furthermore, when P2Y12+ cells were treated with PSB0739 their migratory ability 
towards medium w/o FCS was significantly reduced (Figure 35).  
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Figure 35. P2Y12 blockade inhibits the migration of P2Y12+ Raw 264.7 cells. 5 x 105 cells were seeded 
in 6.5 mm transwell insert with a 5 µm pore size. 10 µM P2Y12 antagonist PSB0739 and/or 50 nM ADP 
were added to DMEM w/o FCS in the lower chamber. Migration was assessed after 16 h by fixing the 
cells at the bottom of the transwell membrane with methanol followed by staining with crystal violet. 
(a) Pictures of the migrated cells at the bottom of the transwell membrane were taken using an 
inverted microscope. (b) Intercalated crystal violet was then resolved with 100 % methanol and 
absorbance at 570 nm was measured by microplate reader (n=3). 
 
To test the hypothesis that upon serum starvation cells release nucleotides that trigger 
migration of these cells, we supplemented the DMEM w/o FCS in the lower chamber of the 
transwell inserts with apyrase which is an ATP/ADP-hydrolyzing enzyme. Apyrase completely 
abrogated the enhanced migration of P2Y12+ cells towards medium w/o FCS (Figure 36 a–b). 
To strengthen these results, we produced conditioned medium (CM) from transgenic Raw 
264.7 cells by culturing the cells in DMEM w/o FCS with or without 50 nM ADP for 24 h. The 
cell supernatants were then used as chemoattractants to assess the migration of transgenic 
Raw 264.7 cells. The CM of both cell lines, P2Y12+ and EV cells, significantly promoted the 
migration of P2Y12+ Raw 264.7 cells compared to EV cells, suggesting that the cell 
supernatants contain nucleotides that trigger the migration of P2Y12+ macrophages. 
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Interestingly, the ADP-CM did not significantly enhance the migration of P2Y12+ Raw 264.7 
cells when compared to the CM of untreated P2Y12+ cells (Figure 36 c). When apyrase was 
added to the CM of untreated P2Y12+ cells and EV cells, the migration of P2Y12+ Raw cells was 
significantly reduced (Figure 36 d). Taken together, these results suggest that serum-starved 
cells release nucleotides that trigger migration of P2Y12+ macrophages in an autocrine 
manner. 
 
 
Figure 36. Nucleotides released by serum-starved cells trigger migration of P2Y12+ Raw 264.7 cells in 
an autocrine manner. 5 x 105 transgenic Raw 264.7 cells were seeded in 6.5 mm transwell insert with 
5 µm pore size. (a–b) 1 U/mL apyrase was added to DMEM w/o FCS in the lower chamber. Migration 
was assessed after 16 h by fixing the cells at the bottom of the transwell membrane with methanol 
followed by staining with crystal violet. (a) Pictures of the migrated cells at the bottom of the transwell 
membrane were taken using an inverted microscope. (b) Intercalated crystal violet was then resolved 
with 100 % methanol and absorbance at 570 nm was measured by microplate reader (n=3). (c) 
Transgenic Raw 264.7 cells were seeded in DMEM w/o FCS and treated with 50 nM ADP for 24 h. The 
CM of ADP-treated and untreated (UT) cells was harvested and used as chemoattractant in the lower 
chamber of a transwell plate. (d) CM of untreated transgenic Raw 264.7 cells was supplemented with 
1 U/mL apyrase. (c–d) Migration was assessed after 6 h by fixation of the migrated cells with methanol 
followed by staining with crystal violet. Intercalated crystal violet was then resolved with 100 % 
methanol and absorbance at 570 nm was measured by microplate reader (n=3). 
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4.4.7 Cell death induces the migration of P2Y12+ Raw 264.7 cells 
 
Since it is known that dying cells release nucleotides that act as find-me signals for phagocytic 
cells expressing purinergic receptors, we set up a transwell co-culture experiment with P2Y12+ 
Raw 264.7 cells and B16F1 melanoma cells, which we pre-treated with 2 µg/mL puromycin to 
induce cell death. Since the transgenic Raw 264.7 cells contain a puromycin resistance they 
were not affected by the treatment. Compared to untreated B16F1 cells, puromycin-treated 
B16F1 cells in the lower transwell chamber significantly promoted the migration of P2Y12+ 
cells (Figure 37). The migration of EV cells towards dying B16F1 cells was only minimally 
induced and was a lot weaker compared to P2Y12+ macrophages (Figure 37 a).   
 
 
Figure 37. Dying B16F1 cells promote the migration of P2Y12+ Raw 264.7 cells in a transwell chamber 
assay. 2 x 104 B16F1 cells were seeded in 24 well plates. Cells were treated with 2 µg/mL puromycin 
for 24 h to induce cell death. Untreated B16F1 cells and medium without cells served as controls. 
5 x 105 transgenic Raw 264.7 cells were seeded in 6.5 mm transwell inserts with a pore size of 5 µm. 
Transwell inserts were then placed in the 24 well plate containing the puromycin-treated B16F1 cells. 
Migration was assessed after 6 h by fixation of the migrated cells with methanol followed by staining 
with crystal violet. (a) Pictures of the migrated cells at the bottom of the transwell membrane were 
taken using an inverted microscope. (b) Intercalated crystal violet was then resolved with 100 % 
methanol and absorbance at 570 nm was measured by microplate reader (n=3).  
 
To test whether nucleotides are responsible for the induced migration of P2Y12+ Raw 264.7 
cells towards dying tumor cells, we added apyrase to the culture medium of the puromycin-
treated B16F1 cells. Addition of the ATP/ADP-hydrolyzing enzyme apyrase significantly 
reduced the migration of P2Y12+ Raw cells. Furthermore, pre-treatment of P2Y12+ Raw 264.7 
cells with the P2Y12 antagonist PSB0739 significantly reduced the migration towards dying 
B16F1 cells (Figure 38). We therefore assume that dying cells release nucleotides that act as a 
find-me signal for P2Y12+ macrophages. 
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Figure 38. Addition of apyrase or P2Y12 antagonist to dying B16F1 cells abrogates the cell death-
induced migration of P2Y12+ Raw 264.7 cells. 2 x 104 B16F1 cells were seeded in 24 well plates. Cells 
were treated with 2 µg/mL puromycin (puro) for 24 h to induce cell death. Untreated (UT) B16F1 cells 
served as control. 1 U/mL apyrase or 10 µM PSB0739 (P2Y12 antagonist) were added to the dying 
B16F1 cells. 5 x 105 transgenic Raw 264.7 cells were seeded in 6.5 mm transwell inserts with a pore 
size of 5 µm. Transwell inserts were then placed in the 24 well plate containing the puro-treated B16F1 
cells. Migration was assessed after 6 h by fixation of the migrated cells with methanol followed by 
staining with crystal violet. (a) Pictures of the migrated cells at the bottom of the transwell membrane 
were taken using an inverted microscope. (b) Intercalated crystal violet was then resolved with 100 % 
methanol and absorbance at 570 nm was measured by microplate reader (n=3).  
 
 
4.4.8 ADP induces cytokine secretion in P2Y12+ Raw 264.7 cells 
 
We showed that ADP induces chemokine secretion in human P2Y12+ U937 cells (Figure 27). 
To assess whether chemokine secretion is also induced in the murine system, we treated 
transgenic Raw 264.7 cells with 50 nM ADP for 24 h and performed a cytokine array, being 
able to analyze 40 different cytokines and chemokines in the supernatant of ADP-treated and 
untreated P2Y12+ Raw 264.7 cells. We found an up-regulation of CXCL2, CCL4 and TNF-α 
secretion in ADP-treated P2Y12+ Raw 264.7 cells compared to untreated cells (Figure 39 a). To 
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proof these results, we performed ELISAs and analyzed the concentration of the three up-
regulated cytokines in the cell supernatants. While we could not detect an increase in CCL4 
secretion in ADP-treated P2Y12+ Raw 264.7 cells, we verified a significantly enhanced TNF-α 
secretion and a tendency towards an increased CXCL2 secretion in ADP-treated P2Y12+ cells 
compared to untreated P2Y12+ cells and ADP-treated EV cells (Figure 39 b).  
 
 
Figure 39. ADP induces TNF-α secretion in P2Y12+ Raw 264.7 cells. (a) 1 x 106 P2Y12+ Raw cells were 
seeded in 6 well plates and treated with 50 nM ADP for 24 h. The cell supernatants were harvested 
and 500 µL were used to analyse the presence of 40 different cytokines and chemokines by mouse 
proteome profiler cytokine array. (b) 1 x 106 transgenic Raw cells were seeded in 6 well plates and 
treated with 50 nM ADP for 24 h. The concentration of the indicated cytokines and chemokines in the 
cell supernatants was assessed by ELISA (n=3). 
 
 
4.4.9 P2Y12 facilitates the adhesion and transmigration of U937 cells 
 
In our previous results we showed that ADP/P2Y12 triggers migration of macrophages. Since 
Since others revealed that P2Y12 is an important adhesion receptor for platelets, facilitating 
platelet-tumor cell interactions and adhesion to endothelial cells [319, 320], we aimed at 
investigating whether P2Y12 supports the adhesion of monocytes to ECs and/or whether 
P2Y12 enhances the leukocyte-endothelial transmigration. For the adhesion assay we seeded 
HUVECs in gelatin-coated 12 well plates. CFSE-labelled, ADP-treated and untreated transgenic 
U937 cells were added to the endothelial monolayer. P2Y12+ U937 cells displayed a stronger 
adherence to HUVECs than EV cells. Interestingly, the adherence of ADP-treated P2Y12+ U937 
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cells was markedly reduced when compared to untreated P2Y12+ cells whereas in EV cells ADP 
treatment had no effect on the adhesion of the cells (Figure 40 a). Next, we assessed whether 
transmigration is also supported by the P2Y12 receptor. We seeded HUVECs in transwell 
inserts and added transgenic U937 cells to the endothelial monolayer. The number of 
transmigrated cells was determined after 6 h by counting the cells in the lower well of the 
transwell chamber by flow cytometry. P2Y12+ U937 cells showed the strongest 
transmigration, whereas the migratory ability was markedly reduced when P2Y12+ U937 cells 
were pre-treated with ADP for 24 h. In total, only very few EV cells migrated through the 
HUVEC monolayer (Figure 40 b). 
 
 
Figure 40. P2Y12 promotes endothelial adhesion and transmigration of U937 cells. (a) 2 x 105 HUVECs 
were seeded in gelatin-coated 12 well plates and grown until they form a monolayer. Transgenic U937 
cells were seeded in 6 well plates and treated with 50 nM ADP for 24 h. 5 x 105 U937 cells were labelled 
with CFSE and added to the endothelial monolayer. Adherence was assessed after 1 h by lysis of the 
adherent cells and measuring fluorescence intensity at 480/520 nm by microplate reader (n=6). (b) 
1 x 105 HUVECs were seeded in 12 mm transwell inserts and grown until they form a monolayer. 
Transgenic U937 cells were seeded in 6 well plates and treated with 50 nM ADP for 24 h. 5 x 105 
transgenic U937 cells were added to the transwell inserts containing the HUVEC monolayer. After 6 h, 
the number of transmigrated cells present in the lower chamber of the transwell was assessed by flow 
cytometry (n=3). 
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5. Discussion 
 
5.1 Characterization of P2Y12 expression in human macrophages 
 
5.1.1 Characterization of P2Y12+ macrophages in vitro 
 
Recently, we identified Lyve-1, Slamf9 and Ms4a8a as novel TAM markers [350, 352, 353]. 
Besides being expressed in human or murine TAM of melanoma in situ, expression of Lyve-1 
and Ms4a8a can be induced by the treatment of pBM or BMDM with 
M-CSF/dexamethasone/IL-4 (MDI) [350, 353, 354]. To identify other markers that might be 
relevant in TAM in vivo we performed gene expression analysis of MDI-treated pBM.   
The purinergic receptor P2Y12 was strongly up-regulated in pBM(MDI) compared to pBM(M-CSF). 
This ADP receptor is expressed on platelets and microglia but has not yet been described to 
be expressed on human TAM. We verified P2Y12 mRNA expression in pBM(MDI) by qRT-PCR. 
Accordingly, Martinez et al. showed that P2Y12 is up-regulated in M2-polarized macrophages 
(M-CSF + IL-4-differentiated pBM) when compared to M1-polarized macrophages 
(M-CSF + IFN-γ + LPS-differentiated pBM), M-CSF-differentiated macrophages or monocytes 
[348]. Interestingly, P2Y12 was shown to be up-regulated in M2-polarized microglia, 
differentiated ex vivo with M-CSF, IL-4 and IL-13 [355]. Hohenhaus et al. showed that P2Y12 is 
up-regulated in GM-CSF-differentiated MDM when compared to monocytes or M-CSF-
differentiated MDM [356]. Since GM-CSF is a stimulus that generates a M1-like macrophage 
phenotype [357], it remains to be elucidated whether P2Y12 is also expressed on pro-
inflammatory macrophages. In our hands, P2Y12 expression was slightly higher in IFN-γ-
treated pBM compared to only M-CSF-treated pBM but the highest expression was induced 
by MDI. Although several studies detected P2Y12 in MDM on mRNA level, none of these 
studies detected P2Y12 expression on protein level probably due to the unavailability of 
specific antibodies in the human system. Since we also failed to specifically detect P2Y12 in 
pBM(MDI) with commercially available antibodies, we generated a rabbit anti-hsP2Y12 peptide 
antibody targeting the C-terminal, intracellular peptide sequence 
SQDNRKKEQDGGDPNEETPM. Specificity of this antibody was validated using transgenic 
P2Y12+ U937 cells. We detected P2Y12 over-expression in P2Y12+ U937 cells compared to EV 
cells by Western blot analysis, FACS, immunocytochemistry and immunofluorescence. We 
used this antibody to verify P2Y12 expression also in pBM(MDI) by Western blot analysis. Other 
combinations of pro-and anti-inflammatory cytokines failed to induce a detectable protein 
expression of P2Y12. In microglial cells it has been described, that P2Y12 expression is up-
regulated by the anti-inflammatory cytokine TGF-ß while pro-inflammatory stimuli such as LPS 
suppress P2Y12 induction [328]. We could not detect P2Y12 expression in TGF-ß-treated pBM. 
As microglial cells have another origin and constitutively express P2Y12, its expression might 
be differently regulated as in MDM.  
Besides P2Y12, our microarray analysis identified up-regulation of other purinergic receptors 
in pBM(MDI) among them P2Y14. This receptor belongs to the same phylogenetic family as 
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P2Y12. While the ADP receptor P2Y12 is mainly expressed on microglia cells and platelets, 
P2Y14 binds UDP-glucose and is involved in mast cell degranulation as well as neutrophil 
chemotaxis. Lacey et al. revealed that P2Y14 is up-regulated in GM-CSF-treated human 
monocytes compared to M-CSF-stimulated monocytes [358]. Lattin et al. found that P2y14 is 
expressed in murine peritoneal macrophages and is up-regulated upon LPS treatment. 
However, P2Y14 is also expressed on other murine leukocyte populations, suggesting that this 
purinergic receptor is almost ubiquitously expressed on immune cells at least in mice [345]. 
Further studies are needed to elucidate whether P2Y14 elicits distinct functions on these cells 
and whether it is also expressed on human and murine TAM.   
Interestingly, we not only detected over-expression of P2Y12 and P2Y14 but also up-regulation 
of the purinergic receptors P2Y1 and P2Y13 in pBM(MDI). Like P2Y12, they are ADP receptors 
[241]. In platelets co-signaling of P2Y1 and P2Y12 is involved in platelet activation and 
aggregation [310]. P2Y13 mRNA was detected in CD14+ monocytes, MDM, and CD33+ myeloid 
cells [338]. In line with our results, Martinez et al. showed that P2Y12, P2Y13 and P2Y14 are 
up-regulated in IL-4-differentiated pBM compared to M-CSF-treated pBM [348]. Interestingly, 
they also found over-expression of the purinergic receptors P2Y8 and P2Y11 which we could 
not detect in our in vitro generated pBM(MDI). The function of purinergic receptors in 
macrophages and especially in TAM has not yet been elucidated and needs further studies. 
Besides purinergic receptors, we also identified up-regulation of several classical M2 markers 
including ADORA3, LYVE1 and CD163 in pBM(MDI) compared to pBM(M-CSF). Most of these 
surface molecules have previously been linked to a M2 macrophage phenotype and are also 
expressed in TAM in vivo [47, 350, 359, 360]. 
To verify that our in vitro generated macrophages resemble an anti-inflammatory M2-like 
phenotype, we further characterized pBM(MDI) regarding their marker profile, cytokine 
expression and cytokine secretion by FACS, qRT-PCR and ELISA, respectively. We could show 
that MDI-treated pBM display increased CD206 and CD163 expression while the expression of 
the cytokine receptors CXCR4 and CCR2 is down-regulated. CD206 and CD163 are typical M2-
associated macrophage markers which are frequently used to detect M2-like TAM in human 
tumors in situ. Presence of CD206+ and/or CD163+ TAM correlates with tumor burden and 
poor prognosis in various tumor entities [351]. Furthermore, we showed that the 
ectonucleotidase CD73 is significantly up-regulated in pBM(MDI) compared to pBM(M-CSF). CD73 
converts AMP to adenosine which is an important immunosuppressive mediator. In the tumor 
microenvironment, adenosine impairs proliferation and cytotoxicity of T cells and triggers M2 
polarization of macrophages. Thus, depletion of CD73 or targeting adenosine receptors 
promotes an anti-tumor immunity thereby impairing tumor growth and progression [293, 295, 
296, 299]. Zanin et al. showed that murine M2-polarized peritoneal macrophages exhibit 
increased expression of the ectonucleotidases CD39 and CD73 thereby converting ATP to AMP 
and finally to adenosine [297]. Besides surface molecules and receptors, cytokine and 
chemokine expression also differ between M1 and M2 macrophages [48]. We detected 
increased expression of IL-10 and TGF-ß in pBM(MDI) whereas expression and secretion of the 
pro-inflammatory mediators TNF-α, IL-1ß and CCL-2 was reduced. M2-like TAM and other 
immunosuppressive cells of the tumor microenvironment (e.g. Tregs, MDSC) express high levels 
of the ant-inflammatory cytokines IL-10 and TGF-ß. They impair anti-tumor immunity by 
inhibiting T cell response, favoring the differentiation of immunosuppressive cells and 
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reducing the production of pro-inflammatory cytokines thereby promoting tumor growth and 
progression [361, 362]. 
 
5.1.2 Signaling pathways underlying the induction of P2Y12 expression 
 
Next, we investigated signaling pathways underlying the induction of P2Y12 expression. Since 
P2Y12 is induced by the combined treatment of pBM with dexamethasone and IL-4, we 
treated pBM with the glucocorticoid receptor inhibitor mifepristone and with a p38 MAPK 
inhibitor upon differentiation with MDI. The p38 MAPK signaling pathway is activated by 
different stimuli including cytokines, growth factors, stress and UV [363]. IL-4 was shown to 
induce p38 MAPK signaling in alternatively activated macrophages. Jiménez-Garcia et al. 
revealed that p38 inhibition blocked the IL-4-induced phosphorylation of STAT6, suggesting 
that p38 is up-stream of STAT6 signaling [364]. We showed that p38 inhibitor only slightly 
reduced P2Y12 induction in pBM(MDI). Similar to our results, Kobayashi et al. showed that in 
contrast to other purinergic receptors, P2Y12 expression in microglia cannot be suppressed 
by the p38 MAPK inhibitor SB203580 [365]. Interestingly, Bhattacharyya et al. showed that 
dexamethasone inhibits the p38 MAPK signaling pathway [366]. This could explain why 
inhibition of p38 MAPK had no significant effect on P2Y12 induction in pBM(MDI). Although we 
showed that dexamethasone alone is not sufficient to induce P2Y12 expression in pBM, the 
glucocorticoid receptor inhibitor mifepristone significantly suppressed P2Y12 induction upon 
MDI treatment. These results indicate that glucocorticoid signaling is indispensable for P2Y12 
induction. Glucocorticoids mediate immunosuppression and thus are frequently used to treat 
inflammatory diseases. Almost all cell types including macrophages express glucocorticoid 
receptors (GR) that acts as transcription factors by binding to glucocorticoid response 
elements (GRE). The promoter region of the P2Y12 gene has a GRE which might be responsible 
for the transcription of P2Y12 after dexamethasone stimulation, but this needs further 
studies. In general, glucocorticoids repress the transcription of pro-inflammatory cytokines 
(e.g. IL-2) and inhibit the production of eicosanoids (prostaglandins, leukotrienes) which are 
important mediators of inflammation [367]. Dexamethasone was shown to induce an 
immunosuppressive M2 macrophage phenotype in various in vitro studies [368]. In the last 
decades, researchers found that glucocorticoid synthesis also occurs in the skin. During 
inflammation in the skin or upon exposure to inflammatory stimuli including UV irradiation, 
cutaneous glucocorticoid synthesis is up-regulated [369]. Thus, it is possible that local 
glucocorticoid synthesis in the skin polarizes macrophages to an anti-inflammatory M2 
phenotype.  
We also investigated whether NF-κB signaling is responsible for P2Y12 induction in MDI-
treated pBM. In thrombin-treated smooth muscle cells, NF-kB was shown to bind to the P2Y12 
promoter, suggesting that thrombin increases P2Y12 expression via activation of NF-κB [370]. 
In pBM, inhibition of NF-κB signaling did not suppress P2Y12 induction. Since NF-κB is an 
important pro-inflammatory signaling pathway and TNF-α or LPS did not induce P2Y12 
expression in pBM, it is not surprising that P2Y12 induction cannot be inhibited with the NF-κB 
inhibitor.  
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5.1.3 Characterization of P2Y12+ macrophages in vivo 
 
Since we detected P2Y12 in MDI-treated pBM in vitro, we aimed at investigating whether 
P2Y12 is also expressed in human TAM of melanoma. To verify specificity of our self-generated 
anti-hsP2Y12 antibody for the application in immunohistochemistry, we first stained human 
glioblastoma sections and specifically detected P2Y12 in microglia cells. Several studies have 
described the expression of P2Y12 on resting microglia. In these cells P2Y12 is involved in 
sensing of nucleotides and chemotaxis during tissue damage [325]. Since microglia cells origin 
from the yolk sac it is not clear whether monocyte-derived tissue macrophages also express 
P2Y12. Moore et al. detected P2Y12 expression in microglia, but failed to detect P2Y12 protein 
expression in in vitro generated MDM [355]. TAM mainly consist of MDM that origin from the 
bone marrow or spleen [371]. To detect P2Y12 in TAM, we analyzed human melanoma 
sections. We established a sequential staining protocol to specifically detect P2Y12 in CD68+ 
and CD163+ macrophages. While CD68 is frequently used to detect myeloid cells in general 
[372, 373], CD163 is a specific marker for mature macrophages [374]. Various studies have 
shown that the presence of CD163+ macrophages correlates with tumor burden and poor 
overall survival in many tumor entities including melanoma [351]. Indeed, we found co-
expression of P2Y12, CD68 and CD163 in primary melanoma sections, as well as melanoma 
metastases. We confirmed existence of P2Y12+ CD163+ macrophages by immunofluorescence. 
Not all CD68+ macrophages were positive for P2Y12, indicating that the purinergic receptor is 
only expressed on a distinct macrophage subpopulation. Furthermore, P2Y12 expression was 
also detected on CD68- cells, which might be platelets or other immune cells as P2Y12 was 
found to be expressed also on ex vivo isolated mast cells and eosinophils [340, 342]. Although 
we found CD68+ cells in melanocytic naevi, we failed to detect P2Y12 expression by in situ 
hybridization and immunohistochemistry indicating that the ADP receptor is either up-
regulated by specific stimuli in the tumor microenvironment or P2Y12+ cells are recruited to 
the tumor site. Since we found P2Y12+ macrophages in the spleen, it is possible that these 
macrophages are also recruited during tumor progression. 
 
5.2 Characterization of P2Y12 expression in murine macrophages 
 
We aimed at investigating whether P2Y12 is also expressed in murine macrophages. It is well 
accepted that there are differences between human and murine M2-polarized macrophages. 
Murine M2 macrophages express Ym1 (Chi3l3) and Fizz1 and which are not expressed by 
human M2 macrophages [375, 376]. However, there are also markers including CD163 and 
CD206 that are shared by human and murine TAM. Previously, our group could show that 
several M2 macrophage markers can be induced in vitro in murine BMDM by dexamethasone 
treatment [353, 354]. To analyze whether we can induce P2y12 expression in these cells, we 
isolated BMDM and stimulated them with M-CSF for 3 days, followed by stimulation with 
different pro- and anti-inflammatory cytokines for 4 days. Like in human pBM, strongest P2y12 
induction was observed upon MDI treatment. However, P2y12 expression could also be 
detected in M-CSF treated BMDM. In line with our results, Barbera-Cremades et al. showed 
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that P2y12 is up-regulated in murine BMDM during M-CSF differentiation [377]. We also 
revealed a much weaker P2y12 expression in LPS or IFN-γ-differentiated M1 macrophages. 
Consistently, Lattin et al. showed that P2y12 is down-regulated in BMDM by LPS [345]. In 
contrast to our results, Zanin et al. showed that purinergic receptors including P2y12 are not 
differentially expressed between murine M1 and M2-polarized peritoneal macrophages. 
However, instead of differentiating BMDM with M-CSF prior to stimulation with pro and anti-
inflammatory cytokines they used murine peritoneal macrophages and treated them with IL-4 
and LPS to generate M2 and M1 macrophages, respectively [297]. 
Although several studies investigated P2y12 induction in murine BMDM or peritoneal 
macrophages, none of these studies focused on P2Y12 expression in tissue-resident 
macrophages. To analyze P2y12 expression in macrophages, we isolated CD11b+ myeloid cells 
from the spleen, peritoneal fluid and from B16F10 tumors of tumor-bearing mice and from 
the spleen and peritoneal fluid of tumor-free C57BL/6 mice and assessed P2y12 expression by 
qRT-PCR. Highest P2y12 expression was detected in splenic macrophages. Here, P2y12 
expression was significantly higher in tumor-free mice compared to tumor-bearing hosts, 
which could indicate that P2Y12+ splenic macrophages are recruited to the tumor site in 
tumor-bearing mice. P2y12 expression in CD11b+ cells from B16F10 tumors was comparable 
to that in splenic macrophages of tumor-bearing mice. Lowest P2y12 expression was observed 
in macrophages of the peritoneal cavity. Consistent with our results, Zanin et al. also reported 
low P2y12 mRNA expression in peritoneal macrophages [297]. Since we detected P2y12 on 
mRNA level, we aimed at investigating whether the P2Y12 protein is also expressed by TAM 
of subcutaneously transplanted B16F10 tumors. We analyzed specificity of a commercially 
available anti-P2Y12 antibody by using transgenic P2Y12+ Raw 264.7 cells and confirmed 
P2Y12 over-expression by Western blot analysis as well as immunocytochemistry. We stained 
murine B16F10 melanomas with this antibody and found P2Y12 expression in murine TAM. 
These P2Y12+ TAM were located mainly at the tumor border. This is not surprising since B16 
tumors are poorly infiltrated by immune cells, including macrophages, compared to other 
highly immunogenic tumor models such as CT26 colon carcinoma or 4T1 breast carcinoma 
[378]. We verified P2y12 expression in murine B16F10 tumors by in situ hybridization 
confirming that P2Y12+ macrophages are located at the tumor border. To our knowledge, we 
are the first to describe P2Y12 protein expression in murine TAM in situ. 
 
5.3 Functional characterization of P2Y12+ macrophages 
 
5.3.1 Gene expression analysis of P2Y12+ U937 cells 
 
We went on characterizing the function of P2Y12+ macrophages. First, we aimed at identifying 
the ADP-induced genes in transgenic P2Y12+ U937 cells. Thus, we treated the cells for 4 h and 
24 h with ADP and performed gene expression analysis. Interestingly, after 4 h of stimulation, 
we found up-regulation of various chemokines and pro-inflammatory cytokines in ADP-
treated P2Y12+ U937 cells (P2Y12 ADP) compared to untreated P2Y12+ U937 cells 
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(P2Y12 CTRL). The highest up-regulated genes were the chemokines CXCL8 (IL-8) and CXCL7. 
P2Y12 ADP also exhibited up-regulation of several other chemokines including CCL3L3, CXCL3, 
CCL20 as well as CXCL2. Besides chemokines, ADP induced growth factors and cytokines 
including IL1B, TGFB3, TNFSF15 and HBEGF in P2Y12+ U937 cells. Also in microglial cells, ADP 
has been shown to induce the release of various cytokines and chemokines in a P2Y12-
dependent manner. Tozaki-Saitoh et al. showed that CCL3 is induced in ADP-treated microglia 
[379]. In addition, the P2Y12 antagonist ticagrelor reduced IL-1ß and CCL2 expression in the 
brain, suggesting that ADP induces the expression of inflammatory cytokines and chemokines 
via P2Y12 [326].  
We confirmed the increased expression of pro-inflammatory cytokines and chemokines in 
ADP-treated P2Y12+ U937 cells by qRT-PCR. Interestingly, we found up-regulation of the same 
genes – except CXCL2 – in ADP-treated pBM(MDI) expressing P2Y12. To investigate whether 
ADP polarizes macrophages towards a pro-inflammatory phenotype, we analyzed the 
expression of typical M1 and M2-associated cytokines in ADP-treated pBM(MDI) by qRT-PCR. 
Whereas ADP induced the expression of TNF-α, the expression of the anti-inflammatory and 
immunosuppressive cytokines IL-10 and TGF-ß was significantly down-regulated in ADP-
treated pBM(MDI). These results suggest that ADP reprograms macrophages towards a pro-
inflammatory phenotype.   
However, we also detected one immunosuppressive cytokine, namely TGF-ß3, up-regulated 
in ADP-treated P2Y12+ U937 cells compared to P2Y12 CTRL. Although TGF-ß is released by M2 
macrophages and is involved in wound healing and immunosuppression, the distinct role of 
different TGF-ß isoforms remains largely unclear [361, 380]. Interestingly, platelets also 
release TGF-ß in response to ADP treatment [319, 381]. Wang et al. reported impaired TGF-ß1 
secretion from ADP-treated platelets of P2y12-deficient mice, resulting in reduced epithelial 
to mesenchymal transition (EMT) of tumor cells and thus reduced invasiveness in vitro. 
Subsequently, P2y12-deficient mice exhibited decreased metastasis [319]. Whether TGF-ß3 
released from ADP-treated P2Y12+ macrophages also induces EMT of tumor cells remains to 
be elucidated.   
We also detected up-regulation of the growth factor HB-EGF in ADP-treated P2Y12+ U937 cells. 
HB-EGF is released by M2 macrophages and induces proliferation of tumor cells in vitro [382, 
383]. HB-EGF expression is strongly up-regulated in PBMC from ovarian cancer patients 
compared to healthy individuals [384]. Since HB-EGF is a membrane-bound growth factor it 
must be enzymatically cleaved to be released and to induce paracrine signaling. In the tumor 
microenvironment, soluble HB-EGF binds to EGFR on tumor cells, thereby promoting tumor 
growth [385]. Carroll et al. showed that the matrix metalloproteinase MMP-9 cleaves HB-EGF 
[384]. We did not detect over-expression of MMP9 but significantly increased expression of 
MMP14 and MMP7 in P2Y12 ADP compared to P2Y12 CTRL. They were both shown to 
promote the cleavage of HB-EGF [386-388]. MMP-14 (MT1-MMP) is a membrane-bound MMP 
that is frequently associated with cancer cell invasion and metastasis [389].   
Besides MMPs, we also detected up-regulation of several other genes in P2Y12 ADP compared 
to P2Y12 CTRL that are associated with cell motility, migration and invasion. One example is 
the matrix remodeling enzyme heparanase that is involved in tumor cell invasion and 
metastasis [390]. We also detected up-regulation of urokinase/plasminogen activator (uPA, 
PLAU) and urokinase/plasminogen activator receptor (uPAR, PLAUR) in ADP-treated P2Y12+ 
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U937 cells. They are involved in the generation of plasmin which mediates fibrinolysis but also 
degradation of the ECM and thus is associated with tumor invasion and metastasis [391]. uPA 
and uPAR are frequently associated with a M2 macrophage phenotype [104, 392]. uPA/uPAR-
mediated signaling induces TGF-ß and IL-4 expression, thereby supporting polarization of 
macrophages [393]. Interestingly, plasminogen activator inhibitor-1 (PAI-1, SERPINE1) and 
plasminogen activator inhibitor-2 (PAI-2, SERPINB2), which inhibit uPA-mediated plasminogen 
activation, were also strongly up-regulated in P2Y12 ADP compared to P2Y12 CTRL. Although 
they seem to reduce tumor cell invasion and metastasis, pro-tumoral and anti-inflammatory 
roles were also reported. PAI-2 is up-regulate during inflammation and seems to limit Th1-
associated cytokine release [394]. PAI-1 was reported to elicit pro-angiogenic function and 
thus promotes tumor progression. Furthermore, it seems to be involved in the recruitment 
and M2-polarization of macrophages [395]. Interestingly, some of these genes we found up-
regulated in ADP-treated P2Y12+ U937 cells, for instance PAI-1 and PAI-2, are also induced in 
tumor cells that are co-cultured with platelets. Since activated platelets release ADP and 
tumor cells might express purinergic receptors it is possible that the same genes that are up-
regulated by ADP in P2Y12+ macrophages are also induced in tumor cells co-incubated with 
platelets [396, 397]. 
Interestingly, ADP up-regulated the ectonucleotidase CD73 in P2Y12+ U937 cells. Since CD73 
converts AMP to the immunosuppressive mediator adenosine, it is crucial for limiting 
inflammatory conditions [136]. Previously, increased CD73 expression was associated with 
M2-polarized macrophages [297]. We also detected increased levels of CD73 in P2Y12 
expressing pBM(MDI) suggesting that ADP signaling via P2Y12 might up-regulate CD73. Different 
stimuli (e.g. chemokines) can induce ATP release also from intact cells. Extracellular ATP can 
either signal in an autocrine manner or can be rapidly cleaved by ectonucleotidases including 
CD39 [252]. Since pBM(MDI) also express CD39 on protein level, which converts ATP to ADP and 
AMP, it is possible that the generated ADP induces CD73 expression via P2Y12. 
We also identified suppressed genes in P2Y12+ U937 cells after ADP treatment for 4 h. 
Interestingly, the purinergic receptor P2RY8 is significantly down-regulated in ADP-treated 
P2Y12+ U937 cells. Since P2RY8 was previously seen as a non-mammalian nucleotide receptor, 
not much is known about its function [398]. However, two studies analyzed its expression in 
promyelocytic cell lines. P2RY8 is strongly expressed by undifferentiated monocytic U937 cells 
as well as HL60 cells and is down-regulated in PMA-differentiated HL60 cells displaying a 
monocytic/macrophage-like phenotype. In general, the authors showed that most purinergic 
receptors exhibit dynamic expression patterns during myeloid cell differentiation. While P2Y2 
was suggested to be involved in monocyte-to-macrophage differentiation, P2Y11 seems to 
play a role in granulocytic differentiation of HL60 cells as well as in the maturation of 
monocyte-derived DCs [399, 400].   
The chemokine receptors CCR2 and CXCR4 are also significantly down-regulated in ADP-
treated P2Y12+ U937 cells. They are both strongly expressed on monocytes and are down-
regulated during differentiation to macrophages [401]. Phillips et al. showed that CCR2 is 
expressed by THP1 monocytes but is down-regulated in THP-1-derived macrophages [402]. 
Creery et al. suggested that M2 macrophages express lower levels of CXCR4, since the Th2 
cytokines IL-4 and IL-13 inhibit the expression of CXCR4 [403]. Indeed, we also detected 
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decreased CCR2 and CXCR4 levels in P2Y12-expressing pBM(MDI) compared to pBM(MCSF). These 
results suggest that ADP-induced signaling via P2Y12 promotes monocyte-to-macrophage 
differentiation by down-regulation of several chemokine receptors as well as the purinergic 
receptor P2RY8. 
To identify late response genes, we performed microarray analysis of P2Y12+ U937 cells 
treated for 24 h with ADP. Like after 4 h of ADP treatment, CXCL7 was still strongly up-
regulated in P2Y12 ADP compared to P2Y12 CTRL. Induction of other genes was much weaker. 
Interestingly, many surface molecules were up-regulated, including the general macrophage 
marker CD68 and the M2 marker MRC1 (CD206). The two tetraspanins CD82 and TSPAN7 were 
also significantly up-regulated in P2Y12 ADP after 24 h. Tetraspanins are cell surface molecules 
with 4 transmembrane domains which are involved in cell growth, motility and adhesion. 
Interestingly, CD82 was shown to be up-regulated during monocyte differentiation, also in 
PMA-differentiated U937 cells [404-406]. Different cytokines including IL-1ß but also the Th2-
associated cytokines IL-4 and IL-13 induce the expression of CD82 [406]. Besides being a 
differentiation marker not much is known regarding the function of CD82 in macrophages. 
However, CD82 was reported to be expressed on T cells and DCs. In the latter cell population 
CD82 inhibits cell motility by modulating actin polymerization and RhoA signaling. On several 
hematopoietic cells, CD82 regulates clustering and adhesiveness of adhesion molecules (e.g. 
α4ß1 integrins, LFA-1) and thus is involved in cell-cell or cell-ECM adhesion [407]. Like CD82, 
TSPAN7 also mediates organization and rearrangement of the cytoskeleton [408].   
These results reinforce our hypothesis that ADP signaling promotes the differentiation of 
monocytic P2Y12+ U937 cells towards macrophages. Moreover, ADP treatment might affect 
the adhesion of P2Y12+ macrophages either to ECs or to components of the ECM thereby 
regulating cell motility and (trans)migration. 
Interestingly, GPR34, which phylogenetically belongs to the P2Y12-like receptor group, was 
significantly up-regulated in ADP-treated P2Y12+ U937 cells. GPR34 is expressed on several 
immune cells including myeloid cells. For a long time GPR34 was an orphan receptor until in 
2006 lyso-phosphatidylserine (lysoPS) was uncovered as an endogenous agonist of the 
receptor [409]. LysoPS promotes various immunological function including mast cell 
degranulation, macrophage engulfment of apoptotic cells and suppression of T cell 
proliferation [410, 411]. Gpr34-deficient mice showed impaired immune response after 
bacterial infection accompanied by increased bacterial load, fewer infiltration of inflammatory 
cells and elevated levels of several cytokines including IL-4, TNF-α and IFN-γ [412]. Like P2Y12, 
GPR34 is highly expressed in P2Y12+ microglia. Preissler et al. revealed impaired phagocytosis 
of Gpr34-deficient microglia while motility was not affected. [413]. Contrary, P2Y12 is involved 
in chemotaxis but does not play a role in phagocytosis [325]. Whether GPR34 is also expressed 
on other tissue-specific macrophages including TAM remains to be elucidated. 
 
 
 
Discussion 
___________________________________________________________________________
100 
5.3.2 ADP induces cytokine and chemokine secretion 
 
Since we showed up-regulation of various chemokines by microarray analysis and qRT-PCR, 
we aimed at investigating whether chemokine secretion is also enhanced by ADP treatment. 
Thus, we determined chemokine concentrations in the cell supernatants of ADP-treated 
P2Y12+ U937 cells by ELISA. We found increased secretion of CXCL8 (IL-8), CXCL7 as well as 
CXCL2 in ADP-treated P2Y12+ U937 cells. While CXCL2 concentration was very low (14 pg/mL), 
CXCL7 concentration in the supernatant was the highest among the analyzed chemokines 
(511 pg/mL). All these chemokines are implicated in chemotaxis of neutrophils and 
angiogenesis [119, 121, 414]. Whereas CXCL2 and IL-8 are predominantly secreted by 
monocytes and macrophages, CXCL7 is mainly released from activated platelets [415]. Several 
in vitro studies showed that CXCL7 promotes neutrophils adhesion to HUVECS and induces 
their transmigration [416]. Finsterbusch et al. showed that platelets directly enhance 
neutrophil migration via CXCL7 secretion [417]. The P2Y12 antagonist ticagrelor reduced 
pulmonary neutrophil infiltration in septic mice [418]. Whether the ADP-conditioned medium 
of P2Y12+ U937 cells attracts neutrophils remains elusive.  
We could not confirm increased secretion of CXCL2, CXCL7 and IL-8 in ADP-treated pBM(MDI). 
Since we also detected up-regulation of IL-1ß and TNF-α mRNA in ADP-treated pBM(MDI), we 
aimed at investigating whether secretion of these pro-inflammatory mediators is enhanced 
upon ADP treatment. As observed for chemokines, we failed to detect elevated cytokine 
concentrations in the cell supernatants of ADP-treated pBM(MDI). One possible explanation for 
the different secretory phenotype of P2Y12+ U937 cells and pBM(MDI) is the presence of other 
purinergic ADP receptors including P2Y1 and P2Y13 in pBM(MDI) as revealed by microarray 
analysis. Since information about their function in macrophages are sparse, it remains elusive 
whether these purinergic receptors counteract the P2Y12-mediated effects. Since pBM are 
treated with dexamethasone and IL-4 prior to ADP stimulation, another hypothesis is that 
these mediators suppress the ADP-induced effects observed in P2Y12+ U937 cells. 
Furthermore, glucocorticoids such as dexamethasone are known to inhibit protein synthesis 
of pro-inflammatory cytokines and chemokines [419].   
Although we failed to detect increased chemokine release of ADP-treated pBM(MDI), ADP was 
shown to promote the release of several chemokines and cytokines from different cell types 
in vitro. While ADP induced the release of IL-1ß, IL-6 and TNF-α in human microglia, it induced 
the expression of CCL2, CCL5 as well as IL-8 in human keratinocytes [420, 421]. Interestingly, 
IL-8 is not only released upon ADP stimulation but also in response to TLR agonists. In 
macrophages, LPS and Pam3CSK4 were both shown to promote nucleotide release and 
subsequent IL-8 secretion by autocrine purinergic signaling via P2Y2 and P2Y6 [422-424]. 
Whether ADP also induces nucleotide release thereby stimulating autocrine purinergic 
signaling and IL-8 secretion needs to be further investigated. 
To investigate whether P2Y12 blockade inhibits the ADP-induced chemokine secretion, we 
treated P2Y12+ U937 cells with the specific and highly potent P2Y12 antagonist PSB0739. 
Indeed, we could abrogate the ADP-induced release of CXCL2, CXCL7 and IL-8 upon inhibition 
of the P2Y12 receptor. Several clinically-approved P2Y12 antagonists including clopidogrel and 
ticagrelor were reported to have anti-inflammatory properties besides reducing platelet 
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activation. Clopidogrel reduced airway inflammation associated with reduced levels of the Th2 
cytokines IL-4 and IL-13 as well as IFN-γ and CCL5 in a mouse model of asthma [341]. Ticagrelor 
attenuated atherogenesis in ApoE-deficient mice accompanied by decreased expression of 
CCL2 and reduced accumulation of macrophages [425]. In the brain, ticagrelor treatment 
reduced the number of infiltrating microglia and the expression of IL-1ß, CCL2 and iNOS after 
cerebral artery occlusion [326]. These results fit with our finding that the P2Y12 antagonist 
PSB0739 abrogates ADP-induced secretion of CXCL2, CXCL7 and IL-8 in macrophages. 
Therefore, we hypothesize that P2Y12 antagonists can reduce inflammation by decreasing the 
attraction of inflammatory cells.  
Since IL-8 is not present in the murine system, we were interested which chemokines are 
expressed in P2Y12+ mouse macrophages upon ADP treatment. It has been described by 
others that CXCL1, CXCL2 and CXCL5 are the functional mouse homologues of IL-8 [426]. We 
performed a cytokine array, able to analyze the presence of 40 different cytokines and 
chemokines in the supernatant of ADP-treated P2Y12+ Raw 264.7 cells (P2Y12 ADP). Like in 
human U937 cells, we detected increased concentration of CXCL2 in the supernatant of P2Y12 
ADP compared to unstimulated cells. We failed to detect CXCL1 and CXCL5 in the cell 
supernatants of ADP-treated P2Y12+ Raw 264.7 cells. Interestingly, we also found increased 
CCL4 and TNF-α concentrations, mediators we did not detect in human ADP-treated P2Y12+ 
U937 cells. Since the cytokine array is not a quantitative method, we performed ELISAs to 
verify these results with an independent assay and to determine the exact concentrations of 
the mediators in the cell supernatants. Although we failed to detect elevated CCL4 levels in 
the supernatants of P2Y12 ADP we found significantly increased TNF-α secretion and a 
tendency for enhanced CXCL2 release in ADP-treated P2Y12+ Raw 264.7 cells compared to 
untreated cells. These results suggest that ADP has similar but not 100 % overlapping 
biological effects in murine and human macrophages. 
 
5.3.3 ADP-induced signaling pathways in P2Y12+ macrophages 
 
We went on characterizing ADP-induced signaling pathways in P2Y12+ U937 cells. We detected 
increased ERK1/2 as well as Akt phosphorylation in ADP-treated P2Y12+ cells compared to EV 
cells. ADP-induced signaling via P2Y12 is best characterized in platelets. Since P2Y12 is a GPCR 
that couples to Gi proteins, the Gα subunit inhibits adenylyl cyclase while the Gßγ subunit 
activates PI3K and its main downstream target Akt. Various studies showed that treatment of 
platelets with PI3K inhibitors abrogates ADP-induced Akt phosphorylation [310]. PI3K/Akt 
signaling via P2Y12 is not only involved in platelet activation but also in microglial chemotaxis 
[427]. ATP-induced Akt phosphorylation in microglial cells can be inhibited with the PI3K 
inhibitor Wortmannin or with the P2Y12 antagonist AR-C69931-MX [324]. Interestingly, in 
microglial cells P2Y12 activation also induces p38 MAPK phosphorylation, which can be 
abrogated with the P2Y12 inhibitor MRS2395 [329, 428]. We failed to detect p38 MAPK 
phosphorylation in ADP-treated P2Y12+ U937 cells and pBM(MDI) (data not shown) indicating 
that this pathway might not be as relevant for ADP-induced activation of these macrophages. 
In line with our results, Soulet et al. showed that besides Akt, ERK1/2 is phosphorylated upon 
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treatment of P2Y12+ CHO cells with 2-MeSADP. Treatment with PI3K inhibitors reduced 
ERK1/2 as well as Akt phosphorylation, suggesting that ERK1/2 activation is downstream of 
PI3K/Akt signaling [306]. 2-MeSADP also induced ERK1/2 phosphorylation in human 
monocyte-derived DCs. Since the P2Y12 antagonist AR-C69931MX inhibited the ADP-induced 
ERK phosphorylation, the authors hypothesized that ERK signaling is induced via P2Y12 [429]. 
Besides activation of Akt and ERK1/2 signaling, we detected increased expression of the 
transcription factor subunits JUN and FOSL1. ERK signaling was shown to induce the 
expression of AP-1 transcription factor subunits [430]. We could show that treatment with 
specific Akt and ERK inhibitors abrogated the ADP-induced expression of JUN and FOSL1. 
Studies reported that the transcription factor AP-1 is important for the expression of pro-
inflammatory cytokines and chemokines [431]. To investigate whether ERK and/or Akt 
signaling are also responsible for the ADP-induced chemokine secretion in P2Y12+ U937 cells, 
we pre-treated the cells with Akt and ERK inhibitors prior to stimulation with ADP. Indeed, 
single inhibition of either Akt or ERK reduced the ADP-induced secretion of CXCL2, CXCL7 and 
IL-8. Similar to our results, Kawamura et al. showed that ERK1/2 inhibition abrogates the ATP-
induced CXCL2 secretion from macrophages [432]. However, we showed that blockade of Akt 
signaling was more efficient than ERK inhibition, while co-administration of Akt and ERK 
inhibitors was most efficient in reducing ADP-induced chemokine release. These results 
suggest that both pathways act synergistically. Although many studies reported a negative 
crosstalk between ERK1/2 and Akt signaling, co-activation of both signaling pathways was also 
reported in several studies [433, 434].  
To investigate whether ADP also induces the same signaling pathways in P2Y12-expressing 
pBM(MDI), we performed Western blot analysis of ADP-treated pBM(MDI) using anti-Akt and anti-
ERK1/2 antibodies. In contrast to P2Y12+ U937 cells, ADP-treated pBM(MDI) lacked 
phosphorylated Akt. However, ADP stimulation resulted in increased ERK1/2 phosphorylation 
and increased expression of the transcription factor subunits FOSL1 and JUN in pBM(MDI). Pre-
treatment with the ERK inhibitor did not reduce cytokine expression suggesting that ERK 
signaling is not responsible for the induction of these cytokines in ADP-treated pBM(MDI). 
However, the P2Y12 antagonist PSB0739 significantly inhibited ADP-induced cytokine 
expression. These results indicate that ADP might activate other P2Y12 downstream signaling 
pathways in pBM(MDI). 
 
5.3.4 ADP promotes the migration of P2Y12+ macrophages 
 
It is well known that nucleotides released by apoptotic and necrotic cells act as find-me or 
danger signals and trigger the migration of phagocytic cells to the site of inflammation [260]. 
Therefore, we aimed to analyze whether ADP acts as a find-me signal for P2Y12+ macrophages. 
Using a transwell migration assay we confirmed the chemoattractant effect of ADP on both, 
P2Y12+ pBM(MDI) and P2Y12+ Raw 264.7 cells. Various studies provided proof for the 
chemotactic role of ADP but also ATP for P2Y12+ microglial cells [328, 355]. Concordantly, 
microglia from P2y12-deficient mice fail to migrate towards an ADP gradient [325]. ADP also 
enhanced the recruitment of other myeloid cells including macrophages and to a lesser extend 
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neutrophils to the site of bacterial infection in vivo, suggesting that the ADP receptors P2Y12 
and P2Y13 are responsible for this effect [435]. In addition, it was shown that recruited 
macrophages secrete chemokines such as CXCL2 and IL-8 which attract more inflammatory 
cells, mostly neutrophils, to the site of infection [424, 432]. We also showed that ADP 
promoted IL-8 and/or CXCL2 release from human and murine P2Y12+ cells indicating that 
P2Y12+ macrophages recruit inflammatory cells to the site of inflammation. 
Interestingly, we found an increased migration of P2Y12+ Raw 264.7 cells not only towards 
ADP but also towards medium without FCS. Supplementation of medium w/o FCS with ADP 
potentiated the migratory capacity of P2Y12+ macrophages. These results suggest that either 
the medium contains factors that trigger migration of P2Y12+ cells or that the cells themselves 
release factors that promote their migration in an autocrine manner. Since the P2Y12 
antagonist PSB0739 abrogated the increased migration of P2Y12+ Raw 264.7 cells towards 
medium without FCS, we hypothesized that serum-starved cells might release nucleotides that 
promote their migration in an autocrine manner. Such an autocrine signaling mechanism for 
the migration of myeloid cells has already been shown for ATP. Chemotactic factors (IL-8, 
fMLP) induce ATP release of neutrophils thereby promoting their chemotaxis by autocrine 
purinergic signaling via P2Y2 [263]. In macrophages, complement component C5a induces ATP 
release, creating a positive feedback loop by purinergic signaling via P2Y2 and P2Y12 [268]. 
Isfort et al. showed that ATP/ADP are not chemoattractants but increase the random 
migration of macrophages, also known as chemokinesis [346]. These results suggest that these 
nucleotides act as short-range signals that are released by the immune cells themselves to 
stimulate their chemotaxis.  
To investigate whether released nucleotides are the reason for the induced migration towards 
medium without FCS, we supplemented the medium in the lower chamber with the ATP/ADP-
hydrolyzing enzyme apyrase. Indeed, apyrase abrogated the migration of P2Y12+ Raw 264.7 
cells towards medium without FCS. To investigate if the release of nucleotides depends on 
P2Y12, we used CM of ADP-treated and untreated transgenic Raw 264.7 cells (P2Y12+ and EV 
cells) as chemoattractants. Like the CM of P2Y12+ cells, the CM of EV cells also induced the 
migration of P2Y12+ cells while the migratory ability of EV cells remained unaffected. These 
results suggest that serum-starved cells release nucleotides independently of P2Y12 
expression. Interestingly, the CM of ADP-treated P2Y12+ cells did not significantly increase the 
migration of P2Y12+ Raw 264.7 cells compared to the CM of untreated P2Y12+ cells, suggesting 
that ADP signaling via P2Y12 does not trigger nucleotide release. However, since we only 
assessed migration after 6 h and did not measure nucleotide concentrations in the CM, we 
cannot completely exclude that the CM of ADP-treated P2Y12+ cells contains higher levels of 
nucleotides. It is possible that initial migration of P2Y12+ cells is stronger induced by ADP-CM 
compared to CM of untreated P2Y12+ cells and that differences cannot be observed at later 
time points when maximal migration is achieved. Since it could also be that the released 
nucleotides trigger chemokine secretion from P2Y12+ Raw 264.7 cells which subsequently 
promote the migration of P2Y12+ macrophages, we treated the CM of P2Y12+ Raw 264.7 cells 
and EV cells with apyrase. The induced migration of P2Y12+ cells towards CM of serum-starved 
cells was completely abrogated when nucleotides were hydrolyzed by apyrase, indicating that 
chemokines don’t play a role in the ADP-induced migration of P2Y12+ Raw264.7 cells. In 
contrast to our results, Zhang et al. showed that CCL2 release in response to ADP and not the 
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nucleotides themselves cause the increased migration of Raw 264.7 cells. By supplementation 
of the CM of ADP-treated cells with apyrase the authors found that cleavage of ADP could not 
abrogate the increased migration of macrophages towards ADP-CM, suggesting that released 
chemokines in response to ADP are the reason for the induced migration [435]. However, in 
contrast to our experiments with P2Y12+ Raw 264.7 cells they used untransfected Raw 264.7 
cells and murine peritoneal macrophages. Since we also detected down-regulation of the 
chemokine receptor CCR2 in ADP-treated-P2Y12+ cells, it is possible that P2Y12+ macrophages 
are mainly attracted by nucleotides and not by CCL2. Furthermore, in contrast to Zhang et al., 
we could not detect increased CCL2 secretion in ADP-treated transgenic Raw 264.7 cells.  
These results suggest that ADP promotes the migration of P2Y12+ macrophages. In addition, 
serum-starved cells release nucleotides that trigger migration of P2Y12+ macrophages via 
autocrine signaling. 
 
5.3.5 Cell death induces the migration of P2Y12+ Raw 264.7 cells 
 
Due to inflammation, necrosis and apoptosis, the tumor microenvironment is characterized 
by high levels of nucleotides. Myeloid cells are recruited to the tumor microenvironment via 
these extracellular nucleotides but also via chemokines that are released by tumor cells and/or 
stromal cells [252]. To investigate whether dying tumor cells can directly induce the migration 
of P2Y12+ macrophages, we established a co-culture with dying B16F1 melanoma cells and 
P2Y12+ Raw 264.7 cells. B16F1 cells were seeded in the lower well of a transwell chamber and 
treated with puromycin for 24 h to induce cell death. Subsequently, transgenic Raw 264.7 cells 
were added to the transwell insert and migration towards the dying melanoma was assessed 
after 6 h. The migration of P2Y12+ cells towards dying melanoma cells was significantly 
enhanced compared to untreated B16F1 cells. Cell death did not significantly promote the 
migration of EV cells. Addition of the P2Y12 antagonist PSB0739 to the dying B16F1 cells 
significantly abrogated the cell death induced migration of P2Y12+ macrophages. 
Furthermore, addition of apyrase to the dying tumor cells also diminished the migration of 
P2Y12+ Raw 264.7 cells. These results indicate that dying tumor cells release nucleotides that 
act as find-me signals for the recruitment of P2Y12+ macrophages. It has been shown, that 
chemotherapeutic agents induce ATP release from dying tumor cells. The authors detected 
decreased intracellular ATP levels and increased extracellular ATP levels irrespective of the 
type of chemotherapeutic agent and tumor cells. ATP release occurred already from early 
apoptotic cells and proceeded during late apoptosis and secondary necrosis [301]. Elliott et al. 
showed that apoptotic cell supernatants induce the migration of THP1 monocytes in vitro. 
Moreover, macrophages were recruited to murine air pouches containing apoptotic cell 
supernatants. Interestingly, apoptotic cell supernatants mainly attracted macrophages, while 
LPS primarily attracted neutrophils indicating that extracellular nucleotides act as a paracrine 
signal for macrophages expressing purinergic receptors. Since they showed that apoptotic cell 
supernatants mainly contain ATP and UTP the authors assumed that the purinergic receptor 
P2Y2 is involved in sensing these nucleotides. Although macrophages of P2y2-/--mice showed 
impaired migration towards apoptotic cell supernatants, the migration was not completely 
abrogated, suggesting the involvement of other nucleotide receptors [260]. Since we showed 
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that P2Y12 is expressed on human and murine macrophages including TAM, and necrotic cell 
death induces the migration of P2Y12+ macrophages, P2Y12 might also be involved in the 
sensing of apoptotic cells in the tumor microenvironment. 
 
5.3.6 P2Y12 facilitates the adhesion and transmigration of U937 cells 
 
Besides its role in microglial chemotaxis and platelet activation, P2Y12 enables the adhesion 
of platelets to leukocytes but also to tumor cells in vitro. Gebremeskel et al. showed that 
P2Y12 facilitates platelet-tumor cell interactions and promotes the adhesion of these 
aggregates to ECs [320]. In addition, ECs express purinergic receptors (e.g. P2Y1), which 
promote leukocyte recruitment and adhesion [436, 437]. We aimed at investigating whether 
P2Y12 over-expression alters the adhesion and transmigration of monocytes through ECs. 
Indeed, adhesion of P2Y12+ U937 cells to HUVEC and transmigration through the endothelial 
monolayer were strongly enhanced when compared to EV cells. Since gene expression analysis 
revealed an up-regulation of the tetraspanins TSPAN7 and CD82 in ADP-treated P2Y12+ U937 
cells and tetraspanins are involved in leukocyte trafficking [407], we aimed at investigating 
whether these ADP-treated cells show an increased adhesion and/or transmigration. When 
P2Y12+ cells were pre-treated with ADP for 24 h the increased adhesion to ECs was abrogated. 
Furthermore, transmigration across an activated HUVEC monolayer was also diminished in 
ADP-treated P2Y12+ U937 cells. These results suggest that the tetraspanins CD82 and TSPAN7 
are not involved in the adhesion and transmigration of P2Y12+ monocytes. Our results suggest 
that P2Y12 itself and not the ADP-induced genes are important for the increased adhesion and 
transmigration of P2Y12+ monocytes. Since we did not detect down-regulation of P2Y12 
expression upon ADP treatment, there must be another explanation for the reduced adhesion 
and transmigration of P2Y12+ cells upon ADP treatment. Hardy et al. showed that P2Y12 
rapidly desensitize upon ADP treatment. This desensitization is mediated by G protein coupled 
receptor kinases and may also result in internalization of the receptor [438]. For GPCR 
including purinergic receptors it is well established that they are internalized upon activation 
[311]. Whether P2Y12 receptor internalization causes the reduced adhesion and 
transendothelial migration of ADP-treated P2Y12+ monocytes has still to be determined. 
Another possible explanation would be that ADP competitively blocks the binding site of 
P2Y12 thereby blocking the adhesion to surface receptors on endothelial cells. It needs further 
studies to answer the question whether this competitive inhibition is the reason for the 
reduced adhesion of ADP-treated P2Y12+ U937 cells. 
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5.4 Concluding remarks 
 
We showed that P2Y12 is expressed in human and murine TAM of melanoma. We detected 
up-regulation of P2Y12 expression upon treatment of pBM as well as BMDM with 
M-CSF/dexamethasone/IL-4, stimuli that promote polarization of M2 macrophages in vitro. 
Indeed, we found co-expression of P2Y12, CD68 and CD163 in macrophages of melanoma 
in situ suggesting that P2Y12 is primarily expressed by M2-like TAM. Whether presence of 
P2Y12+ TAM correlates with overall survival of melanoma patients remains to be elucidated. 
P2Y12 seems not to be a specific marker for TAM since it is also expressed on a subpopulation 
of splenic macrophages and murine peritoneal macrophages. Since we found increased 
migration of P2Y12+ macrophages towards extracellular nucleotides, we suggest that P2Y12+ 
macrophages are recruited to hypoxic regions in the tumor stroma rich in apoptotic and 
necrotic cells. In addition, we could show that ADP signaling in monocytes induces the 
expression and secretion of several chemokines (CXCL2, CXCL7 and CXCL8/IL-8) that are 
involved in angiogenesis and chemotaxis of neutrophils. Whether the number of P2Y12+ 
macrophages correlates with the presence of neutrophils and/or CD31+ ECs in melanoma 
specimens remains to be determined.   
In P2Y12-expressing pBM(MDI), ADP induces the expression of TNF-α and IL-1ß while reducing 
the expression of anti-inflammatory cytokines IL-10 and TGF-ß suggesting that ADP 
reprograms macrophages towards a pro-inflammatory phenotype. Whether P2Y12+ 
macrophages modulate the anti-tumor immunity by inhibiting or activating T cell response 
needs further studies. Tumor transplantation models using mice with P2y12-depleted 
macrophages are needed to evaluate the role of P2Y12+ macrophages in tumor growth and 
progression. 
 
 
Figure 41. Schematic overview of the function of P2Y12+ macrophages. 
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INK4A inhibitor of cyclin-dependent kinase 4a 
iNOS inducible nitric oxide synthase 
IRES internal ribosomal entry site 
JNK c-Jun N-terminal kinase 
KLH keyhole limpet hemocyanin 
LB lysogeny broth 
LFA-1 lymphocyte function-associated antigen 1 
LLC Lewis lung carcinoma 
LPS lipopolysaccharide 
LTD4 leukotriene D4 
LTE4 leukotriene E4 
Ly6C lymphocyte antigen 6 C 
Lyve-1 lymphatic vessel endothelial hyaluronan receptor 
M-CSF macrophage-colony stimulating factor 
MACS magnetic activated cell sorting 
MAPK mitogen activated protein kinase 
MC1R melanocortin 1 receptor 
MCP-1 monocyte chemoattracting protein-1 
MCS multiple cloning site 
mDC myeloid DC 
MDI M-CSF/dexamethasone/IL-4 
MDM monocyte-derived macrophages 
MDSC myeloid derived suppressor cell 
MFI median fluorescence intensity 
MHC major histocompatibility complex 
MITF microphthalmia-associated transcription factor 
mm mus musculus  
M-MDSC monocytic MDSC 
MMM marginal metallophilic macrophages 
MMP matrix metalloproteinase 
MRC1 mannose receptor C-type 1 
mRNA messenger RNA 
MS multiple sclerosis 
MSH melanocyte-stimulating hormone 
MT-MMP membrane-type matrix metalloproteinase 
MZM marginal zone macrophages 
NEAA non-essential amino acids 
NF-κB nuclear factor κ-light-chain-enhancer of activated B cells 
NK cell natural killer cell 
NO nitric oxide 
NOS nitric oxide synthase 
ns not significant 
OD optical density 
P P2Y12 
PAGE polyacrylamide gelelectrophoresis 
PAI plasminogen activator inhibitor 
PAMP pathogen associated molecular patterns 
pBM peripheral blood monocytes 
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PBMC peripheral blood mononuclear cells 
PBS phosphate buffered saline 
PBST PBS tween 
PCR polymerase chain reaction 
PD1 programmed cell death 1 
pDC plasmacytoid DC 
PD-L1 programmed cell death-ligand 1 
PDGF platelet derived growth factor 
PFA paraformaldehyde 
PGD2 prostaglandin D2 
PGE2 prostaglandin E2 
PI3K phosphatidylinositol 3-kinase 
PLC phospholipase C 
PMA phorbol 12-myristate 13-acetate 
PMN-MDSC polymorphonuclear MDSC 
PPBP pro platelet basic protein 
PRR pattern recognition receptor 
PTEN phosphatase and tensin homolog 
puro puromycin 
PVDF polyvinylidenfluorid 
qRT-PCR quantitative real-time PCR 
rev reverse 
RFP red fluorescent protein 
RFU relative fluorescence units 
RNA ribonucleic acid 
ROS reactive oxygen species 
RT room temperature 
SDS sodium dodecyl sulphate 
SSC side scatter 
STAT signal transducer and activator of transcription 
TAE Tris-acetate-EDTA 
TAM tumor-associated macrophages 
TCR T cell receptor 
TEMED tetramethylethylenediamine 
TEM TIE2-expressing macrophages 
TERT telomerase reverse transcriptase 
TGF transforming growth factor 
TGS Tris-Glycine-SDS 
Th 1 / 2 / 17 T helper 1 / 2 / 17 
TIL tumor infiltrating lymphocytes 
TLR toll-like receptor 
TNF tumor necrosis factor 
TNFSF tumor necrosis factor superfamily 
Treg regulatory T cell 
TSPAN7 tetraspanin 7 
U units 
UDP uridine diphosphate 
uPA urokinase/plasminogen activator 
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uPAR urokinase/plasminogen activator receptor 
UT untreated 
UTP uridine triphosphate 
UV ultraviolet  
VEGF vascular endothelial growth factor 
WB Western blot 
WT wild type 
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